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1 Allergic asthma
Allergic asthma is a chronic inflammatory disorder of the airways characterized by
reversible airflow obstruction, persistent airway hyperresponsiveness, chronic airway
inflammation and airway remodeling (1). Airway hyperresponsiveness is an increased
sensitivity of the airway smooth muscle to a wide variety of bronchospasmogenic
stimuli such as methacholine. As a result of the chronic inflammation, airway tissue
is continuously being injured and healed resulting in structural changes (called
remodeling) of airway tissue that may account for the decline in airway function
seen in asthmatic patients over several years (2).
The term allergy was introduced in 1906 by Clemens from Pirquet as  “an
altered capacity of the body to react to a foreign substance” (3), which was an
extremely broad definition that included all immunological reactions. Allergy is
now defined as a symptomatic reaction to an innocuous environmental antigen
(allergen). It results from the interaction between the antigen and
immunoglobulin(Ig)E antibodies or primed T-cells produced by earlier exposure to
the same antigen (sensitization) (4).
The etiology of asthma is complex and multifactorial, involving the interaction
between genetic and environmental factors. The term atopy from the Greek atopos,
meaning “out of place” is used for the state of individuals that have an exaggerated
tendency to produce IgE antibodies against allergens and have clinical manifestations
of one, or more, atopic diseases (i.e. allergic rhinitis, asthma and atopic eczema) (4).
Some allergic diseases operate (e.g. contact dermatitis and hypersensitivity
pneumonitis) operate through IgE-independent mechanisms and in this sense can be
considered as non-atopic, allergic conditions. Also a subgroup of asthmatic patients
demonstrates no signs of atopy (5). These asthmatics show negative skin tests and
there is no clinical or family history of allergy. Furthermore, serum total IgE
concentrations are within the normal range and there is no evidence of specific
antibodies directed against common allergens.
Several genes or gene families are involved in asthma and allergy: genes that are
inflammation-specific, sensitization-specific and genes specific for the type of asthma
or allergic disease (6).
The incidence, morbidity and mortality of asthma have increased worldwide
over the last two to three decades (7). This observation is best explained by changes
in environmental factors, such as early childhood infection, environmental pollution,
allergen exposure, and diet and changes in other factors including increased awareness
of the disease, improved diagnostics and psycho-social influences (8-10).
1.1 The allergic inflammatory response
Professional antigen-presenting cells (APCs), such as dendritic cells (DCs),
macrophages and B-cells, initiate immune responses to inhalant antigens that have
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penetrated the respiratory mucosa. In animal models of allergic asthma, the DCs
have been identified as the principal APC involved in the induction and maintenance
of Th2 allergic responses (11). Upon antigen up-take, DCs traffic to T-cell rich regions
of lymphoid tissue and display processed peptide fragments of the antigen in the
context of major histocompatibility complex (MHC) class II molecules to naïve
antigen-specific CD4+ (helper) T-cells (Figure 1).
Figure 1:Schematic representation of the pathophysiology of allergic asthma.
Clonal expansion is the proliferation of antigen-specific lymphocytes in response
to antigenic stimulation and precedes their differentiation into effector cells.
Experiments in mice have shown that there can be a substantial increase (~ 1000-
fold) in the precursor frequency of antigen-specific T-cells in immune animals
compared with naïve animals (see 12).
Second, activated T helper cells differentiate into one of the two distinct subsets
on the basis of their cytokine profile. This classification was first proposed for mouse
T-cells by Mosmann et al. (13) and subsequently for human T-cells by Kapsenberg
et al. (14). CD4+ T helper 1 (Th1) cells are characterized by the production of
interleukin-2 (IL-2) and interferon-γ (IFN-γ), whereas Th2 cells produce IL-4, IL-5,
IL-9, IL-10 and IL-13. Th2 cells are optimized to combat helminithic parasite
infections. However, Th2 cells are also the dominant Th phenotype observed in
patients with allergic disorders such as asthma (15-17). Many subsequent studies in
mice and man have confirmed the pivotal role of allergen-specific Th2 cells in the
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pathogenesis and maintenance of allergic asthma, their cytokines orchestrating the
inflammatory immune response resulting in airway symptoms (reviewed in 18).
IL-4 favors the development of Th2 cells, thus perpetuating the Th2 response
(19, 20). Furthermore, IL-4 and IL-13 are required for the induction of proliferation
and isotype switching to IgE by B-cells that recognize the allergen (21, 22). Antigen-
specific IgE binds to the high-affinity receptor for IgE, FcεRI (CD64) on mast cells
(sensitization). Upon re-exposure to the same allergen (challenge), submucosal mast
cells in the lower airways will be activated when their surface-bound IgE is cross-
linked by the allergen, resulting in the release of large amounts of inflammatory
mediators, including histamine and leukotrienes (23). These short-lived mediators
are responsible for the early asthmatic phase reaction that occurs within seconds and
consists of bronchoconstriction and increased secretion of fluid and mucus, making
breathing more difficult by trapping inhaled air in the lungs. The immediate allergic
reaction usually resolves within one to two hours, but is followed by a more excessive
inflammation, known as the late-phase response. This late phase involves leukotrienes,
cytokines and chemokines, which recruit and activate other effector cells, notably
Th2 lymphocytes, eosinophils and basophils that induce airflow obstruction, mucus
secretion, smooth muscle hypertrophy, epithelial shedding and thickening of the
bronchial wall (24, 25).
The Th2 cytokine IL-5 is an important mediator for the development, migration,
and activation of eosinophils. This granulocyte is always present in the allergic lung,
but its precise role in the pathogenesis of allergic asthma or more specifically its role
in the late-phase response or development in non-specific airway hyperresponsiveness
is still a matter of debate (26, 27).
An important feature of asthma is chronic inflammation of the airways, which
is characterized by the continued presence of increased numbers of Th2 lymphocytes,
eosinophils and other leukocytes (24). Although allergic asthma is initially driven
by a response to a specific allergen, the subsequent chronic inflammation seems to
be perpetuated even in the apparent absence of further exposure to allergen, resulting
in airway hyperresponsiveness to non-specific stimuli and airway remodeling. At
present, treatment of asthma consists of long-term suppression of airway inflammation
plus relief of symptoms with quick-acting bronchodilators (primarily dry powder
β2-adrenoceptor agonists). Inhaled corticosteroids are the most effective agents
available for the reduction of inflammation and improvement of pulmonary function,
but their potential side effects when used in escalating doses have led to adjunctive
therapies including long-acting β2-agonists, sustained-release theophylline and
leukotriene antagonists (25, 28). In view of the crucial role of allergen-specific Th2
cells in allergic asthma, these cells might be an interesting and more specific
therapeutic target (29, 30).
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2 T-cell co-stimulation
The current concept of how lymphocytes become activated is originally derived
from the two-signal hypothesis from studies with B-cells first proposed by Bretscher
and Cohn in 1970 (31) and subsequently expanded to T-cells by Lafferty and
Cunningham (32). After modifications by others, it is generally believed that optimal
activation of lymphocytes requires specific antigen recognition by the T-cell receptor
(TCR), presented in the form of processed peptides in association with MHC class II
molecules (signal 1) and additional signals (collectively called signal 2 or co-
stimulatory signals), delivered by the same APC (33, 34). APCs are activated to
express co-stimulatory ligands upon binding and ingesting pathogens through
receptors of the innate immune system.
This requirement for the simultaneous delivery of antigen-specific and co-
stimulatory signals by one cell in the activation of T-cells means that only such
activated APCs can initiate T-cell responses and prevents uncontrolled activation of
potentially self-reactive by broadly expressed self-antigens in non-lymphoid tissues,
so-called peripheral self-tolerance. Thus, the two-signal theory is one of the major
mechanisms limiting the development of destructive immune responses to self-tissues
(auto-immunity). Indeed, antigen binding to the TCR in the absence of co-stimulation
not only fails to activate the cell; it also leads to a state of antigen-specific
unresponsiveness, called anergy. Such anergic T-cells are refractory to antigen-
specific re-stimulation even when the antigen is presented by a professional APC
(35-39).
2.1.1 The CD28/CTLA4:B7-1/B7-2 pathway
Although many receptor-ligand pairs of T-cell co-stimulation have been identified
(40), the CD28/CTLA4:B7-1/B7-2 pathway is the primary pathway of T-cell co-
stimulation (reviewed in 41-44) (Figure 2 on page 13).
CD28 is member of the Ig superfamily with a single Ig variable-like extracellular
domain in addition to its transmembrane and cytoplasmic domains. Expressed as a
disulphide-linked homodimeric glycoprotein, it is constitutively present on the surface
of naïve T-cells. Following T-cell activation, the levels of CD28 increase (45).
The ligands of CD28, B7-1 (CD80) and B7-2 (CD86), are also members of the
Ig superfamily, with two Ig-like extracellular domains (one variable-like and one
constant-like). On most APC populations, B7-2 is expressed constitutively at low
levels and is rapidly up-regulated, whereas B7-1 is inducibly expressed later after
activation. The earlier expression pattern of B7-2 suggests that B7-2 is the more
important co-stimulator for initiating T-cell responses. However, this remains to be
substantiated. B7-1 and B7-2 appear to support T-cell activation equivalently (46).
Differential outcomes of the CD28:B7-1 versus CD28:B7-2 interaction seem mainly
The ligands of CD28, B7-1 (CD80) and B7-2 (CD86), are also members of the Ig
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superfamily, with two Ig-like extracellular domains (one variable-like and one
constant-like). On most APC populations, B7-2 is expressed constitutively at low
levels and is rapidly up-regulated, whereas B7-1 is inducibly expressed later after
activation. The earlier expression pattern of B7-2 suggests that B7-2 is the more
important co-stimulator for initiating T-cell responses. However, this remains to be
substantiated. B7-1 and B7-2 appear to support T-cell activation equivalently (46).
Differential outcomes of the CD28:B7-1 versus CD28:B7-2 interaction seem mainly
to reflect distinct expression patterns and kinetics, but there might be some intrinsic
functional differences.
CD28 signals promote T-cell activation by augmenting and sustaining T-cell
responses initiated by TCR signaling. CD28 co-stimulation has been shown to
stimulate proliferation by increasing the secretion of the autocrine growth factor IL-
2 and the induction of IL-2 receptor expression. In addition, CD28 increases T-cell
survival by the induction of the anti-apoptotic factor Bcl-xL. Some reports indicate
that CD28 ligation might favor differentiation of T-cells into Th2 cells (47-52).
Furthermore, CD28 plays an important role in B-cell differentiation and germinal
center formation (53). Finally, CD28 also directs T-cell migration into inflammatory
sites by inducing the production of specific chemokines and the regulation of
chemokine receptors (54). In the absence of TCR signaling, CD28 engagement does
not usually have a physiological effect.
The second receptor for the B7 ligands, cytotoxic T-lymphocyte antigen 4
(CTLA4; CD152), is expressed on T-cells only after a period of activation and delivers
inhibitory signals. Cell surface expression of CTLA4 is very tightly regulated, with
most of the CTLA4 protein residing within cytoplasmic vesicles (55). CTLA4 shares
about 30% identity with CD28 at the amino acid level and is also an Ig superfamily
protein with a single extracellular variable-like domain expressed as a disulphide-
linked homodimer that is capable of binding the B7 molecules, but with a much
higher affinity (56). This suggests that CTLA4, as it becomes expressed on the surface
of activated T-cells, might preferentially interact with B7-1 and B7-2, and thus aid
in the termination of immune responses.
CTLA4 inhibits T-cell proliferation by reducing IL-2 production and IL-2
receptor expression and by arresting T-cells at the G1 phase of the cell cycle (57-
59). In addition, CTLA4 has been shown to limit the extent of Th2 differentiation
(60-63). The importance of negative regulatory signals through CTLA4 is illustrated
in mice deficient in CTLA4 (CTLA4−/−). These mice die within three to four weeks
after birth expansion from a lymphoproliferative disease characterized by CD28-
mediated polyclonal T-cell activation and progressive infiltration of T-cells in critical
visceral organs (64-66). Recent studies also indicate that CTLA4 not only serves to
counterbalance CD28 signals but also can inhibit immune responses independently
of CD28 (67-69).
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Figure 2:Schematic representation of some T-cell co-stimulatory receptors and their ligands.
Because CTLA4 has a higher affinity for the B7 ligands compared with CD28,
CTLA4-Ig has been widely used to block T-cell co-stimulation in an array of
experimental animal models of T-cell-mediated diseases (41, 56).
CTLA4 engagement has also been implicated in the induction of peripheral
tolerance (60, 70-72), which might be induced not because of the absence of B7-1/
B7-2-mediated co-stimulation but as a consequence of CTLA4:B7-1/B7-2
interactions.
2.1.2 The ICOS:B7RP-1 pathway
Although CD28 is a key co-stimulatory molecule, it does not account for all co-
stimulatory function in T-cells. Studies in vitro have demonstrated that effector and
memory T-cells are less dependent on co-stimulation in comparison with naïve T-
cells (48, 73, 74), whereas studies in vivo on the effectiveness of giving CTLA4-Ig
after priming of immune responses have yielded conflicting results (75). These results
suggested that alternative co-stimulatory pathways may exist.
One of the alternative T-cell co-stimulatory molecules is the recently discovered,
third member of the CD28 family member inducible co-stimulator (ICOS) (reviewed
in 44, 76, 77) that has been cloned in human (78, 79), mice (80, 81) and rat (82).
ICOS shares approximately 30-40% sequence similarity with CD28 and CTLA4
and also possesses a single extracellular Ig-variable-like domain. However, despite
its structural similarities to CD28 and CTLA4, ICOS does not bind to B7-1 and B7-
2 but binds to its own ligand B7 related protein 1 (B7RP-1), a novel B7 family
TCR peptide/
MHC II
B7-1
B7-2
CD28
T cell
antigen
presenting
cellICOS
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member (83, 84) (also referred to as B7h (85), GL50 (86), or LICOS (87) in mice
and as B7-H2 (88) or ICOSL (89) in humans).
ICOS is rapidly expressed on the surface of T-cells as a disulphide-linked
homodimer after TCR engagement and is retained on many memory T-cells (78, 80,
81, 83, 90, 91), suggesting that ICOS provides co-stimulatory signals to activated T-
cells. Indeed, during the initial activation of naïve T-cells, ICOS signals only modestly
influence T-cell proliferation and IL-2 production in comparison with CD28 signaling
(78, 80, 81, 83, 88, 91). However, ICOS co-stimulation is equivalent to that mediated
by CD28 for the production of Th effector cytokines IL-4, IL-5, IFN-γ, and TNF-α
and is more effective in enhancing IL-10 production (78, 84, 88, 90-95). ICOS−/−
mice demonstrated that ICOS has a critical role in Ig isotype class switching and
germinal center formation (96-98).
Compared with B7-1 and B7-2, B7RP-1 has a unique expression pattern, in that
it is differentially induced on lymphoid tissues and is also expressed in non-lymphoid
tissues in mice (85-87) and humans (87, 99). The up-regulated expression of B7RP-
1 in peripheral tissues by inflammatory cytokines might indicate a physiological
role of B7RP-1 in the reactivation of memory and effector T-cells (85, 99).
2.1.3 Other members of the CD28 and B7 families
Since the unraveling of the human genome, the CD28 and B7 families are rapidly
growing (reviewed in 44, 77, 100, 101) and now also count programmed death (PD)-
1 (102) and PDL-1 (B7-H1) (103) and PD-L2 (B7-DC) (104, 105) as members,
respectively. Interaction of PD-1 with either PD-L1 or PD-L2 has been shown to
result in inhibition of T- and B-cell responses (104, 106). Interestingly, PD-L1 and
PD-L2 have also been reported to co-stimulate T-cell responses (103, 105) raising
the possibility that there may be additional receptor(s) for these ligands, in analogy
with the B7-1/B7-2:CD28/CTLA4 system.
The newest member of the B7 family, B7-H3 appears to engage a co-stimulatory
molecule on activated T-cells that does not correspond to any of the known CD28
family members (107). B7-H3-Ig fusion protein co-stimulates CD4+ and CD8+ T-
cell proliferation, IFN-γ production and CD8+ lytic activity.
Moreover, generation of mice lacking both CD28 and CTLA-4 has produced
evidence for a third B7-1/B7-2 receptor (108).
2.2 Receptor-ligand pairs involved in T-cell co-stimulation from the TNF
families
Receptor-ligand pairs involved in T-cell co-stimulation are also found in the rapidly
expanding tumor necrosis factor (TNF) receptor-ligand superfamilies (reviewed in
109-111). A common function of these receptor-ligand pairs is the regulation of
cell-mediated activation and/or apoptosis, in other words, the regulation of life and
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death. Molecules with T-cell co-stimulatory function and their ligands include
CD27:CD27L (CD70), CD40:CD40L (CD154), OX40(CD134):OX40L and 4-1BB:4-
1BBL (see Table 1).
2.2.1 The CD40L:CD40 pathway
The best-characterized pair of counter-receptors from this family is CD40 ligand
(CD40L; CD154) transiently expressed on activated CD4+ T-cells that interacts with
CD40 found on many cell types, including APCs (reviewed in 112, 113). In addition
to evidence for direct T-cell co-stimulation via CD40L (114-119), triggering of CD40
contributes indirectly to T-cell co-stimulation by the up-regulation of the B7-1 and
B7-2 expression on APCs, thus enhancing T-cell activation through CD28-mediated
signaling (120, 121). Ligation of CD40 on B-cells, together with IL-4 (21), is necessary
for their activation and the induction of isotype switching to IgE (122).
2.3 Yet other receptor-ligand pairs involved in T-cell co-stimulation
Some other pathways that have been shown to co-stimulate T-cells are listed in
Table 1.
Table 1: Overview of T-cell co-stimulatory receptors and their ligands. Adapted from (40, 101)
Receptor on T-cell Ligand(s)
CD28 and B7 subfamilies of the Ig superfamily
CD28 B7-1 (CD80)/B7-2 (CD86)
CTLA4 (CD152) B7-1 (CD80)/B7-2 (CD86)
ICOS B7RP-1 (B7h, GL-50, LICOS, B7-H2, ICOSL)
PD-1 PD-L1 (B7-H1)/PD-L2 (B7-DC)
unknown yet B7-H3 (B7RP-2)
Tumor necrosis factor receptor/ligand superfamilies
CD40L (CD154) CD40
OX40 (CD134) OX40L
4-1BB (CD137) 4-1BBL
CD27 CD27L (CD70)
LIGHT HVEM
Other receptor-ligand pairs of T-cell co-stimulation
CD2 LFA-3 (human CD58; mouse CD48)
LFA-1 (CD11a:CD18) ICAM-1 (CD54)/ICAM-2 (CD102)
ICAM-3 DC-SIGN (CD209)
unknown yet heat-stable antigen (HSA; CD24)
dipeptidyl peptidase IV (CD26) adenosine deaminase
CD81 unknown yet
OX-2 (CD200) unknown yet
CD100 plexin-B1 (non-lymphoid tissues)
CD72 (lymphoid tissues)
SLAM (CD150) measles virus, CD46 and SLAM itself
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3 Murine models of allergic asthma
To study the cellular and molecular mechanisms involved in the pathogenesis of
allergic asthma, murine models have been very useful (123, 124). Many pathogenic
mechanisms such as the central role of Th2 cells were first elucidated in mice and
subsequently confirmed in humans. In general, mice are injected parenterally with a
model antigen like ovalbumin (OVA), eggs and antigen of the Schistosoma mansoni
parasite (125) or human relevant antigens (e.g. derived from house dust mite (126),
the fungus Aspergillus fumigatus (127) or cockroach (128)) to induce systemic
sensitization. This sensitization usually occurs in the presence of the adjuvant
aluminum hydroxide that induces a Th2-dominant response in vivo. After
sensitization, antigen-specific IgE can be detected in the sera of mice. Subsequently,
the same antigen is administered once or repeatedly through the airways to focus the
inflammatory process in the bronchi and lungs. Upon antigen challenge, several
characteristic features of the clinical disease can be observed in mice. These features
include airway hyperresponsiveness in vivo to bronchospasmogenic stimuli such as
methacholine, an influx of inflammatory cells in the broncho-alveolar lavage fluid
(BALF) and lung tissue, mucus production and up-regulated levels of antigen-specific
IgE in serum (129). Mice can develop both an early and late-phase “asthmatic”
responses (130). Murine models can also be used to study various aspects of airway
remodeling after protocols involving chronic challenge with antigens (128, 131).
Because the mouse is broadly used as experimental animal, many transgenic and
gene deficient strains have been generated (132) and diverse mouse-specific antibodies
and recombinant proteins (e.g. cytokines) are available for experimental interference.
However, the extrapolation from these models to the human condition is not
straightforward (133, 134), as reflected by some recent clinical disappointments;
anti-IL-5 mAb (135) and IL-12 treatment (136) did not seem to modulate the late
asthmatic response or airway hyperresponsiveness. These studies relied on a “single”
mediator hypothesis, and strategies designed to suppress inflammatory cell function
might prove more successful. In addition, in most studies, experimental treatment is
administered during the development of asthma manifestations in mice, whereas
patients start therapy after the development of airway symptoms. In general, continued
emphasis on how the disease process can be best modeled is warranted to optimize
murine models as a tool for testing new forms of therapies (133, 134, 137).
3.1 The role of T-cell co-stimulation in murine models of allergic asthma
Also the role of various T-cell co-stimulatory molecules has been studied in murine
models of allergic asthma.
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3.1.1 The CD28/CTLA4:B7-1/B7-2 pathway
The critical role of CD28 signaling in the development of Th2-dominated allergic
inflammatory responses in mice has been demonstrated in both gene targeting and
blocking studies. No asthma-like symptoms could be induced in CD28−/− mice (51,
52, 138) or B7-1/B7-2−/− mice (139). Administration of CTLA4-Ig or monclonal
antibodies (mAbs) against the B7 molecules at the time of antigen sensitization or
challenge of wild-type mice (140-144) greatly reduced the allergen-induced
manifestations of asthma.
3.1.2 The ICOS:B7RP-1 pathway
ICOS−/− mice were susceptible to the influx of inflammatory cells in the BALF induced
by airway challenge in primed mice (96). In blocking studies, the ICOS:B7RP-1
pathway was interrupted during antigen-sensitization and/or airway challenge (80,
125) or solely during the final aerosol challenge (92). Collectively, these studies
suggest that ICOS co-stimulation may contribute more to the effector phase than to
the initiation of Th2-dominated allergic inflammatory responses (80, 92, 96, 125).
3.1.3 The CD40L:CD40 pathway
The importance of the CD40L:CD40 pathway in the induction of asthma-like
symptoms has only been investigated in mice deficient in either CD40L or CD40
(145-147). Because ligation of CD40 on B-cells, together with IL-4 (21), is required
for their activation and IgE isotype switching (122), the absence of (allergen-specific)
IgE in serum was anticipated in all of these studies. However, conflicting results
were obtained regarding the involvement of the CD40L:CD40 pathway in the
development of airway hyperresponsiveness and BALF eosinophilia.
3.1.4 Other receptor-ligand pairs involved in T-cell co-stimulation
Manifestations of allergic asthma were reduced in OX-40−/− mice (148), presumably
because of its regulation of the number of CD4+ T-cells that persist over time (149).
In OVA-sensitized and challenged CD81−/− mice, similar levels of OVA-specific
IgE were found, whereas airway hyperresponsiveness and lung inflammation were
reduced compared with wild-type mice (150). In immunized CD81−/− mice, antigen-
specific cytokine production by the draining lymph nodes was dramatically reduced
but proliferation was unaffected, as was cytokine production upon polyclonal
stimulation. Moreover, a slight increase in T-cells and a considerable decrease in B-
cells in peripheral lymphoid tissues were observed. Perhaps, the impaired Th2
response in vivo is due to the deficiency in T-cell interactions with B-cells and other
APCs (150).
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4 Blockade of T-cell co-stimulation in humans
Administration of CTLA4-Ig to patients with psoriasis vulgaris in a phase I trial
produced a dose-dependent improvement in skin lesions (151, 152). Also in patients
with rheumatoid arthritis, CTLA4-Ig and a second-generation molecule based on
CTLA4-Ig (LEA29Y) produced improvements in the signs and symptoms of the
disease according to standard criteria (153). After administration of recombinant
CD40L to cancer patients, encouraging antitumor activity, including a long-term
complete remission, was observed (154).
5 Aim and outline of this thesis
In this thesis, the role of various T-cell co-stimulatory molecules in OVA-induced
models of allergic asthma in BALB/c mice was further investigated to determine if
blockade of T-cell co-stimulation might be of therapeutic interest.
A recent study using a novel mouse strain lacking both CD28 and CTLA4
demonstrated considerable residual CD4+ T-cell proliferation in vitro that was
dependent on B7-1 or B7-2, suggesting the existence of an additional, third B7-1/
B7-2 receptor (108). In addition, CD28/CTLA4−/− mice mounted a substantial Th1-
mediated cardiac allograft rejection response in vivo, in contrast with long-term
allograft survival in B7-1/B7-2−/− mice (155, 156). In the study described in chapter
2, it was investigated if T-cell co-stimulation via the putative B7-1/B7-2 receptor
contributes to the induction of Th2-mediated manifestations of allergic asthma using
this novel CD28/CTLA4−/− mouse strain.
In contrast to animal studies in which the effect of an experimental treatment
on the development of asthma-like symptoms is examined, asthma patients usually
start therapy after the development of airway symptoms, while exposure to
environmental allergen mostly continues. Studies in vitro have demonstrated that
effector and memory T-cells are less dependent on co-stimulation in comparison
with naïve T-cells (48, 73, 74), whereas studies in vivo on the effectiveness of giving
CTLA4-Ig after priming of immune responses have yielded conflicting results (75).
To more closely resemble the OVA-induced animal model of allergic asthma to the
clinical situation, we designed a new protocol in which treatment starts after
development of airway inflammation while OVA exposures are continued (ongoing
model). After validation with the “gold-standard” corticosteroid dexamethasone,
CTLA4-IgG was applied in this ongoing murine model of allergic asthma (chapter
3).
Studies on the role of ICOS in murine models of allergic asthma have suggested
that ICOS has a more prominent role in the effector phase than in the initiation of
Th2-dominated allergic inflammatory responses (80, 92, 96, 125). Therefore, the
effects of ICOS blockade during the development of asthma-like symptoms in mice
(induction model) were compared with the effects of ICOS blockade after the
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development of airway symptoms when OVA exposures were continued (ongoing
model) (chapter 4).
In the absence of co-stimulation, TCR triggering results in the development of
antigen-specific T-cell anergy that is unresponsiveness to antigenic re-stimulation
in the presence of co-stimulation (Refs. 35-39 and paragraph 2). In vivo, blockade of
T-cell co-stimulation around the time of engraftment was shown to allow for long-
term allograft survival in several transplantation models (157). It has been
demonstrated both in vitro and in vivo that blockade of the CD28/CTLA4:B7-1/B7-
2 pathway in combination with the CD40L:CD40 pathway is more effective in the
induction of antigen-specific tolerance than blockade of either pathway alone (158-
162). Short-lived treatment of asthma patients that results in tolerance to the inhalant
allergen and hence long-lasting improved clinical status would be a very attractive
therapeutic approach. Therefore, in the study described in chapter 5, it was
investigated if blockade of T-cell co-stimulation during the aerosol challenge period
of OVA-sensitized mice results in long-term amelioration of asthma-like symptoms
that is, not only immediately after the aerosol challenge period but also upon OVA
re-challenge after serum clearance of experimental treatment (anti-CD40L mAb
(MR1), murine CTLA4-IgG or the combination of these agents).
In the last chapter, the main results of the studies described in chapters 2-5 are
summarized and discussed (chapter 6).
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ABSTRACT
The existence of a third B7-1/B7-2 receptor was postulated in a recent study using a
novel mouse strain lacking both CD28 and CTLA4 (CD28/CTLA4−/−) that
demonstrated a substantial B7-1/B7-2-dependent Th1-mediated cardiac allograft
rejection response, in contrast with long-term allograft survival in B7-1/B7-2−/− mice
(1). In the present study, we investigated if T-cell co-stimulation via the putative
B7-1/B7-2 receptor plays a role in the induction of Th2-mediated asthma-like
symptoms in mice. BALB/c wild-type, CD28/CTLA4−/− and B7-1/B7-2−/− mice were
sensitized and aerosol challenged with ovalbumin (OVA). At 24 h after the last
aerosol, wild-type mice showed airway hyperresponsiveness in vivo to methacholine
and up-regulated levels of serum OVA-specific IgE compared with the situation
shortly before OVA challenge. In addition, eosinophils and IL-5 in the broncho-
alveolar lavage fluid and Th2 cytokine production by lung cells upon OVA re-
stimulation in vitro were observed. In agreement with an earlier study, we failed to
induce any of the asthma-like symptoms in B7-1/B7-2−/− mice (2). Importantly, also
CD28/CTLA4−/− mice showed no asthma-like symptoms upon OVA sensitization or
challenge. These data clearly demonstrate that T-cell co-stimulation via the putative
B7-1/B7-2 receptor appears to have no role in the induction of Th2-mediated asthma-
like symptoms in this murine model and, conversely, that CD28 signaling is critical
(3-5).
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INTRODUCTION
Allergic asthma is a complex inflammatory disease of the airways characterized by
reversible airflow obstruction, persistent airway hyperresponsiveness to
bronchospasmogenic stimuli such as methacholine, chronic eosinophilic airway
inflammation, and airway remodeling (6). Allergen-specific CD4+ type 2 helper T-
(Th2) cells play a pivotal role in the pathogenesis and progression of allergic asthma
by orchestrating the inflammatory response (7).
Over the past decade, it is well established that for optimal activation, T-
lymphocytes require nonspecific co-stimulatory signals in addition to the antigen-
specific signal conferred by the T-cell receptor (TCR) (8-10). Although many
receptor-ligand pairs for T-cell co-stimulation have been identified since, CD28 is
the primary co-stimulatory molecule, constitutively present on the surface of T-
cells. Engagement of CD28 on naïve T-cells by its ligands B7-1 (CD80) or B7-2
(CD86) on antigen-presenting cells provides a potent co-stimulatory signal to T-
cells activated through their TCR that contributes to elements of T-cell activation
such as proliferation and IL-2 secretion. The second receptor for the B7-1/B7-2
ligands, CTLA4, is expressed on activated T-cells and delivers an inhibitory signal
to terminate the T-cell response (11). In experimental murine models of allergic
asthma, blockade of the CD28/CTLA4:B7-1/B7-2 pathway of T-cell co-stimulation
during the antigen sensitization and/or challenge period ameliorates the asthma-like
symptoms (12-17).
Interestingly, a recent study using a novel mouse strain lacking both CD28 and
CTLA4 (CD28/CTLA4−/−) provided evidence for the existence of an additional
receptor for the B7-1 and B7-2 molecules (1). In this study, CD28/CTLA4−/− CD4+
T-cells demonstrated considerable residual B7-1/B7-2-dependent proliferation upon
polyclonal stimulation in vitro. In addition, T-cell co-stimulation via this putative
B7-1/B7-2 receptor was shown to contribute substantially to Th1-mediated cardiac
allograft rejection in vivo, in contrast with long-term allograft survival in B7-1/B7-
2−/− mice (18, 19).
The role of this putative B7-1/B7-2 receptor in other T-cell-mediated disease
models is unknown at the moment. With regard to Th2-mediated allergic asthma, no
asthma-like symptoms can be induced in B7-1/B7-2−/− mice (2) nor in wild-type
mice treated with monoclonal antibodies (mAbs) against both B7-1 and B7-2
throughout the antigen sensitization and challenge period (4). In CD28−/− mice,
however, the failure to induce manifestations of allergic asthma is accompanied by
the presence of lymphocytes and IFN-γ in the broncho-alveolar lavage fluid (BALF)
(4, 20) and the priming of lymphocytes in the lungs, spleen and lymph nodes (4, 5,
20). These data on residual T-cell activation in CD28−/− mice but not in B7-1/B7-2−
/−
 mice (2), suggest a potential role for the putative B7-1/B7-2 receptor. Co-stimulation
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by the supposed B7-1/B7-2 receptor would then result in allergen-specific T-cell
activation that is not strong enough to induce the asthma-like symptoms. However,
the failure to induce these symptoms in CD28−/− mice might also be due to negative
signaling by CTLA4 (21-23) that opposes potential T-cell co-stimulation via the
putative B7-1/B7-2 receptor. So, unmasking the possible role of co-stimulation by
the supposed B7-1/B7-2 receptor in T-cell activation requires the absence of both
CD28 and CTLA4.
Therefore, in the present study, we investigated if T-cell co-stimulation via the
putative B7-1/B7-2 receptor contributes to the induction of Th2-dominated model
of allergic asthma using the novel CD28/CTLA4−/− mouse strain. To this end, BALB/
c wild-type mice, CD28/CTLA4−/− mice and B7-1/B7-2−/− mice were sensitized and
aerosol challenged with the experimental allergen ovalbumin (OVA). At 24 h after
the last OVA aerosol, wild-type mice show airway hyperresponsiveness to the non-
specific stimulus methacholine, allergen-specific IgE in serum and an infiltration of
eosinophils in the BALF. In addition, Th2-type cytokines were observed in the BALF
and supernatant of OVA re-stimulated lung cell cultures. In agreement with an earlier
study by Mark et al. (2), we failed to induce any of these asthma-like symptoms in
the B7-1/B7-2−/− mice. Interestingly, also CD28/CTLA4−/− mice showed no
manifestations of allergic asthma upon OVA sensitization and challenge. In addition,
we were unable to demonstrate signs of residual OVA-specific CD4+ T-cell activation
in CD28/CTLA4−/− mice. So, T-cell co-stimulation via the putative B7-1/B7-2 receptor
appears to have no role in the induction of Th2-mediated asthma-like symptoms in
this murine model. Conversely, further evidence is provided for the critical role of
CD28 signaling in the development of Th2-dominated allergic inflammatory
responses (3-5).
MATERIALS AND METHODS
Animals
Specific pathogen-free wild-type BALB/c mice were obtained from Charles River
(Someren, The Netherlands). BALB/c CD28/CTLA4−/− mice (1) and BALB/c B7-1/
B7-2−/− mice (24) were generated in the laboratory of Dr. A.H. Sharpe (Brigham and
Women’s Hospital and Harvard Medical School, Boston, MA, USA) which is an
institution accredited by the American Association for the Accreditation of Laboratory
Animal Care (AALAC). In the Netherlands, these mice were bred and maintained in
a pathogen-free animal facility of the Central Laboratory Animal Institute (Utrecht).
Female and male (4:2) 12-13 wk-old mice were used for our studies. Animal
care and use were performed in accordance with the guidelines of the Dutch
Committee of Animal Experiments.
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Antigen sensitization and challenge
All mice were sensitized and challenged with OVA (chicken egg albumin, crude
grade V, Sigma, St. Louis, MO, USA). Systemic sensitization was performed by two
intraperitoneal (i.p.) injections of 10 µg OVA adsorbed onto 2.25 mg aluminum
hydroxide (alum; ImjectAlum, Pierce, Rockford, IL, USA) in 0.1 ml pyrogen-free
saline on day 0 and 7. On day 35, 38 and 41, mice were challenged by inhalation of
an OVA aerosol in a plexiglass exposure chamber (5 liter) for 20 min. The aerosols
were generated by nebulizing an OVA solution (10 mg/ml in pyrogen-free saline)
using a Pari LC Star nebulizer (PARI Respiratory Equipment, Richmond, VA, USA;
particle size 2.5–3.1 µm) driven by compressed air at a flow rate of 6 liters/min.
Measurement of airway responsiveness in vivo
Airway responsiveness was measured in conscious, unrestrained mice on day 30 (5
d before the OVA aerosol challenge period) and at 24 h after the last OVA aerosol
challenge on day 42, by recording respiratory pressure curves in response to inhaled
nebulized methacholine (acetyl-β-methylcholine chloride; Sigma) using barometric
whole-body plethysmography (Buxco; EMKA Technologies, Paris, France). Airway
responses were expressed in enhanced pause (Penh), an index of airway obstruction
as described in detail previously (25). Briefly, mice were placed in a whole-body
chamber and pressure differences between this chamber and a reference chamber
were recorded. After baseline Penh values were obtained for 3 min and averaged,
animals were exposed to a saline aerosol and a series of methacholine aerosols
(solutions doubling in concentration, ranging from 1.56–50 mg/ml in saline). Aerosols
were generated by a Pari LC Star nebulizer for 3 min and after each nebulization
readings were taken for 3 min and averaged.
Determination of OVA-specific IgE levels in serum
At day –3 and day 32 (3 d before challenge), approximately 0.25 ml blood was
recovered from mice by an incision the tail vein. After measurement of airway
responsiveness in vivo at 24 h after the last OVA aerosol challenge on day 42, mice
were sacrificed by i.p. injection of 1 ml 10% urethane (Sigma) in sterile saline and
bled by cardiac puncture. Serum was prepared from blood samples and stored at -
20°C until determination of OVA-specific IgE levels by ELISA. Briefly, maxisorp
96-wells flat-bottomed microtiter plates (Nunc A/S, Roskilde, Denmark) were coated
overnight at 4°C with 1 µg/ml rat anti-mouse IgE mAb (clone R35-72, PharMingen,
San Diego, CA, USA) diluted in phosphate-buffered saline (PBS). The next day, the
ELISA was performed at room temperature using ELISA buffer (PBS containing
0.5% bovine serum albumin [BSA, Sigma], 2 mM EDTA, 136.9 mM NaCl, 50 mM
Tris, 0.05% Tween-20 [Merck, Whitehouse Station, NJ, USA], pH 7.2) for blocking
and dilution of samples, standard and reagents and PBS containing 0.05% Tween-20
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for washing between incubations. After blocking of wells for 1 h, serum samples
and a duplicate dilution series of an OVA-specific reference serum (starting 1:40)
were added to the wells and incubated for 2 h. An OVA-specific IgE reference serum
was obtained by sensitization and challenge of mice with OVA as above-decribed
and arbitrarily assigned a value of 1,000 experimental units/ml (EU/ml). Hereafter,
1 µg/ml of OVA labeled to digoxigenin (DIG) by a DIG protein labeling kit (Roche
Diagnostics, Basel, Switzerland) was added for 1.5 h, followed by incubation with
1:500 diluted anti-DIG-Fab fragments coupled to horseradish peroxidase (Roche
Diagnostics) for 1 h. Color development was performed with o-phenylenediamine-
dichloride substrate (0.4 mg/ml, Sigma) and 4 mM H2O2 in PBS and the reaction
was stopped by adding 4 M H2SO4. The optical density was read at 490 nm, using a
Benchmark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). Results
were analyzed with Microplate Manager PC software (Bio-Rad Laboratories). The
lower detection limit of the ELISA was 4 EU/ml IgE.
Analysis of the BALF
BAL was performed immediately after bleeding of the mice as described in detail
previously (26). Briefly, the airways were lavaged through a tracheal cannula with 1
ml saline at 37°C containing 5% BSA and 2 µg/ml aprotinine (Roche Diagnostics).
The recovered lavage fluid of this first ml was kept apart for determination of the
amount of IL-5 in the supernatant by ELISA. Subsequently, mice were lavaged four
times with 1 ml aliquots of saline only at 37°C. Recovered lavage fluid of the second
through fifth ml was pooled and cells (including those from the first ml) were pelleted
(387 × g, 4°C, 10 min), and resuspended in 0.15 ml cold PBS. The total number of
cells in the BALF was determined using a Bürker-Türk counting-chamber (Karl
Hecht Assistent KG, Sondheim/Röhm, Germany). For differential BALF cell counts,
cytospin preparations were made (15 × g, 4°C, 5 min) using a cytocentrifuge (Shandon
Life Science, Cheshire, UK), and cells were fixed and stained with Diff-Quick (Dade
A.G., Düdingen, Switzerland). Per cytospin, at least 200 cells were counted and
differentiated into mononuclear cells (monocytes, macrophages and lymphocytes),
eosinophils and neutrophils by standard morphology and staining characteristics.
The investigator counting the cells was blinded to the treatment groups.
Culture of lung cells
Lungs were lavaged as above-described and perfused via the right heart ventricle
with 4 ml saline at 37°C containing 100 U/ml heparin (Leo Pharmaceuticals, Weesp,
The Netherlands) to remove any blood and intravascular leukocytes. Complete lung
tissue was removed and transferred to cold sterile PBS. Lungs were then minced and
digested in 3 ml RPMI 1640 containing 2.4 mg/ml collagenase A and 1.0 mg/ml
DNase I (grade II) (both from Roche Diagnostics) for 30 min at 37°C. Enzyme
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activity was stopped by adding 1 ml fetal calf serum (FCS). The lung tissue digest
was filtered through a 70-µm nylon cell strainer (Becton Dickinson Labware, Franklin
Lakes, NJ, USA) with 10 ml RPMI 1640 to obtain a single-cell suspension. The
lung-cell suspension was washed, resuspended in culture medium (RPMI 1640
supplemented with 10% FCS, 1% glutamax I and gentamicin [both from Life
Technologies, Gaithersburg, MD, USA] and 50 µM β-mercaptoethanol [Sigma]),
and the total number of lung cells was determined using a Bürker-Türk counting-
chamber. Lung cells (8 × 105 lung cells/well) were cultured in 96-well round-bottomed
plates (Greiner Bio-One, Kremsmuenster, Austria) in the presence or absence of
OVA (10 µg/ml). In addition, lung cells were polyclonally stimulated with plate-
bound rat anti-mouse CD3 mAb (clone 17A2 rIgG2b, 50 µg/ml, coated overnight at
4°C). The hybridoma for the 17A2 mAb to CD3 was obtained from the American
Type Tissue Collection, Manassas, VA, USA) and purified Ab was used. After 5 d
of culture at 37°C in 5% CO2, the supernatant was harvested, and stored at -20°C
until determination of cytokine levels by ELISA.
Measurement of cytokines
Supernatants of the first ml BALF and lung cell-cultures were analyzed for IFN-γ,
IL-5 and IL-10 content by sandwich ELISA using Ab pairs and standards purchased
from PharMingen, according to the manufacturer’s instructions. The lower detection
limits of the ELISAs were 16 pg/ml for IFN-γ, 32 pg/ml for IL-5, and 63 pg/ml for
IL-10.
Statistical analysis
All data are expressed as mean ± standard error of mean (SEM). The airway dose-
response curves to methacholine were statistically analyzed by a general linear model
of repeated measurements followed by post-hoc comparison between groups. Data
were log10 transformed before analysis to equalize variances in all groups. Statistical
analysis on BALF cell counts was performed using the non-parametric Mann Whitney
U test. For all other parameters, results were statistically analyzed using a Student’s
t test (two-tailed, homosedastic). Differences between groups were considered
statistically significant at the p < 0.05 level. Statistical analyses were performed
using SPSS for Windows version 10.0.5 (SPSS, Chicago, IL, USA).
RESULTS
BALB/c wild-type, CD28/CTLA4−/− and B7-1/B7-2−/− mice were i.p. sensitized to
10 µg OVA adsorbed to alum on day 0 and 7 and aerosol challenged with a 1.0%
OVA solution for 20 min on day 35, 38 and 41.
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Absence of OVA-specific IgE in the sera from CD28/CTLA4−/− and B7-1/B7-2−/− mice
To determine allergen-specific IgE levels in serum, blood was withdrawn from each
mouse before sensitization to OVA (pre-serum), after sensitization but before the
OVA aerosol challenge period (post-sensitization serum) and at 24 h after the last
OVA aerosol (final serum). In the pre-sera from the three BALB/c strains, no OVA-
specific IgE could be detected. After sensitization to OVA, antigen-specific IgE was
found in the sera from wild-type mice (11,664 ± 2,034 EU/ml) and these levels were
greatly up-regulated upon OVA aerosol challenge (103,487 ± 15,811 EU/ml, p <
0.0005). In contrast, in both the post-sensitization- and final sera from CD28/CTLA4−
/−
 and B7-1/B7-2−/− mice the amount of OVA-specific IgE was below the detection
level of the ELISA (4 EU/ml).
These data suggest that no sensitization to OVA had taken place in the animals
deficient in CD28 and CTLA4 or the B7 molecules.
Absence of airway hyperresponsiveness in CD28/CTLA4−/− and B7-1/B7-2−/− mice
Airway responsiveness in vivo to methacholine was determined in conscious,
unrestrained mice by barometric whole-body plethysmography and was first measured
after sensitization to OVA but before the aerosol challenge period. As shown in
Figure 1, all three OVA-sensitized BALB/c strains, demonstrated a dose-dependent
increase in Penh, an index of airway obstruction, in response to aerosolized
methacholine and the complete methacholine dose-response curves (DRCs) did not
differ between the strains (p =1 for each combination of two strains). Airway
responsiveness in vivo was measured again at 24 h after the last OVA aerosol.
Figure 1: Absence of airway hyperresponsiveness in CD28/CTLA4−/− and B7-1/B7-2−/− mice.
BALB/c wild-type (first and second bar), CD28/CTLA4−/−- (third and fourth bar) and B7-1/B7-2−/−
mice (fifth and sixth bar) were sensitized to OVA adsorbed to alum and challenged with three OVA
aerosols. Airway responsiveness in vivo to aerosolized methacholine was measured in conscious,
unrestrained mice by whole-body plethysmography before (striped bars) and at 24 h after (plain bars)
the OVA aerosol challenge period. Values are expressed as mean ± SEM (n = 5-6 per group).
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Upon OVA aerosol challenge, wild-type mice developed airway hyperresponsiveness
because the second methacholine DRC is significantly different from the DRC
obtained before challenge in this group of mice (p < 0.05). In contrast, airway
responsiveness to methacholine before- and at 24 h after the OVA aerosol challenge
period was not different in CD28/CTLA4−/− and B7-1/B7-2−/− mice, when comparing
the complete DRCs (p = 1 and p = 1, respectively). Comparing the airway responses
to the separate concentrations of the methacholine DRC before- and after OVA
challenge, CD28/CTLA4−/− mice showed airway hyperresponsiveness to 50 mg/ml
methacholine (p < 0.05) (Figure 1). However, in a duplicate experiment, CD28/
CTLA4−/− mice demonstrated no induction of hyperresponsiveness upon OVA
challenge to each separate concentration of the methacholine DRC (data not shown).
So, no residual airway hyperresponsiveness was induced in mice lacking both
CD28 and CTLA4 upon OVA-sensitization and challenge.
Absence of eosinophils and IL-5 in the BALF from CD28/CTLA4−/− and
B7-1/B7-2−/− mice
The number of various leukocytes in the BALF was used as a measure for the
infiltration of these cells in the airways and was determined at 24 h after the last
OVA aerosol challenge. OVA sensitization and challenge from wild-type mice
resulted in an influx of inflammatory cells in the BALF, predominantly eosinophils
besides mononuclear cells (monocytes, macrophages and lymphocytes) and a few
neutrophils (Figure 2). In contrast, as in naïve wild-type mice (data not shown), only
mononuclear cells were present in the BALF from CD28/CTLA4−/− and B7-1/B7-2−
/−
 mice upon OVA-sensitization and challenge and the number of mononuclear cells
was significantly less compared with OVA-sensitized and challenged wild-type mice
(p < 0.005 and p < 0.05, respectively).
Figure 2: Absence of eosinophils in the BALF from CD28/CTLA4−/− and B7-1/B7-2−/− mice.
BALB/c wild-type (open bars), CD28/CTLA4−/− (closed bars) and B7-1/B7-2−/− mice (shaded bars)
were sensitized to OVA adsorbed to alum and challenged with three OVA aerosols. At 24 h after the
last OVA aerosol challenge, BALF was recovered and the cellular composition was determined. Values
are expressed as mean ± SEM (n = 5-6 per group).
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The influx of inflammatory cells in the BALF of OVA-sensitized and challenged
wild-type mice was accompanied by the presence of IL-5 (0.67 ± 0.08 ng/ml), but no
detectable levels of IFN-γ, pointing to a Th2-dominated response. Because IL-5 is
involved in the migration of eosinophils, this is in accordance with the BALF
eosinophilia observed in this group of mice. In contrast, no IL-5 (and no IFN-γ)
could be detected in the BALF from CD28/CTLA4−/− and B7-1/B7-2−/− mice.
So, no residual Th2-dominated inflammatory response could be observed in
the BALF from CD28/CTLA4−/− mice upon OVA-sensitization and challenge.
Lung T-cells from CD28/CTLA4−/− and B7-1/B7-2−/− mice are not primed
A single-cell suspension of lung tissue was prepared at 24 h after the last OVA
aerosol. To determine antigen-specific T-cell cytokine responses, lung cells were
re-stimulated with 10 µg/ml OVA for 5 d. In addition, lung T-cells were polyclonally
stimulated with 50 µg/ml anti-CD3 mAb to determine their intrinsic capacity to
produce cytokines or cultured with medium only.
Lung cell cultures derived from OVA-sensitized and challenged wild-type mice
only produced a small amount of IFN-γ upon stimulation with anti-CD3 mAb (0.042
± 0.014 ng/ml) (Figure 3) and this amount was reduced compared with cultures from
naïve wild-type mice (0.128 ± 0.021 ng/ml; data not shown in Figure 3). However,
these cultures produced fair amounts of the Th2 cytokines IL-5 and IL-10 upon re-
stimulation with OVA (8.20 ± 1.35 ng/ml and 4.73 ± 1.48 ng/ml, respectively) and
polyclonal stimulation (7.97 ± 1.45 ng/ml and 3.31 ± 0.71 ng/ml, respectively). So,
OVA-specific T-cells were present in lung tissue derived from OVA-sensitized and
challenged wild-type mice that showed a clear Th2-response upon antigenic re-
stimulation in vitro.
Polyclonal stimulation of lung cell cultures derived from CD28/CTLA4−/− and
B7-1/B7-2−/− mice sensitized and challenged with OVA, resulted in significantly
more IFN-γ production (0.52 ± 0.09 ng/ml, p <0.005 and 0.39 ± 0.13 pg/ml, p <0.05,
respectively) compared with cultures from OVA-sensitized and challenged wild-
type mice (0.042 ± 0.014 ng/ml). In contrast, significantly less IL-10 could be observed
in the supernatant of these cultures after 5 d of stimulation with anti-CD3 mAb (1.09
± 0.12 ng/ml, p < 0.01 and 0.69 ± 0.17 pg/ml, p < 0.01, respectively), compared with
those from OVA-sensitized and challenged wild-type mice (3.31 ± 0.71 ng/ml). IL-
5 could only be detected in the supernatant of cultures derived from CD28/CTLA4−
/−
 mice (0.94 ± 0.25 ng/ml) and this amount was significantly less compared with
cultures from OVA-sensitized and challenged wild-type mice stimulated with anti-
CD3 mAb (7.97 ± 1.45 ng/ml, p < 0.001). Antigenic re-stimulation of lung cell
cultures from OVA-sensitized and challenged CD28/CTLA4−/− and B7-1/B7-2−/− mice
did not result in cytokine production above medium control values.
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Figure 3: Lung T-cells from CD28/CTLA4−/− and B7-1/B7-2−/− mice are not primed.
BALB/c wild-type (open bars), CD28/CTLA4−/− (closed bars) and B7-1/B7-2−/− mice (shaded bars)
were sensitized to OVA adsorbed to alum and challenged with three OVA aerosols. At 24 h after the
last OVA aerosol challenge, a single-cell suspension of lung tissue was prepared. Lung cells were
stimulated for 5 d with 50 µg/ml anti-CD3 mAb or 10 µg/ml OVA or cultured with medium only and
IFN-γ, IL-5 and IL-10 in the supernatant of the cultures was determined. Values are expressed as
mean ± SEM (n = 5-6 per group).
So, these data suggest that T-cells present in lung tissue derived from CD28/
CTLA4-/- and B7-1/B7-2-/- mice were not primed after sensitization and challenge
with OVA in vivo, as determined by undetectable cytokine production upon OVA
re-stimulation ex vivo. Interestingly, these unprimed T-cells seemed to be
characterized by an enhanced IFN-γ reactivity because these cultures produced
significantly more IFN-γ upon polyclonal stimulation not only compared with wild-
type mice sensitized and challenged with OVA but also in comparison with naïve
wild-type mice (data not shown in Figure 3).
DISCUSSION
A recent study using a novel mouse strain lacking both CD28 and CTLA4
demonstrated considerable residual CD4+ T-cell proliferation in vitro that was
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dependent on B7-1 or B7-2, suggesting the existence of an additional third B7-1/B7-
2 receptor (1). In addition, CD28/CTLA4−/− mice mounted a substantial Th1-mediated
cardiac allograft rejection response in vivo, in contrast with long-term allograft
survival in B7-1/B7-2−/− mice (18, 19). The role of this putative B7-1/B7-2 receptor
in other T-cell-mediated disease models is unknown at the moment. Therefore, in
the present study, we investigated if T-cell co-stimulation via the supposed B7-1/
B7-2 receptor has a role in the induction of Th2-dominated murine model of allergic
asthma. Sensitization and aerosol challenge of wild-type mice with OVA resulted in
airway hyperresponsiveness to methacholine and the influx of eosinophils in the
BALF, cardinal airway features of patients suffering from allergic asthma. In addition,
OVA-specific IgE in serum, IL-5 in the BALF and Th2 cytokine production by lung
cells upon OVA re-stimulation in vitro were observed. In agreement with an earlier
study (2), we failed to induce any of the asthma-like symptoms in the B7-1/B7-2−/−
mice. Interestingly, also CD28/CTLA4−/− mice showed no manifestations of allergic
asthma upon OVA sensitization and challenge. So, these data clearly demonstrate
that T-cell co-stimulation via the putative B7-1/B7-2 receptor appears to have no
role in the induction of Th2-mediated asthma-like symptoms in this murine model.
Conversely, these data provide further evidence for the critical role of CD28 signaling
in the development of Th2-dominated allergic inflammatory responses (3-5).
Previously, it has been demonstrated that no asthma-like symptoms can be
induced in CD28−/− mice (4, 5, 20). In these mice, however, the contribution of other
molecules including the putative B7-1/B7-2 receptor to T-cell co-stimulation might
be masked by negative signaling via CTLA4 (21-23). Following the observation
that no manifestations of allergic asthma could be induced in CD28−/− mice, two
research groups administered CTLA4-Ig to these mice (4, 5) to determine whether
the absence of asthma-like symptoms was due exclusively to the lack of a positive
signal by CD28 or whether an unopposed negative signal via CTLA4 was inhibiting
the T-cell response. Incongruent results were obtained because in one study CTLA4-
Ig administration had no effect (4), whereas treatment of CD28−/− mice with CTLA4-
Ig restored lymphocyte but not eosinophil recruitment to the airways in the second
study (5).
Importantly, CTLA4-Ig prevents the interaction of the B7-1 and B7-2 molecules
with both CTLA4 and the putative B7-1/B7-2 receptor, thus not allowing for
discrimination between these two pathways regulating T-cell activation. In addition,
treatment of mice with CTLA4-Ig might leave some B7-1 and B7-2 molecules
uncovered (27) that may bind CTLA4 (and the supposed B7-1/B7-2 receptor), whereas
deficiency of a gene encoding a particular molecule guarantees the complete absence
of this molecule. Therefore, unraveling the potential role of co-stimulation by the
putative B7-1/B7-2 receptor required the absence of both CD28 and CTLA4. This
study demonstrates that the additional deficiency of the CTLA4 molecule in mice
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did not result in considerable residual manifestations of allergic asthma by unmasking
co-stimulation via the supposed B7-1/B7-2 receptor.
In CD28−/− mice, the failure to induce manifestations of allergic asthma is
accompanied by signs of residual T-cell activation; lymphocytes and IFN-γ are present
in the BALF (4, 20) and lymphocytes obtained from the lungs, spleen and lymph
nodes respond to antigenic re-stimulation in vitro (4, 5, 20). Likewise, the absence
of the key airway features in CD28/CTLA4−/− mice might leave open the possibility
that OVA-specific CD4+ T-cells in these mice are in fact co-stimulated via the putative
B7-1/B7-2 receptor, resulting in T-cell activation that is not strong enough to induce
airway pathology. However, the data presented in this report provide no evidence
for residual T-cell activation in CD28/CTLA4−/− mice. First, the amount of antigen-
specific IgE in serum after OVA immunization was below the detection level,
suggesting that no or insufficient systemic Th2 cells have developed because B-
cells require help by systemic Th2 cells for isotype switching to IgE (28). It should
be noted, that airway hyperresponsiveness in vivo and airway eosinophilia can be
induced in mice in the absence of systemic IgE (29) but has been shown to be critically
dependent on CD4+ cells (30-33). Second, T-cells present in lung tissue derived
from CD28/CTLA4−/− mice produced no cytokines upon antigenic re-stimulation in
vitro, indicating that they were not primed upon OVA sensitization and challenge in
vivo.
Yet it remained possible, that OVA-specific CD28/CTLA4−/− CD4+ cells in the
lung draining lymph nodes were co-stimulated via the putative B7-1/B7-2 receptor
but had failed to migrate to the airways. To test this hypothesis, also the thoracic
lymph nodes (TLNs) were isolated at 24 h after the last OVA aerosol challenge in
the presented experiment. Whereas wild-type, CD4+ lymphocytes produced a small
amount of IFN-γ and fair amounts of IL-4, IL-5 and IL-10 upon polyclonal stimulation
in vitro, no cytokines were detectable in the supernatant of CD4+ TLN cell cultures
derived from both CD28/CTLA4−/− and B7-1/B7-2−/− mice (data not shown). In
addition, the percentage of CD4+ cells in the TLN was very similar in OVA-sensitized
and challenged CD28/CTLA4−/− and B7-1/B7-2−/− mice, indicating that no residual
CD4+ T-cell expansion had occurred in CD28/CTLA4−/− mice. Finally, FACS analysis
demonstrated no enhanced expression of activation markers such as CD25, CD62L
and CD69 on CD4+ TLN cells obtained from CD28/CTLA4−/− mice in comparison
with B7-1/B7-2−/− mice (data not shown). In conclusion, we were unable to
demonstrate any sign of residual T-cell activation in both the TLNs and lungs from
CD28/CTLA4−/− mice upon OVA-sensitization and challenge in vivo.
The discrepancy of residual T-cell activation in CD28−/− mice (4, 5, 20) versus
no signs of T-cell activation in CD28/CTLA4−/− mice in this experiment might be
explained by the different antigens and protocols used for the induction of
manifestations of allergic asthma. For example, Mathur et al. used eggs and antigen
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of the Schistosoma mansoni parasite (4) and Lambrecht et al. passively sensitized
naïve CD28−/− mice with OVA-pulsed myeloid dendritic cells (20).
Antigenic re-stimulation of lung cell cultures from OVA-sensitized and
challenged CD28/CTLA4−/− and B7-1/B7-2−/− mice did not result in Th1 or Th2
cytokine production above medium control values. Interestingly, the seemingly
unprimed T-cells from both OVA-sensitized and challenged CD28/CTLA4−/− and
B7-1/B7-2−/− mice were characterized by an enhanced IFN-γ reactivity. Lung cell
cultures derived from these mice produced more IFN-γ upon polyclonal stimulation,
not only compared with wild-type mice displaying Th2-mediated asthma-like
symptoms upon OVA sensitization and challenge but also compared with naïve wild-
type mice. In agreement herewith, BALF CD4+ T-cells obtained after challenge
from passively sensitized CD28−/− mice were shown to have an increased tendency
to produce IFN-γ upon polyclonal stimulation compared with wild-type mice (20).
Moreover, CD4+ CD28/CTLA4−/− cells produced more IFN-γ and less IL-4 and IL-
10 upon secondary polyclonal stimulation in vitro compared with wild-type CD4+
cells (1). These findings are consistent with the importance of CD28 for Th2
differentiation (3). In addition, this observation might explain why it is seems
impossible to prime antigen-specific T-cells towards the Th2 phenotype -as opposed
to a Th1-mediated cardiac allograft rejection (1, 19, 23, 34)- even though a protocol
was used that normally results in very strong Th2-mediated inflammatory responses
in BALB/c mice. However, the enhanced IFN-γ reactivity did not prime OVA-specific
T-cells towards the Th1 phenotype either as observed locally in lung T-cell re-
stimulation and systemically by the absence of the Th1 cell-dependent IgG2a isotype
(35). In wild-type mice, besides a high level of IgE also OVA-specific IgG2a can be
detected upon sensitization and challenge with OVA (data not shown).
Apparently, the putative B7-1/B7-2 receptor has a differential role in Th1-
mediated cardiac allograft rejection and Th2-mediated allergic asthma. Perhaps, the
expression of the supposed B7-1/B7-2 receptor is differentially regulated on Th1
versus Th2 cells. Indeed, T helper cells can be divided not only on the basis of their
cytokine profile but also on their differential expression (kinetics) of cell surface
molecules such as chemokine receptors and the CD28-related T-cell co-stimulator
(ICOS) (36-38). Future studies regarding the induction of other T-cell-mediated
diseases in CD28/CTLA4−/− mice might help to clarify the precise role of the supposed
B7-1/B7-2 receptor in T-cell responses. Ultimately, cloning of the gene encoding
the putative B7-1/B7-2 receptor will greatly facilitate research on this receptor.
Whereas CD28−/− mice are still capable of raising a number of in vivo immune
responses, including cardiac allograft rejection (1, 19, 23, 34), induction of allogeneic
graft-versus-host disease (39), generation of cytotoxic T-cells (40) and certain
delayed-type hypersensitivity responses (41), the present study provides further
evidence for the critical role of CD28 signaling in the development of Th2-dominated
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allergic inflammatory responses (3-5, 20). Moreover, as anticipated by the data on
the failure to induce asthma-like symptoms in B7-1/B7-2−/− mice (Ref. 2 and this
study), T-cell co-stimulatory receptors that interact with other ligands than B7-1 and
B7-2, e.g. ICOS, appear to play no major role in the induction of asthma manifestations
in this model. So, blockade of CD28 in allergic asthma appears to be a very promising
therapeutic option.
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ABSTRACT
We investigated whether CTLA4-Ig can reverse established asthma manifestations
in a novel murine model of ongoing disease. In BALB/c mice, sensitized to ovalbumin
(OVA) without adjuvant, airway inflammation was induced by a first series of OVA
aerosol challenges. Murine CTLA4-IgG was then administered, followed by a second
series of OVA inhalations. In control-treated mice, two series of OVA challenges
induced up-regulation of OVA-specific IgE in serum, eosinophils in the broncho-
alveolar lavage fluid (BALF) and IL-5 production by lung lymphocytes upon OVA
re-stimulation in vitro, compared with saline-challenged mice. CTLA4-IgG
significantly inhibited all of these parameters in OVA-challenged mice. Importantly,
mCTLA4-IgG performed better than the gold-standard dexamethasone because this
corticosteroid did not inhibit the up-regulation of OVA-specific IgE in serum. In a
more “severe” ongoing model, induced by sensitization to OVA emulsified in
aluminum hydroxide, resulting in airway hyperresponsiveness to methacholine and
stronger inflammatory responses, mCTLA4-IgG was less effective in that only the
number of eosinophils in the BALF was reduced (p = 0.053), whereas dexamethasone
inhibited both BALF eosinophilia and cytokine production by lung lymphocytes.
So, CTLA4-Ig might be an effective alternative therapy in established allergic asthma,
especially in situations of mild disease.
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INTRODUCTION
Allergic asthma is prevalent worldwide, but especially in developed countries its
prevalence is increasing to epidemic proportions (1). Patients with asthma suffer
from acute broncho-constriction and mucus formation directly after inhalation of
the allergen. Chronic symptoms include
airway hyperresponsiveness to broncho-spasmogenic stimuli, inflammation and
airway remodeling.
CD4+ T helper cells recognizing the allergenic peptides and differentiating into the
type 2 subset of CD4+ T helper cells (Th2 cells), are crucial for the initiation and
progression of allergic asthma (2). Th2 cells are characterized by the array of cytokines
they secrete, which are optimized to combat parasite infections (3). However, Th2
cells are developed undesirably in allergic disorders such as asthma, their cytokines
causing airway symptoms either directly or mediated by other immune cells and
their mediators (4).
In view of the essential role of Th2 cells in allergic asthma, these cells are
interesting target cells for therapy. One therapeutic strategy is the prevention of
optimal activation of allergen-specific CD4+ T-cells by blocking their co-stimulatory
requirements. For complete activation, CD4+ T-cells need nonspecific co-stimulatory
signals in addition to the signal provided by the T-cell receptor (TCR) after interacting
with the MHC class II/antigenic peptide complex on the same antigen-presenting
cell. CD28 is the primary T-cell co-stimulatory molecule, constitutively present on
the surface of T-cells. Upon interaction with its ligands B7-1 (CD80) and/or B7-2
(CD86), CD28 tranduces a signal that enhances T-cell proliferation and cytokine
secretion and sustains the T-cell response. The second receptor for the B7 ligands,
CTLA4 (CD152) is detectable on the cell surface 24 h after T-cell activation in vitro
and in vivo and down-regulates T-cell responses. Because CTLA4 has a higher affinity
for the B7 ligands compared with CD28, CTLA4-Ig has been widely used to block
T-cell co-stimulation in an array of experimental animal models of T-cell-mediated
diseases (5).
Previous studies have shown that blockade of T-cell co-stimulation by
administration of CTLA4-Ig ameliorates the asthmatic manifestations in murine
models (6-10). In all of these studies, CTLA4-Ig was administered before the onset
of asthma manifestations. However, asthmatic patients start therapy after the onset
of T-cell-mediated airway symptoms, while exposure to environmental allergen very
often continues. In addition, it has been shown that memory- and recently activated
effector T-cells are less dependent on CD28-mediated co-stimulation for their
activation than naïve T-cells (11-14). This might limit the therapeutic potential of
CTLA4-Ig when administered after the development of T-cell-mediated airway
symptoms in an ongoing disease.
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To more closely resemble our adjuvant-free, ovalbumin (OVA)-induced animal
model of allergic asthma (15, 16) to the clinical situation, we designed a new protocol
in which treatment starts after the onset of airway inflammation while OVA exposures
continue. In the present study, we applied murine CTLA4-IgG in this model of
ongoing disease to determine if co-stimulatory blockade is also effective after the
onset of T-cell-mediated airway inflammation. We are the first to demonstrate that,
in an ongoing murine model of allergic inflammation, mCTLA4-IgG significantly
inhibited the up-regulation of OVA-specific IgE in serum, the number of eosinophils
in broncho-alveolar lavage fluid (BALF) and IL-5 production by lung lymphocytes
in vitro. Importantly, mCTLA4-IgG performed better than the gold-standard
dexamethasone because this corticosteroid did not inhibit the up-regulation of OVA-
specific IgE in serum. In a more “severe” ongoing model, induced by sensitization
to OVA emulsified in aluminum hydroxide (alum) resulting in airway
hyperresponsiveness and stronger inflammatory responses, mCTLA4-IgG was less
effective in that only the number of eosinophils in the BALF was reduced (p =0.053),
whereas dexamethasone inhibited both BALF eosinophilia and cytokine production
by lung lymphocytes.
MATERIALS AND METHODS
Animals
Animal care and use were performed in accordance with the guidelines of the Dutch
Committee of Animal Experiments. Specific pathogen-free male BALB/c mice (6
wk old) were obtained from the Central Laboratory Animal Institute (Utrecht, The
Netherlands). The mice were housed in macrolon cages in a laminar flow cabinet
and provided with food and water ad libitum.
Sensitization and challenge
All mice were sensitized to OVA (chicken egg albumin, crude grade V, Sigma, St.
Louis, MO). Active sensitization was performed without an adjuvant by giving seven
intraperitoneal (i.p.) injections of 10 µg OVA in 0.5 ml pyrogen-free saline on alternate
days (one injection per day). Three weeks after the last sensitization, mice were
exposed to either 16 OVA challenges (2 mg/ml in pyrogen-free saline) or 16 saline
aerosol challenges for 5 min on consecutive days (one aerosol per day). An additional
group of mice first received eight OVA aerosols, followed by eight saline aerosols
(OVA/saline, “spontaneous resolution group”) (see Table 1).
For the experiment in the more “severe” ongoing model, all mice were sensitized
to OVA by active sensitization with two i.p. injections (7 d apart) of 0.1 ml alum-
precipitated antigen, comprising 10 µg OVA adsorbed onto 2.25 mg alum
(ImjectAlum; Pierce, Rockford, IL). Two weeks after the second sensitization, mice
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were exposed to either six OVA challenges (10 mg/ml in pyrogen-free saline) or six
saline aerosol challenges for 20 min every third day (one aerosol every third day).
An additional group of mice first received three OVA aerosols, followed by three
saline aerosols (OVA/saline, “spontaneous resolution group”) (see Table 2).
The aerosol was performed in a plexiglas exposure chamber (5 liter) coupled to
a Pari LC Star nebulizer (PARI Respiratory Equipment, Richmond, VA; particle
size 2.5–3.1 µm) driven by compressed air at a flow rate of 6 liters/min. Aerosol was
given in groups composed of no more than eight animals.
Experimental treatment protocols
Both saline and OVA-challenged mice were divided in two groups of eight mice.
One group of mice received experimental treatment, and the other group received
control treatment. The spontaneous resolution group received control treatment in
both independent experiments.
In experiment A, murine CTLA4-IgG fusion protein was used as the experimental
treatment, consisting of murine CTLA4 fused via an ECD-immunoglobulin junction
to the hinge and Fc regions of human IgG1 (9). Human total IgG was used as control
treatment in this experiment. Ten minutes before the ninth aerosol, mice were
intravenously (i.v.) injected with 110 µl saline containing either 143 µg mCTLA4-
IgG or human total IgG. Ten minutes before each of the seven following aerosols,
mice were subcutaneously injected with 72 µg of the antibodies in a volume of 55
µl. In experiment B, dexamethasone (1:40 diluted in saline) was used as experimental
treatment and saline as control treatment. Ten minutes before the ninth through the
sixteenth aerosol, mice were injected i.p. with 0.0125 mg dexamethasone in 0.25 ml
pyrogen-free saline or saline alone (see Table 1).
In the experiment using the more “severe” ongoing model, the group of saline-
challenged mice (n = 8) and the spontaneous resolution group (n = 8) received control
treatment. OVA-challenged animals were divided into three groups of eight animals
each, receiving either control treatment, murine CTLA4-IgG fusion protein or
dexamethasone. Ten minutes before the fourth aerosol, a single dose of control
treatment (human total IgG, 280 µg in 0.2 ml saline) or murine CTLA4-IgG fusion
protein (280 µg in 0.2 ml saline) was i.v. administered. This single dose resulted in
very similar concentrations of the antibodies in the final sera as observed in those
from the experiment in the milder ongoing model of airway inflammation.
Dexamethasone treatment (0.0125 mg in 0.25 ml pyrogen-free saline) was started
10 min before the fourth aerosol and was followed by six daily i.p. injections (one
injection per day) during the period of the second series of OVA aerosols (see Table
2).
Human total IgG was purchased from ICN Pharmaceuticals (Costa Mesa, CA)
and dissolved in saline. This solution was treated with 10% (v/v) polymyxin B-
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agarose (Sigma) for 1 h at 4oC to remove lipopolysaccharide. After incubation, the
agarose-beads were removed by centrifugation and the supernatant was sterilized.
Murine CTLA4-IgG fusion protein was kindly provided by Dr. P. Jardieu
(Immunology, Genentech, South San Francisco, CA) and constructed as described
previously (9). The endotoxin level was less than 1 endotoxin U/mg. Dexamethasone
(Dexadreson) was purchased from Intervet Nederland BV (Boxmeer, The
Netherlands).
In all experiments, airway responsiveness to methacholine, OVA-specific IgE
levels in serum, cellular infiltration in the BALF and T-cell responses in lung tissue
were measured 24 h after the last challenge in each mouse.
Measurement of airway responsiveness in vivo
Airway responsiveness was measured in conscious, unrestrained mice using
barometric whole-body plethysmography by recording respiratory pressure curves
(Buxco; EMKA Technologies, Paris, France) in response to inhaled methacholine
(acetyl-β-methylcholine chloride; Sigma). Airway responsiveness was expressed in
enhanced pause (Penh), as described in detail previously (17). Briefly, mice were
placed in a whole-body chamber and basal readings were obtained and averaged for
3 min. Aerosolized saline, followed by doubling concentrations of methacholine
(ranging from 1.6–50 mg/ml saline), were nebulized for 3 min and readings were
taken and averaged for 3 min after each nebulization. Dose-response curves to
methacholine were statistically analyzed by a general linear model of repeated
measurements followed by post-hoc comparison between groups. Data were LOG
transformed before analysis to equalize variances in all groups.
Determination of OVA-specific IgE levels in serum
After measurement of in vivo airway responsiveness, mice were sacrificed by i.p.
injection of 1 ml 10% urethane in pyrogen-free saline (Sigma). Subsequently, mice
were bled by cardiac puncture and OVA-specific IgE was measured by ELISA.
Briefly, microtiter plates (Nunc A/S, Roskilde, Denmark) were coated overnight at
4°C with 2 µg/ml rat anti-mouse IgE monoclonal antibody (mAb) (clone EM95)
diluted in phosphate-buffered saline (PBS). The next day, the ELISA was performed
at room temperature. After blocking with ELISA buffer (PBS containing 0.5% bovine
serum albumin [Sigma], 2 mM EDTA, 136.9 mM NaCl, 50 mM Tris, 0.05% Tween-
20 [Merck, Whitehouse Station, NJ], pH 7.2) for 1 h, serum samples and a duplicate
standard curve (starting 1:10), diluted in ELISA buffer, were added for 2 h. An
OVA-specific IgE reference standard was obtained by i.p. immunization with OVA
and arbitrarily assigned a value of 10,000 experimental units/ml (EU/ml). After
incubation, 1 µg/ml of OVA coupled to digoxigenin (DIG), which was prepared
from a kit containing DIG-3-o-methylcarbonyl-ε-aminocaproic acid-N-hydroxy-
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succinimide-ester (Roche Diagnostics, Basel, Switzerland) in ELISA buffer was added
for 1.5 h, followed by incubation with anti-DIG-Fab fragments coupled to horseradish
peroxidase (Roche Diagnostics) 1:500 diluted in ELISA buffer for 1 h. Color
development was performed with o-phenylenediamine-dichloride substrate (0.4 mg/
ml, Sigma) and 4 mM H2O2 in PBS and stopped by adding 4 M H2SO4. The optical
density was read at 492 nm, using a Benchmark microplate reader (Bio-Rad
Laboratories Hercules, CA). The detection limit of the ELISA was 0.5 EU/ml IgE.
Analysis of the cellular composition in the BALF
Directly after bleeding of the mice, broncho-alveolar lavage was performed. Briefly,
the airways were lavaged 5 times through a tracheal cannula with 1 ml aliquots of
pyrogen-free saline warmed to 37°C. The recovered lavage fluid was pooled and
cells herein were pelleted (32 × g, 4°C, 5 min) and resuspended in 0.15 ml cold PBS.
The total number of cells in the BAL fluid (BALF) was determined using a Bürker-
Türk counting-chamber (Karl Hecht Assistent KG, Sondheim/Röhm, Germany). For
differential BALF cell counts, cytospin preparations were made and stained with
Diff-Quick (Dade A.G., Düdingen, Switzerland). Per cytospin 400 cells were counted
and differentiated into mononuclear cells (monocytes, macrophages and
lymphocytes), eosinophils and neutrophils by standard morphology. Statistical
analysis was performed using the non-parametric Mann Whitney U test.
Determination of cytokine production by OVA re-stimulated lung cells in vitro
Cytokine production by antigen re-stimulated T-cells in lung tissue was determined
as described previously (16). Briefly, the lungs were lavaged as described above and
perfused via the right ventricle with 4 ml saline containing 100 U/ml heparin (Leo
Pharmaceuticals, Weesp, The Netherlands) to remove any blood and intravascular
leukocytes. Complete lung tissue was removed and transferred to cold sterile PBS.
Lungs were then minced and digested in 3 ml RPMI 1640 containing 2.4 mg/ml
collagenase A and DNase I (grade II) (both from Roche Diagnostics) for 30 min at
37°C. Collagenase activity was stopped by adding fetal calf serum (FCS). The lung
tissue digest was filtered through a 70 µm nylon cell strainer (Becton Dickinson
Labware, Franklin Lakes, NJ) with 10 ml RPMI 1640 to obtain a single-cell
suspension. The lung-cell suspension was washed, resuspended in culture medium
(RPMI 1640 containing 10% FCS, 1% glutamax I, gentamicin [all from Life
Technologies, Gaithersburg, MD] and 50 µM β-mercaptoethanol [Sigma]) and the
total number of lung cells was determined using a Bürker-Türk counting-chamber.
Lung cells (8 × 105 lung cells/well) were cultured in round-bottom 96-well plates
(Greiner Bio-One, Kremsmuenster, Austria) in the presence of OVA (10 µg/ml) or
medium only. As a positive control, cells were cultured in the presence of plate-
bound rat anti-mouse CD3 mAb (clone 17A2, 50 µg/ml, coated overnight at 4°C).
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Each in vitro stimulation was performed in triplicate. After 5 d of culture at 37°C,
the supernatant was harvested, pooled per stimulation, and stored at -20°C until
cytokine levels were determined by ELISA.
The IFN-γ, IL-4, and IL-5, IL-10 and IL-13 ELISAs were performed according
to the manufacturer’s instructions (PharMingen, San Diego, CA). The detection limits
of the ELISAs were 160 pg/ml for IFN-γ, 16 pg/ml for IL-4, 32 pg/ml for IL-5 and
100 pg/ml for IL-10 and IL-13.
Statistical analysis
All data are expressed as mean ± standard error of mean (SEM). Unless stated
otherwise, the differences between groups were statistically analyzed using a Student’s
t-test (two-tailed, homosedastic). Results were considered statistically different at
the p < 0.05 level. Statistical analyses were performed using SPSS for Windows
version 10.0.05 (SPSS, Chicago, IL).
RESULTS
Table 1 shows the design of two independent experiments using a novel murine
model of ongoing disease. Experimental treatments were mCTLA4-IgG in Experiment
A and the gold-standard dexamethasone in Experiment B. Group 5 was used to
compare the effect of experimental treatment on established asthma manifestations
(Group 4) to stopping with OVA aerosols while continuing with saline aerosols
(hereafter referred to as the “spontaneous resolution group”).
Table 1: Design of the two experiments using a novel murine model of ongoing disease.
Mice were sensitized, challenged, and treated as described in MATERIALS AND METHODS. Each
experimental group consisted of at least six animals.
Airway hyperresponsiveness in vivo is induced by the first series of OVA aerosols
but disappears after the second series of aerosols
As shown previously, one of the advantages of whole-body plethysmography is that
the airway responsiveness in vivo of experimental animals can be measured several
Group Sensitization Challenge 
Aerosol (1-8) 
              
Aerosol (9-16) 
Treatment 
Experiment A 
 
Experiment B 
1 OVA saline saline human total IgG saline 
2 OVA saline saline murine CTLA4-IgG dexamethasone 
3 OVA OVA OVA human total IgG saline 
4 OVA OVA OVA murine CTLA4-IgG dexamethasone 
5 OVA OVA saline human total IgG saline 
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times during an experiment because it is performed in conscious, unrestrained animals
(18). To verify that hyperresponsiveness was induced in OVA-sensitized mice by
the first series of OVA aerosol challenges, airway responsiveness to aerosolized
methacholine was measured 24 h in each of the two independent experiments after
the first series of aerosols, just before treatment and the second series of aerosols. A
dose-response curve (DRC) of doubling concentrations methacholine was performed
in each mouse. The DRC to methacholine of OVA-challenged animals was
significantly different (p < 0.01, Experiment A and p < 0.01, Experiment B) from
those of saline-challenged mice. Figure 1A shows the responses to the methacholine
DRC of saline- and OVA-challenged animals from Experiment A.
To determine if mCTLA4-IgG or dexamethasone could reverse established
hyperresponsiveness, airway responsiveness was measured again 24 h after the second
series of aerosols in Experiments A and B. However, in control-treated groups, OVA
challenge did not result in hyperresponsiveness to methacholine compared with saline
challenge; Penh values of OVA-challenged mice were just as low as those from
saline-challenged animals at all concentrations of the methacholine DRC in both
experiments. In Figure 1B, the maximal responses to 50 mg/ml methacholine of
Experiment A are shown. Hence, an effect of mCTLA4-IgG or dexamethasone on
established, OVA-induced airway hyperresponsiveness could not be determined in
this model of ongoing disease.
So, OVA-challenged mice show airway hyperresponsiveness in vivo compared
with saline-challenged animals after the first series of aerosols, but this nonspecific
hyperresponsiveness disappears after the second series of aerosols.
Figure 1: Airway hyperresponsiveness is induced by the first series of OVA aerosols, but has
disappeared after the second series of aerosols. Airway responsiveness to aerosolized methacholine
was measured in conscious, unrestrained mice 24 h after the first (A) and second (B) series of aerosols.
BALB/c mice were OVA-sensitized and challenged with either eight saline aerosols (n = 16; open
bars) or eight OVA aerosols (n = 24; closed bars) (A). Subsequently, mice were challenged with
eight saline aerosols (open bars and shaded bars) or eight additional OVA aerosols (closed bars).
During this second series of aerosols, mice received control treatment (human total IgG) or mCTLA4-
IgG (B). Values are expressed as mean ± SEM (n = 8 per group). Results of Experiment A, representative
for both experiments, are shown.
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CTLA4-IgG inhibits the up-regulation of serum OVA-specific IgE in the ongoing
murine model of airway inflammation
In Experiments A and B, which evaluated mCTLA4-IgG and dexamethasone as
experimental treatment respectively, serum levels of OVA-specific IgE were
determined in all mice 24 h after the second series of aerosols.
In control-treated mice, OVA challenge induces a significant up-regulation of
serum OVA-specific IgE compared with saline challenge (273% increase, p < 0.01
and 150% increase, p < 0.01; shown in Figures 2A and 2B, respectively). CTLA4-
IgG-treated, OVA-challenged mice show significantly reduced levels of OVA-specific
IgE compared with control-treated, OVA-challenged animals (43% inhibition, p <
0.05). This level of allergen-specific IgE in serum was very similar to that observed
in the sera of mice from the spontaneous resolution group (Group 5, Table 1) (56%
inhibition compared with control-treated, OVA-challenged mice, p < 0.01) (Figure
2A). In contrast, dexamethasone treatment has no effect on the OVA-induced up-
regulation of serum antigen-specific IgE (Figure 2B).
So, mCTLA4-IgG is able to partially inhibit the up-regulation of serum OVA-
specific IgE levels in the ongoing model of airway inflammation.
Figure 2: CTLA4-IgG inhibits the up-regulation of serum OVA-specific IgE in the ongoing murine
model of airway inflammation. Serum OVA-specific IgE was determined in all mice 24 h after the
second series of aerosols. BALB/c mice were OVA-sensitized and challenged with 16 saline aerosols
(open bars), 16 OVA aerosols (closed bars) or 8 OVA/8 saline aerosols (shaded bars). During the
second series of aerosols, mice received control treatment, mCTLA4-IgG (A) or dexamethasone (B).
Values are expressed as mean ± SEM (n = 6-8 per group). ** p < 0.01, as compared with saline-
challenged animals of the same treatment group. # p < 0.05, ## p < 0.01, as compared with control-
treated, OVA-challenged animals.
CTLA4-IgG and dexamethasone inhibit the number of eosinophils in the BALF in
the ongoing murine model of airway inflammation
The number of cells in the BALF was used as a measure for the infiltration of cells
in the airways and determined in all mice 24 h after the second series of aerosols. In
the lavage fluid of saline-challenged mice no (or sometimes a few) eosinophils can
be observed. However, OVA challenge results in a significant (p < 0.01) increase in
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the number of eosinophils compared with saline challenge of the same treatment
group in each of the two independent experiments (Figure 3). Both mCTLA4-IgG-
or dexamethasone-treated, OVA-challenged mice show significantly reduced numbers
of eosinophils in the BALF compared with control-treated, OVA-challenged mice
(83% inhibition, p < 0.01 and 97% inhibition, p < 0.01; shown in Figures 3A and 3B,
respectively). In mice from the spontaneous resolution group, a similar reduction
compared with control-treated, OVA-challenged mice was observed (82% inhibition,
p < 0.01 and 90% inhibition, p = 0.052; shown in Figures 3A and 3B, respectively).
So, both mCTLA4-IgG and dexamethasone are able to inhibit the number of
eosinophils in the BALF in the ongoing model of airway inflammation.
Figure 3: CTLA4-IgG and dexamethasone inhibit the number of eosinophils in the BALF in the
ongoing murine model of airway inflammation. The number of eosinophils in the BALF in all mice
was determined 24 h after the second series of aerosols. BALB/c mice were OVA-sensitized and
challenged with 16 saline aerosols (open bars), 16 OVA aerosols (closed bars) or 8 OVA/8 saline
aerosols (shaded bars). During the second series of aerosols, mice received control treatment, mCTLA4-
IgG (A) or dexamethasone (B). Values are expressed as mean ± SEM (n = 6-8 per group). ** p < 0.01,
as compared with saline-challenged animals of the same treatment group. ## p < 0.01, as compared
with control-treated, OVA-challenged animals.
In each of the two independent experiments, no significant differences in the
absolute number of neutrophils were observed in the BALF between the experimental
groups (data not shown). In Experiment A, the absolute numbers of mononuclear
cells (monocytes, macrophages and lymphocytes) were not significantly different
between the experimental groups. In Experiment B, dexamethasone treatment of
OVA-challenged animals resulted in a reduction in the number of mononuclear cells
compared with control-treated, OVA-challenged animals (32% inhibition, p < 0.05).
CTLA4-IgG inhibits lung cell IL-5 production after OVA re-stimulation in vitro in
the ongoing murine model of airway inflammation
A single-cell suspension of complete lung tissue of each mouse was prepared 24 h
after the second series of aerosols. To determine T-cell responses upon antigenic re-
stimulation, lung cells were cultured for 5 d in the presence of OVA. In agreement
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with previous studies from our laboratory (16), no IFN-γ or IL-4 could be detected
in the supernatant of these total lung-cell cultures after 5 d. In addition, we could not
detect IL-10 and IL-13 in the supernatant of these OVA re-stimulated lung-cell
cultures in this study. Lung-cell cultures derived from control-treated, OVA-
challenged mice show significantly increased levels of IL-5 after re-stimulation with
OVA in vitro compared with cultures from control-treated, saline-challenged animals
(269 % increase, p < 0.01 and 121% increase, p < 0.05; shown in Figures 4A and 4B
respectively). Allergen-stimulated lung-cell cultures derived from mCTLA4-IgG-
treated, OVA-challenged mice show significantly reduced levels of IL-5 in the
supernatant compared with cultures from control-treated, OVA-challenged animals
(48% inhibition, p < 0.05). This degree of inhibition was similar to that observed in
the cultures from mice of the spontaneous resolution group (48% inhibition, p <
0.05) (Figure 4A).
Dexamethasone treatment of OVA-challenged mice slightly decreased the IL-5
production by lung tissue cells after re-stimulation with OVA in vitro, compared
with lung cells from control-treated, OVA-challenged animals (Figure 4B).
Polyclonal stimulation of T-cells with anti-CD3 mAb resulted in high levels of
IFN-γ, IL-4, IL5, IL-10 and IL-13 in the supernatant of lung-cell cultures derived
from all experimental groups, indicating that there was no intrinsic T-cell defect to
produce any of these cytokines (data not shown).
So, mCTLA4-IgG is able to inhibit the IL-5 production by lung-cell cultures
after in vitro re-stimulation with allergen in the ongoing model of airway
inflammation.
Figure 4: CTLA4-IgG inhibits lung-cell IL-5 production after OVA re-stimulation in vitro in the
ongoing murine model of airway inflammation. Total lung-cell cultures prepared from each mouse 24
h after the second series of aerosols were cultured for 5 d in the presence of OVA. BALB/c mice were
OVA-sensitized and challenged with 16 saline aerosols (open bars), 16 OVA aerosols (closed bars)
or 8 OVA/8 saline aerosols (shaded bars). During the second series of aerosols, mice received control
treatment, mCTLA4-IgG (A) or dexamethasone (B). Values are expressed as mean ± SEM (n = 11-14
per group) averaged from two independent experiments (A) or as mean ± SEM (n = 6-8 per group)
(B). * p < 0.05. ** p < 0.01, as compared with saline-challenged animals of the same treatment group.
# p < 0.05, as compared with control-treated, OVA-challenged animals.
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In a more “severe” ongoing murine model, the effects of mCTLA4-IgG are less
pronounced
The experiments described above are performed in a relatively mild model of airway
inflammation; that is, animals are sensitized to OVA without adjuvant and challenged
with low doses of OVA. Most research groups, however, use a protocol in which
animals are allergen-sensitized in the presence of the Th2-dominant response-inducing
alum as adjuvant and challenged with high doses of allergen. This protocol results in
a model with stronger responses and appears to represent a more “severe” type of an
inflammatory response. Whereas the extent of airway hyperresponsiveness is similar,
~ 10 times as much serum OVA-specific IgE and at least twice as many eosinophils
in BALF can be observed after a first series of OVA aerosols when using this protocol,
compared with the mild protocol (D.T. Deurloo, unpublished observations).
Interestingly, it has been shown that the various models respond differently to
modulation (19, 20). Therefore, we wanted to evaluate the effects of mCTLA4-IgG
and dexamethasone in a more “severe” ongoing model as well (adapted from Refs.
17 and 21). Table 2 shows the design of this experiment.
Table 2: Experimental design to determine the effects of mCTLA4-IgG and dexamethasone in a more
“severe” ongoing model.
Mice were sensitized, challenged, and treated as described in MATERIALS AND METHODS. Each
experimental group consisted of at least six animals.
In the more “severe” ongoing model, airway responsiveness to methacholine
was measured in all mice 24 h after the second series of aerosols. In contrast to the
milder ongoing model of airway inflammation, OVA challenge induces airway
hyperresponsiveness to methacholine compared with saline challenge not only after
a first series of aerosols (D.T. Deurloo, unpublished observations), but also after two
series of aerosols in control-treated mice (p < 0.05) (Figure 5A). CTLA4-IgG- or
dexamethasone-treated, OVA-challenged mice show reduced nonspecific
responsiveness at the higher concentrations of methacholine, but the complete DRCs
to methacholine are not significant different compared with the DRC of control-
treated, OVA-challenged mice. Also, the mice from the spontaneous resolution group
(Group 5, Table 2) showed no significantly reduced airway responsiveness compared
with control-treated, OVA-challenged mice (Figure 5A).
Group Sensitization Challenge 
Aerosol (1-3) 
 
Aerosol (4-6) 
Treatment 
1 OVA/alum saline saline human total IgG 
2 OVA/alum OVA OVA human total IgG 
3 OVA/alum OVA OVA murine CTLA4-IgG 
4 OVA/alum OVA OVA dexamethasone 
5 OVA/alum OVA saline human total IgG 
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Figure 5: The effects of mCTLA4-IgG and dexamethasone in a more “severe” ongoing murine model.
BALB/c mice were OVA-sensitized and challenged with six saline aerosols (open bars), six OVA
aerosols (closed bars) or three OVA/three saline aerosols (shaded bars). Mice received control treatment
(human total IgG), mCTLA4-IgG or dexamethasone (dex). Treatment started just before the second
series of aerosols. Airway responsiveness to aerosolized methacholine was measured in conscious,
unrestrained mice 24 h after the second series of aerosols. The response to the highest concentration
(50 mg/ml) of the methacholine dose-response curve is depicted (A). Serum OVA-specific IgE (B),
the number of eosinophils in the BALF (C) and cytokine production by OVA re-stimulated lung cells
in vitro (D) was determined in all mice 24 h after the second series of aerosols. V alues are expressed
as mean ± SEM (n = 6-8 per group). * p < 0.05, ** p < 0.01, as compared with saline-challenged
animals. # p < 0.05, ## p < 0.01, as compared with control-treated, OVA-challenged animals.
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Figure 5B shows that, in comparison with the milder model of ongoing disease,
much higher serum levels of OVA-specific IgE can be observed in all experimental
groups of the more “severe” ongoing model 24 h after the second series of aerosols
(compare Figure 5B with Figure 2). In control-treated mice, OVA challenge induces
a significant up-regulation of serum OVA-specific IgE compared with saline challenge
(280% increase, p < 0.01). Both mCTLA4-IgG and dexamethasone have no effect
on the OVA-induced up-regulation of specific IgE levels. Notably, the mice from
the spontaneous resolution group show no significantly different levels of serum
IgE compared with control-treated, OVA-challenged mice (Figure 5B).
Also in the more “severe” ongoing model, no eosinophils are found in the BALF
of saline-challenged animals 24 h after the second series of aerosols. In control-
treated mice, OVA challenge induces a significant (p < 0.01) increase in the number
of eosinophils in the BALF compared with saline challenge (Figure 5C). The absolute
number of eosinophils observed in the BALF of OVA-challenged mice in the more
“severe” ongoing model is enormous compared with the number of eosinophils in
the BALF recovered from OVA-challenged mice in the milder ongoing model of
allergic inflammation (compare Figure 5C with Figure 3). CTLA4-IgG-treated, OVA-
challenged mice have reduced numbers of eosinophils compared with control-treated,
OVA-challenged animals, but this suppression does not reach the level of significance
(40% inhibition, p = 0.053). In contrast, dexamethasone-treated, OVA-challenged
mice demonstrate significantly reduced numbers of eosinophils compared with
control-treated, OVA-challenged animals (73% inhibition, p < 0.01). In mice from
the spontaneous resolution group, a similar reduction compared with control-treated,
OVA-challenged mice was observed (82% inhibition, p < 0.01) (Figure 5C).
No significant differences in the absolute number of neutrophils were observed
in the BALF between the experimental groups (data not shown). In control-treated
mice, OVA challenge induces a significant increase in the number of BALF
mononuclear cells (201% increase, p < 0.01) compared with saline challenge. Both
in the spontaneous resolution group and in the group of dexamethasone-treated, OVA-
challenged animals, a significant reduction in the absolute number of mononuclear
cells was observed compared with control-treated, OVA-challenged animals (36%
inhibition, p < 0.05 and 49% inhibition, p < 0.01).
Also in this experiment, we prepared a single-cell suspension of complete lung
tissue of each mouse 24 h after the second series of aerosols to re-stimulate lung
cells in vitro. Similar to the lung-cell cultures from the milder ongoing model of
airway inflammation, also these lung-cell cultures produced no IFN-γ or IL-4 after 5
d of culture in the presence of OVA. However, lung cells obtained from control-
treated, OVA-challenged mice produced significantly more IL-5, - and in this more
“severe” ongoing model also IL-10 and IL-13 - compared with control-treated, saline-
challenged animals upon antigenic re-stimulation (177 % increase, p < 0.05; 577%
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increase, p < 0.01; and 786% increase, p < 0.05, respectively) (Figure 5D). The
lung-cell cultures derived from mice treated with mCTLA4-IgG and challenged with
OVA produced similar levels of these cytokines after OVA re-stimulation in vitro as
those of control-treated, OVA-challenged animals. Also in the supernatant of lung-
cell cultures obtained from mice from the spontaneous resolution group, no difference
in the cytokine levels was observed when compared with control-treated, OVA-
challenged mice. In contrast, dexamethasone significantly inhibited IL-10 production
by the lung-cell cultures (45% inhibition, p < 0.05), whereas IL-5 and IL-13 production
was slightly reduced (Figure 5D).
Polyclonal stimulation of T-cells with anti-CD3 mAb resulted in high levels of
IFN-γ, IL-4, IL5, IL-10 and IL-13 in the supernatant of lung-cell cultures derived
from all experimental groups (data not shown).
So, in a more “severe” ongoing model, mCTLA4-IgG was less effective
compared with the milder ongoing model of airway inflammation in that only airway
hyperresponsiveness was attenuated at the higher concentrations of the methacholine
DRC and the number of eosinophils in the BALF was reduced. In comparison,
dexamethasone not only attenuated hyperresponsiveness at the higher concentrations
of the methacholine DRC, but it also significantly inhibited BALF eosinophilia and
lung IL-10 production in vitro together with a reduction in IL-5 production.
DISCUSSION
In the present study, we sought to determine if co-stimulatory blockade by murine
CTLA4-IgG can reverse established asthma manifestations in an OVA-induced
murine model of ongoing disease. CTLA4-IgG inhibited the up-regulation of OVA-
specific IgE in serum, BALF eosinophilia and lung cell IL-5 production in vitro in a
mild ongoing model of airway inflammation. Whereas airway hyperresponsiveness
to methacholine was present in this ongoing model in OVA-sensitized mice after the
first series of OVA aerosol challenges that induced airway inflammation, this
nonspecific hyperresponsiveness had disappeared after the second series of OVA
aerosols. Hence, the effect of mCTLA4-IgG on this parameter could not be
determined. Importantly, mCTLA4-IgG performed better than the gold-standard
dexamethasone because this corticosteroid did not inhibit serum levels of OVA-
specific IgE. In a more “severe” ongoing model (adapted from Refs. 17 and 21),
mCTLA4-IgG was less effective in that only the number of eosinophils in the BALF
was reduced (p = 0.053). However, in this more “severe” ongoing model, airway
hyperresponsiveness was present after the second series of OVA aerosols and
attenuated by mCTLA4-IgG administration. Dexamethasone inhibited both BALF
eosinophilia and cytokine production by lung lymphocytes in this more “severe”
ongoing murine model.
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So, we are the first to demonstrate that in a murine model of ongoing disease,
co-stimulatory blockade by mCTLA4-IgG can also be effective after the onset of
asthma manifestations. During the time course of this ongoing model of the disease,
the types and numbers of the various allergen-specific CD4+ T-cell subsets, based
on their activation status, constantly changes. After sensitization, OVA-specific
memory T-cells have developed. In the two models of ongoing disease, recently
activated effector T-lymphocytes are present after the first series of OVA aerosol
challenges at the time of treatment. In addition, naïve T-cells might be recruited and
activated during the two series of OVA aerosols. In vitro studies have demonstrated
that memory- and previously activated effector T-cells are less dependent on CD28-
mediated co-stimulation than naïve T-cells (11, 13, 14), whereas in vivo studies on
the effectiveness of giving CTLA4-Ig after priming of immune responses have yielded
conflicting results (12). An example of a successful study is the recent clinical report
on the administration of CTLA4-Ig to patients with psoriasis vulgaris in a phase I
trial that produced a dose-dependent improvement in skin lesions (22). It is possible
that the effectiveness of CTLA4-Ig on established disease depends on its ability to
block the development and contribution to disease of newly recruited naïve CD4+
T-cells. If this is true, especially in our mild ongoing model, the contribution of
newly recruited naïve CD4+ T-cells may be considerable. Alternatively, CTLA4-Ig
may be effective in an ongoing or a memory response under some conditions,
determined by the type of antigen inducing the immune response, the lymphoid
microenvironment or the T-cell cytokine pattern elicited during the immune response
(12, 13).
We investigated the role of the CD28/B7 T-cell co-stimulatory pathway in two
murine models of ongoing disease. The crucial role of CD28-mediated co-stimulation
in the generation of effective T-cell responses has been well documented (5).
However, two new pairs of the CD28/B7 families have been identified recently
(reviewed in 23). Inducible co-stimulatory molecule (ICOS), as indicated by its name,
is expressed on the surface of T-cells upon activation and binds to B7RP-1 (also
known as B7h, B7-H2, GL-50, ICOSL or LICOS) present on a variety of cells.
Interestingly, on the basis of many recent studies, it appears that ICOS functions
primarily to induce T-cell effector function. For example, engagement of ICOS
appeared to be important for the cytokine responses of recently activated effector T-
cells. Although ICOS engagement might support activation of naïve T-cells, it could
be more important for enhancing ongoing and/or memory responses. The other new
member of the CD28 family, programmed death 1 (PD-1), like CTLA4, appears to
mediate an inhibitory signal to T-cells upon binding to its ligands PD-L1 (or B7-H1)
and PD-L2. In contrast to CTLA4-deficient mice, which all die at three to four wk of
age, severe autoimmune symptoms are observed only in approximately half of the
PD-1-deficient mice, even at 14 mo of age, suggesting that PD-1 is not the primary
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inhibitory signal for T-cells (23). Still more B7 family members are being identified
at the time of writing this report (24, 25). A detailed understanding of the roles and
interplay of these T-cell co-stimulatory pathways might result in new therapeutic
possibilities for the manipulation of T-cell-mediated diseases (e.g., a treatment
consisting of CTLA4-Ig in combination with an agent blocking other co-stimulatory
pathway[s]).
Blocking co-stimulation might not only result in the suppression of the immune
response but in some cases might induce antigen-specific tolerance. When T-cells
receive an antigen-specific signal through the TCR in the absence of co-stimulatory
signals, this results in non-responsiveness upon subsequent optimal T-cell activation,
according to the classical model of T-cell anergy (26, 27). Alternatively, some research
groups have suggested that in vivo administration of CTLA4-Ig might leave small
amounts of B7 uncovered that bind to CTLA4 due to its higher affinity. This would
imply that CTLA4-Ig administration results in the absence of CD28 ligation, whereas
part of the CTLA4 molecules is ligated. CTLA4 ligation has been implicated in the
induction of peripheral tolerance (28, 29). Of course, tolerance induction is very
attractive in the therapy of asthmatic patients because this would mean that after a
single period of treatment, patients have improved clinical status for a considerable
time after cessation of therapy. Therefore, we are currently investigating whether
the effects of mCTLA4-IgG are transient or long lasting in the (ongoing) murine
models of allergic asthma.
Allergen-specific IgE in serum, BALF eosinophilia and IL-5 production by lung
cells are very characteristic features seen in patients with asthma. These manifestations
were significantly inhibited by mCTLA4-IgG in the mild ongoing murine model of
airway inflammation. Because IL-5 is involved in the growth, migration and activation
of eosinophils, the decreased IL-5 production by lung cells isolated from mCTLA4-
IgG-treated, OVA-challenged mice correlates with the inhibition of BALF
eosinophilia observed in this group. Unfortunately, we cannot draw any conclusions
about the effect of mCTLA4-IgG on OVA-induced airway hyperresponsiveness
because hyperresponsiveness to methacholine had disappeared in control-treated,
OVA-challenged animals after the second series of aerosols. We can only speculate
on the mechanism of this disappearance of airway hyperresponsiveness. One
possibility is that two series of eight OVA aerosols might induce tolerance. This
would mean that in our milder ongoing murine model, partial tolerance is induced,
namely for nonspecific hyperresponsiveness and not for the other parameters,
suggesting that the loss of airway hyperresponsiveness is probably not due to
immunologic tolerance. Unless hyperresponsiveness is regulated by a different subset
of (allergen-specific) CD4+ T-cell than the allergen-specific CD4+ T-cell responsible
for both isotype switching of B cells to IgE and BALF eosinophilia. This T-cell most
likely is also CD4+ because airway hyperresponsiveness is abolished by in vivo
depletion of CD4+ T-cells (30).
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Another explanation comes from a study by Palmans and colleagues evaluating
the effect of prolonged allergen exposure on airway function and structure in rats.
Although airway hyperresponsiveness to aerosolized carbachol and increased total-
and inner airway wall area were present after 2 wk of OVA exposure in sensitized
rats, these features were absent after 12 wk of OVA exposure, whereas the influx of
eosinophils into and around the airways persisted, as did IgE synthesis. The authors
suggest that the loss of hyperresponsiveness is related to the development of
compensatory mechanisms, the loss of which could contribute to the persistent airway
hyperresponsiveness in human asthma (31). However, we wonder how likely these
compensatory mechanisms apply to our mild ongoing model because both the time
span of antigen exposures and the dose of antigen are much smaller. Future studies
might clarify this issue.
In the more “severe” ongoing model, mCTLA4-IgG is less effective compared
with the milder ongoing model. The levels of circulating OVA-specific IgE and lung
IL-5 production in vitro are not inhibited and the number of eosinophils in the BALF
is reduced to a smaller extent compared with the milder model of airway inflammation.
However, nonspecific airway hyperresponsiveness is present after the second series
of OVA aerosols in this more “severe” ongoing model and mCTLA4-IgG attenuated
OVA-induced airway hyperresponsiveness (Figure 5A). The stronger responses of
this ongoing model compared with the mild ongoing model of airway inflammation
(compare Figure 5 with Figures 2-4) -hence the designation more “severe” - might
be more difficult to inhibit. After induction of asthma manifestations by a first series
of OVA aerosols, saline challenge of mice during the second series of aerosols
(spontaneous resolution group) also resulted in no or a small diminution of allergic
asthma manifestations compared with control-treated, OVA-challenged animals.
Interestingly, it has been shown that the various murine models of allergic asthma
induced by different sensitization and challenge protocols respond differently to
modulation. For example, no airway hyperresponsiveness was developed in mast
cell-deficient mice following sensitization and challenge with OVA, whereas OVA
sensitization and challenge in congenic littermates did induce nonspecific
hyperresponsiveness. However, OVA-sensitized, mast cell-deficient mice developed
nonspecific hyperresponsiveness by increasing the frequency and antigen dose of
challenge (19). These and other findings suggest that the relative contribution of
allergen-specific IgE-dependent mast cell activation and BALF eosinophilia to the
development of nonspecific airway hyperresponsiveness not only depends on the
strain of mice used but also on the sensitization and challenge protocol (32). So,
apart from the quantitative differences between the two murine models of ongoing
disease, there might be qualitative differences as well, perhaps indicating differential
activation of T-cell signaling pathways under the various conditions of allergen
exposure.
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From the results obtained from this and previous studies (18, 33), we conclude
that in our mild and more “severe” (ongoing) models, neither allergen-specific IgE
nor BALF eosinophilia are solely responsible for the development or maintenance
of airway hyperresponsiveness. Additional evidence for the dissociation of BALF
eosinophilia and nonspecific hyperresponsiveness in the more “severe” ongoing
model comes from an experiment in which two different routes of administration for
mCTLA4-IgG were compared. Whereas local (intranasal) administration of
mCTLA4-IgG results in a diminution of hyperresponsiveness similar to systemic
(intravenous) administration of mCTLA4-IgG compared with control-treated OVA-
challenged animals, only systemic administration of mCTLA4-IgG resulted in reduced
BALF eosinophilia (D.T. Deurloo, unpublished observation).
For optimal treatment of asthma patients, it remains to be determined which
(ongoing) model best represents their clinical situation. The use of various mouse
strains combined with various sensitization- and challenge protocols might be
meaningful because the group of patients with asthma is very heterogeneous, both
genetically and in the way they are exposed to environmental allergens. As an
advantageous feature of the mild (ongoing) model, it can be said, however, that the
percentage of eosinophils found in the BALF is very similar to that observed in the
lavage fluid of mild to severe asthmatics (10-20%, 24 h after allergen provocation
[34]).
The gold-standard dexamethasone performed equally well as mCTLA4-IgG in
the mild ongoing model of airway inflammation, except that circulating OVA-specific
IgE levels were not inhibited. This observation on allergen-specific IgE levels is in
agreement with previous studies both in humans and mice (35, 36). In the more
“severe” ongoing model, however, dexamethasone treatment of OVA-challenged
mice was more effective in comparison with mCTLA4-IgG administration. If we
extrapolate the results from this study to the human situation, these data imply that
patients with mild disease can benefit from specific treatment with CTLA4-Ig,
whereas the more generally suppressive drug dexamethasone, perhaps in combination
with CTLA4-Ig, is required for patients suffering from more severe disease.
In summary, we described the effects of mCTLA4-IgG after induction of asthma
manifestations in two murine models of ongoing disease, which differed in severity
of the disease. In a mild ongoing model of allergic airway inflammation, mCTLA4-
IgG was very effective, whereas in a more “severe” ongoing model, its effects were
less pronounced. We conclude from this study that CTLA4-Ig might be an effective
alternative therapy for established allergic asthma, especially in situations of mild
disease. Future experimental studies investigating the long-term effects of mCTLA4-
IgG in (ongoing) murine models of allergic asthma will further clarify its therapeutic
potential.
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ABSTRACT
Asthmatic patients usually start therapy after the development of airway symptoms,
while exposure to environmental allergen mostly continues. Current data suggest
that inducible T-cell co-stimulator (ICOS) has a more prominent role in the effector
phase than in the initiation of Th2-dominated allergic inflammatory responses. In
the present study, we compared the effects of ICOS blockade during the development
of asthma-like symptoms in mice (induction model) with the effects of ICOS blockade
after the development of airway symptoms when antigen exposures were continued
(ongoing model). For the induction model, BALB/c mice were sensitized to ovalbumin
(OVA) and challenged with three OVA aerosols. Treatment of mice with ICOS-Fc
throughout the aerosol challenge period significantly reduced the number of
inflammatory cells in the broncho-alveolar lavage fluid compared with control-treated
animals but airway hyperresponsiveness in vivo and serum OVA-specific IgE levels
were unaltered. In the ongoing model, OVA-sensitized mice received ICOS-Fc solely
during the period of the fourth to sixth aerosol, after development of asthma
manifestations. Administration of ICOS-Fc had no effect on any of the final asthma
manifestations. Likewise, ICOS-Fc did not inhibit IL-5 production by primed OVA-
specific lung T-cells ex vivo. So, in this ongoing murine model, ICOS appears to
play no role in the regulation of Th2 effector cell function in the lung.
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INTRODUCTION
Allergic asthma is a complex inflammatory disease of the airways characterized by
reversible airflow obstruction, persistent airway hyperresponsiveness, chronic
eosinophilic airway inflammation and airway remodeling (1). Allergen-specific T
helper (Th) type 2 cells play a pivotal role in both the initiation and progression of
allergic asthma by orchestrating the inflammatory response. Th2 cells are
characterized by the array of effector cytokines they secrete, such as IL-4, IL-5, IL-
9, IL-10 and IL-13, which are optimized to combat parasite infections (2). However,
Th2 cells are developed undesirably in allergic disorders such as asthma, their
cytokines causing airway symptoms either directly or mediated by other immune
cells and their mediators (3). In animal models of allergic asthma, various
experimental treatments have therefore been explored that target the allergen-specific
T-cell, including blockade of their co-stimulatory requirements (4, 5).
For optimal activation, CD4+ T-cells require nonspecific co-stimulatory signals
in addition to the antigen-specific signal conferred by the T-cell receptor (TCR) (6-
8). CD28 is the best-characterized T-cell co-stimulatory receptor, constitutively
present on the surface of naïve T-cells. Engagement of CD28 by its ligands B7-1
(CD80) or B7-2 (CD86) on antigen-presenting cells provides potent co-stimulatory
signals to T-cells activated through their TCR that enhance activation and sustain
the T-cell response. The second receptor for the B7 ligands, CTLA4 (CD152), is
expressed on activated T-cells and delivers inhibitory signals to terminate the T-cell
response (9).
The critical role of CD28 signaling in the development of Th2-dominated allergic
inflammatory responses in mice has been demonstrated in both gene targeting and
blocking studies. No asthma-like symptoms could be induced in CD28-deficient
(CD28−/−) mice (Refs. 10-12 and chapter 2) or B7-1/B7-2−/− mice (Ref 13 and chapter
2). Administration of CTLA4-Ig or monoclonal antibodies (mAbs) against the B7
molecules at the time of antigen sensitization or challenge of wild-type mice greatly
reduced the allergen-induced manifestations of asthma (14-18).
In contrast to these experimental studies, asthmatic patients start therapy after
the development of airway symptoms, while exposure to environmental allergen
mostly continues. Studies in vitro have demonstrated that effector and memory T-
cells are less dependent on co-stimulation in comparison with naïve T-cells (19-21),
whereas studies in vivo on the effectiveness of giving CTLA4-Ig after priming of
immune responses have yielded conflicting results (22). In an ovalbumin (OVA)-
induced murine model of ongoing disease in which treatment started after the
development of asthma-like symptoms and antigen exposures were continued,
CTLA4-IgG was still effective (23). However, airway eosinophilia and the up-
regulation of OVA-specific IgE levels could only be partially inhibited. In this ongoing
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murine model of allergic asthma, the partial inhibition by CTLA4-IgG may be due
to the predominance of antigen-experienced (memory and effectors) over newly
recruited naïve OVA-specific T-cells at the time of treatment. These antigen-
experienced T-cells may be regulated by other co-stimulatory molecules.
A possible candidate is the recently discovered CD28 family member inducible
co-stimulator (ICOS) that binds its own B7 family member, B7 related protein 1
(B7RP-1) (also known as B7h, B7-H2, GL50 or ICOSL or LICOS) (reviewed in 24,
25). ICOS is induced rapidly on T-cells after TCR engagement and is retained on
many memory T-cells, suggesting that ICOS provides co-stimulatory signals to
activated T-cells. Indeed, during the initial activation of naïve T-cells, the effects of
ICOS on T-cell proliferation and IL-2 production are modest in comparison to those
of CD28. Signals through ICOS seem to be more important for the regulation of
cytokine production by effector T-cells.
ICOS−/− mice were susceptible to the influx of inflammatory cells in the broncho-
alveolar lavage fluid (BALF) induced by airway challenge in primed mice (26). In
blocking studies, the ICOS:B7RP-1 pathway was interrupted during antigen-
sensitization and/or airway challenge (27, 28) or solely during the final aerosol
challenge (29). Collectively, these blocking studies suggest that ICOS co-stimulation
may contribute more to the effector phase than to the initiation of Th2-dominated
allergic inflammatory responses (26-29).
In the present study, we compared the effects of ICOS blockade by ICOS-Fc
during the development of asthma-like symptoms in mice (induction model) with
the effects of ICOS-Fc administration after the development of airway symptoms
when antigen exposures were continued (ongoing model) (23). In both OVA-induced
models, airway hyperresponsiveness to methacholine in vivo, OVA-specific IgE levels
in serum and the cellular composition of the BALF was determined at 24 h after the
last aerosol. In agreement with an earlier study (27), administration of ICOS-Fc
significantly inhibited the number of inflammatory cells in the BALF, but had no
effect on airway hyperresponsiveness in vivo and serum OVA-specific IgE levels.
However, in the ongoing model, administration of ICOS-Fc failed to reduce any of
the final asthma-like symptoms. Likewise, ICOS-Fc did not inhibit lung cell IL-5
production upon OVA re-stimulation in vitro. So, in this ongoing murine model,
ICOS appears to play no role in the regulation of Th2 effector cell function in the
lung.
MATERIALS AND METHODS
Animals
Specific pathogen-free male BALB/c mice were obtained from Charles River
(Maastricht, The Netherlands). Six wk old mice were used for our studies. Animal
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care and use were performed in accordance with the guidelines of the Dutch
Committee of Animal Experiments.
Determination of the ability of human ICOS-Fc to bind murine B7RP-1
The ability of human ICOS fused to the Fc region of human IgG (hICOS-Fc; produced
in the laboratory of Dr. A.J. Coyle, Millenium Pharmaceuticals, Cambridge, MA,
USA) to bind murine B7RP-1 was determined by flow cytometric analysis. CHO
cells stably transfected with cDNA encoding murine B7RP-1 (kindly provided by
Dr. C.P.M. Broeren, Department of Immunology, Faculty of Veterinary Medicine,
Utrecht University) or non-transfected CHO cells (105 cells/well) were incubated in
a 96 well round-bottomed plates (Greiner Bio-One, Kremsmuenster, Austria) with
FACS buffer (PBS, 1% fetal calf serum [FCS], 0.1% NaN3) containing 1:500 diluted
supernatant of the hybridoma of the 2.4G2, IgG2b mAb (rat anti mouse FcγII/III
receptor). After blocking, cells were incubated with 10 µg/ml human IgG (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or hICOS-Fc. Hereafter, cells were
incubated with 1 µg/ml goat F(ab’)2 anti-human IgG-γ-FITC (Protos Immunosearch,
Burlingame, CA, USA). All incubations were performed for 20 min at 4°C in the
dark. Cells were analyzed on a FACS Calibur using Cell Quest (Becton-Dickinson,
San Jose, CA, USA).
Culture of thoracic lymph node- and lung cells
Mice (n = 4) were sensitized and challenged as described below for the experiment
in the induction model of allergic asthma. At 24 h after the last OVA aerosol, lungs
were lavaged as described below. First, lung-draining lymph nodes were collected
from the thorax and transferred to cold sterile PBS. Thoracic lymph nodes (TLNs)
from four mice were pooled; this experiment was performed in duplicate. Next,
lungs were perfused via the right heart ventricle with 4 ml saline at 37°C containing
100 U/ml heparin (Leo Pharmaceuticals, Weesp, The Netherlands) to remove any
blood and intravascular leukocytes. Complete lung tissue was removed and transferred
to cold sterile PBS and subsequently cultured from each mouse individually.
TLNs were filtered through a 70-µm nylon cell strainer (Becton Dickinson
Labware, Franklin Lakes, NJ, USA) with 5 ml RPMI 1640 to obtain a single-cell
suspension. Lungs were minced and digested in 3 ml RPMI 1640 containing 2.4 mg/
ml collagenase A and 1.0 mg/ml DNase I (grade II) (both from Roche Diagnostics,
Basel, Switzerland) for 30 min at 37°C. Enzyme activity was stopped by adding 1
ml FCS. The lung tissue digest was filtered with 10 ml RPMI 1640 to obtain a
single-cell suspension. The TLN- and lung-cell suspensions were washed,
resuspended in culture medium (RPMI 1640 supplemented with 10% FCS, 1%
glutamax I and gentamicin [both from Life Technologies, Gaithersburg, MD, USA]
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and 50 µM β-mercaptoethanol [Sigma]), and the total number of cells were determined
using a Bürker-Türk counting-chamber.
Cells (2 × 105 TLN cells/well, 8 × 105 lung cells/well) were cultured in 96-well
round-bottomed plates (Greiner Bio-One) in the presence of OVA (chicken egg
albumin, crude grade V, Sigma, St. Louis, MO, USA). (10 µg/ml) and various
concentrations of hICOS-Fc or human total IgG (ranging from 0-50 µg/ml). In
addition, cells were cultured with medium only as negative control. After 5 d of
culture at 37°C in 5% CO2, the supernatant was harvested, and stored at -20°C until
determination of cytokine levels by ELISA.
Antigen sensitization and challenge and experimental treatment protocol
All mice were sensitized to OVA. Systemic sensitization was performed by two
intraperitoneal (i.p.) injections of 10 µg OVA adsorbed onto 2.25 mg aluminum
hydroxide (alum; ImjectAlum, Pierce, Rockford, IL, USA) in 0.1 ml pyrogen-free
saline on day 0 and 7.
For the experiment in the induction model of allergic asthma, mice were
challenged three times by inhalation of an OVA aerosol for 20 min on day 28, 31
and 34. Throughout the antigen challenge period (day 28-34), mice received 70 µg
human total IgG as control treatment or 70 µg hICOS-Fc as experimental treatment
dissolved in 0.2 ml pyrogen-free saline (one i.p. injection per day). This dosage
regimen was designed on the basis of successful studies with ICOS-Ig described in
literature (27-30).
For the experiment in the ongoing murine model of allergic asthma, mice
received six saline aerosols, six OVA aerosols, or three OVA aerosols followed by
three saline aerosols (“spontaneous resolution group”) for 20 min on day 27, 30, 33,
36, 39 and 42 (see Table 1). Throughout the period of the fourth to sixth aerosol
challenge (day 36-42), mice received 70 µg control treatment or 70 µg hICOS-Fc in
0.2 ml pyrogen-free saline (one i.p. injection per day) as indicated in Table 1. On
days that treatment coincided with an aerosol challenge, treatment was administered
30 min before aerosol challenge.
The aerosols were generated in a plexiglass exposure chamber (5 liter) by
nebulizing an OVA solution (10 mg/ml in pyrogen-free saline) or saline using a Pari
LC Star nebulizer (PARI Respiratory Equipment, Richmond, VA, USA; particle
size 2.5–3.1 µm) driven by compressed air at a flow rate of 6 liters/min.
Human total IgG was purchased from ICN Pharmaceuticals (Costa Mesa, CA,
USA) and dissolved in pyrogen-free saline. This solution was treated with 10% (v/v)
polymyxin B-agarose (Sigma; washed twice with saline) for 1 h at 4°C to remove
lipopolysaccharide. After incubation, agarose beads were removed by centrifugation,
and the supernatant was sterilized.
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Measurement of airway responsiveness in vivo
Airway responsiveness was measured in conscious, unrestrained mice on day 22 and
35 (6 d before the OVA aerosol challenge period and at 24 h after the last OVA
aerosol challenge, respectively [experiment in the induction model of allergic asthma])
or on day 43 only (at 24 h after the last aerosol challenge [experiment in the ongoing
model of allergic asthma]), by recording respiratory pressure curves in response to
inhaled nebulized methacholine (methacholine (acetyl-β-methylcholine chloride;
Sigma) using barometric whole-body plethysmography (Buxco; EMKA
Technologies, Paris, France). Airway responses were expressed in enhanced pause
(Penh), an index of airway obstruction as described in detail previously (31). Briefly,
mice were placed in a whole-body chamber and pressure differences between this
chamber and a reference chamber were recorded. After baseline Penh values were
obtained for 3 min and averaged, animals were exposed to a saline aerosol and a
series of methacholine aerosols (solutions doubling in concentration, ranging from
1.56–50 mg/ml in saline). Aerosols were generated by a Pari LC Star nebulizer for 3
min and after each nebulization readings were taken for 3 min and averaged.
Determination of OVA-specific IgE levels in serum
In the experiment in the induction model of allergic asthma, at day 25 (3 d before the
OVA aerosol challenge period), approximately 0.25 ml blood was recovered from
mice by an incision the tail vein. After measurement of airway responsiveness in
vivo at 24 h after the last OVA aerosol challenge on day 35 (experiment in the
induction model of allergic asthma) or day 43 (experiment in the ongoing model of
allergic asthma), mice were sacrificed by i.p. injection of 1 ml 10% urethane (Sigma)
in sterile saline and bled by cardiac puncture. Serum was prepared from blood samples
and stored at -20°C until determination of OVA-specific IgE levels by ELISA. Briefly,
maxisorp 96-wells flat-bottomed microtiter plates (Nunc A/S, Roskilde, Denmark)
were coated overnight at 4°C with 1 µg/ml rat anti-mouse IgE mAb (clone R35-72,
PharMingen, San Diego, CA, USA) diluted in phosphate-buffered saline (PBS). The
next day, the ELISA was performed at room temperature using ELISA buffer (PBS
containing 0.5% bovine serum albumin [BSA, Sigma], 2 mM EDTA, 136.9 mM
NaCl, 50 mM Tris, 0.05% Tween-20 [Merck, Whitehouse Station, NJ, USA], pH
7.2) for blocking and dilution of samples, standard and reagents and PBS containing
0.05% Tween-20 for washing between incubations. After blocking of wells for 1 h,
serum samples and a duplicate dilution series of an OVA-specific reference serum
(starting 1:40) were added to the wells and incubated for 2 h. An OVA-specific IgE
reference serum was obtained by sensitization and challenge of mice with OVA as
above-described for the induction model of allergic asthma and arbitrarily assigned
a value of 1,000 experimental units/ml (EU/ml). Hereafter, 1 µg/ml of OVA labeled
to digoxigenin (DIG) by a DIG protein labeling kit (Roche Diagnostics) was added
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for 1.5 h, followed by incubation with 1:500 diluted anti-DIG-Fab fragments coupled
to horseradish peroxidase (Roche Diagnostics) for 1 h. Color development was
performed with o-phenylenediamine-dichloride substrate (0.4 mg/ml, Sigma) and 4
mM H2O2 in PBS and the reaction was stopped by adding 4 M H2SO4. The optical
density was read at 490 nm, using a Benchmark microplate reader (Bio-Rad
Laboratories, Hercules, CA, USA). Results were analyzed with Microplate Manager
PC software (Bio-Rad Laboratories). The lower detection limit of the ELISA was 4
EU/ml IgE.
Analysis of the BALF
BAL was performed immediately after bleeding of the mice by lavage of the airways
through a tracheal cannula with 1 ml saline at 37°C containing 5% BSA and 2 µg/ml
aprotinine (Roche Diagnostics). The recovered lavage fluid of this first ml was kept
apart for determination of cytokines in the supernatant by ELISA. Subsequently,
mice were lavaged four times with 1 ml aliquots of saline only at 37°C. Recovered
lavage fluid of the second through fifth ml was pooled and cells (including those
from the first ml) were pelleted (387 × g, 4°C, 10 min), and resuspended in 0.15 ml
cold PBS. The total number of cells in the BALF was determined using a Bürker-
Türk counting-chamber (Karl Hecht Assistent KG, Sondheim/Röhm, Germany). For
differential BALF cell counts, cytospin preparations were made (15 × g, 4°C, 5 min)
using a cell container (Kendro Heraues Instruments, Asheville, NC, USA), and cells
were fixed and stained with Diff-Quick (Dade AG, Düdingen, Switzerland). Per
cytospin, at least 200 cells were counted and differentiated into mononuclear cells
(monocytes, macrophages and lymphocytes), eosinophils and neutrophils by standard
morphology and staining characteristics.
Measurement of cytokines
Supernatants of the first ml BALF and TLN cell-cultures were analyzed for IFN-γ,
IL-4, IL-5 and IL-10 content by sandwich ELISA using Ab pairs and standards
purchased from PharMingen, according to the manufacturer’s instructions. The lower
detection limits of the ELISAs were 16 pg/ml for IFN-γ, 16 pg/ml for IL-4, 32 pg/ml
for IL-5, and 63 pg/ml for IL-10.
Statistical analysis
All data are expressed as mean ± standard error of mean (SEM). The airway dose-
response curves to methacholine were statistically analyzed by a general linear model
of repeated measurements followed by post-hoc comparison between groups. Data
were log10 transformed before analysis to equalize variances in all groups. Statistical
analysis on BALF cell counts was performed using the non-parametric Mann Whitney
U test. For all other parameters, results were statistically analyzed using a Student’s
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t test (two-tailed, homosedastic). Differences between groups were considered
statistically significant at the p < 0.05 level. Statistical analyses were performed
using SPSS for Windows version 10.0.5 (SPSS, Chicago, IL, USA).
RESULTS
Human ICOS-Fc binds murine B7RP-1
First, the ability of human ICOS fused to the Fc region of human IgG (hICOS-Fc) to
bind murine B7RP-1 was examined by flow cytometric analysis. To this end, CHO
cells stable transfected with cDNA encoding murine B7RP-1 were pre-incubated
with 10 µg/ml hICOS-Fc or isotype control antibody (human IgG), followed by
incubation with goat anti-human-IgG-FITC. As shown in Figure 1A, pre-incubation
of cells with hICOS-Fc resulted in a shift of the fluorescence signal. Untransfected
CHO cells displayed no staining upon this pre-incubation (Figure 1B).
A B
Figure 1: Human ICOS-Fc binds murine B7RP-1. CHO cells transfected with murine B7RP-1 (A) or
untransfected CHO cells (B) were pre-incubated with 10 µg/ml hICOS-Fc (solid line) or isotype
control antibody (human IgG, dotted line), followed by incubation with goat anti-human-IgG-FITC.
Human ICOS-Fc inhibits IL-5 production by primed murine lymphocytes derived
from the thoracic lymph nodes but not those derived from the lungs in vitro
Next, the effect of hICOS-Fc on cytokine production by primed antigen-specific T-
cells was determined ex vivo. Asthma-like symptoms were induced in BALB/c mice
by systemic sensitization to OVA adsorbed to alum followed by three OVA aerosol
challenges. At 24 h after the last aerosol, single-cell suspensions of the thoracic
lymph nodes (TLNs) and lung tissue were prepared. Lymphocytes were re-stimulated
for 5 d with 10 µg/ml OVA in the presence of various concentrations of either hICOS-
Fc or human total IgG as control. As shown in Figure 2, in the presence of human
total IgG, lymphocytes derived from both tissues produced IL-5 upon re-stimulation
with OVA, whereas no IFN-γ could be detected in the supernatants above medium
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control values (data not shown), indicative of a Th2 response. Human ICOS-Fc dose-
dependently inhibited IL-5 production by TLN cells upon antigenic re-stimulation
(Figure 2A). Notably, hICOS-Fc did not inhibit IL-5 production by OVA re-stimulated
lung lymphocytes (Figure 2B).
Figure 2: Human ICOS-Fc inhibits IL-5 production by primed murine lymphocytes derived from the
thoracic lymph nodes but not those derived from the lungs in vitro. BALB/c mice (n = 4) were sensitized
to OVA adsorbed to alum and challenged with three OVA aerosols. At 24 h after the last OVA aerosol
challenge, single-cell suspensions of the thoracic lymph nodes (A; pooled from four mice; experiment
performed in duplicate) and lung tissue (B; cultured from each mouse individually) were prepared.
Lymphocytes were re-stimulated with 10 µg/ml OVA in the presence of various concentrations of
either hICOS-Fc or human total IgG as control, and after 5 d the level of IL-5 in the supernatant of the
cultures was determined.
Effects of ICOS blockade on the development of asthma-like symptoms in mice
The effects of ICOS blockade in vivo were first determined on the development of
Th2-dominated allergic inflammatory responses. To this end, asthma-like symptoms
were induced in BALB/c mice by systemic sensitization to OVA adsorbed to alum
followed by three OVA aerosol challenges. Throughout the antigen challenge period,
one group of animals received human total IgG as control treatment and a second
group received hICOS-Fc.
Airway hyperresponsiveness in vivo
Airway responsiveness to methacholine in vivo was determined in conscious,
unrestrained mice by barometric whole-body plethysmography and was measured
well after sensitization to OVA but before the aerosol challenge period and at 24 h
after the last OVA aerosol. As shown in Figure 3A, OVA-sensitized, yet untreated,
BALB/c mice demonstrated a dose-dependent increase in Penh, an index of airway
obstruction, in response to aerosolized methacholine. Upon OVA aerosol challenge,
control-treated mice developed non-specific airway hyperresponsiveness because
the complete methacholine dose-response curve (DRC) is significantly different from
the DRC obtained before challenge (p < 1 × 10-6). Treatment of mice with hICOS-Fc
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during the OVA aerosol challenge period had no effect on the development of
hyperresponsiveness in vivo. At the higher concentrations of the methacholine DRC,
the airway responses of hICOS-Fc-treated mice seemed to be even higher compared
with control-treated animals. However, both the complete DRC and the airway
responses to the separate concentrations of methacholine were not significantly
different between the two treatment groups.
Figure 3: Effects of ICOS blockade on the development of asthma-like symptoms in mice. BALB/c
mice were sensitized to OVA adsorbed to alum and challenged with three OVA aerosols. Throughout
the aerosol challenge period, mice received control treatment (human total IgG, open bars; n = 8) or
hICOS-Fc (closed bars; n = 8). Airway responsiveness in vivo to aerosolized methacholine (A) and
OVA-specific IgE levels in serum (B) were first determined well after sensitization to OVA but before
the OVA aerosol challenge period in yet untreated animals (shaded bars; n = 16). At 24 h after the last
OVA aerosol, airway responsiveness in vivo (A) and OVA-specific IgE levels in serum (B) were
determined again in addition to cellular compostion in the BALF (C) and the level of Th2 cytokines in
the BALF (D). Values are expressed as mean ± SEM. *** p < 0.001, as compared with yet untreated,
OVA-sensitized animals. # p < 0.05 and ## p < 0.01, as compared with control-treated, OVA-challenged
animals.
OVA-specific IgE levels in serum
To determine allergen-specific IgE levels in serum, blood was withdrawn from each
mouse well after sensitization to OVA but before the aerosol challenge period and at
24 h after the last OVA aerosol. In sera from naïve BALB/c mice, no OVA-specific
IgE could be detected (chapter 2). After sensitization to OVA, antigen-specific IgE
A
0
2
4
6
8
10
12
14
16
basal saline 1.56 3.13 6.25 12.5 25 50
methacholine (mg/ml)
a
irw
a
y 
re
sp
o
n
se
 
(P
e
n
h)
untreated
human total IgG
hICOS-Fc
***
***
B
0
10
20
30
40
50
60
70
80
OV
A-
sp
e
ci
fic
 Ig
E 
(x1
03
 
EU
/m
l)
untreated
human total IgG
hICOS-Fc
***
***
C
0
1
2
3
4
5
6
eo's neutro's MNCs total
cell type
n
u
m
be
r 
o
f c
e
lls
 
(x1
06
) human total IgG
hICOS-Fc
##
#
p  = 0.06
D
0
0.5
1
1.5
2
2.5
3
IL-5 IL-10
cytokine
co
n
ce
n
tra
tio
n
 
(ng
/m
l) human total IgG
hICOS-Fc
#
Chapter 4
82
was found in the sera from the yet untreated mice (4,171 ± 675 EU/ml) (Figure 3B).
In control-treated mice, these levels were greatly up-regulated upon OVA aerosol
challenge (51,458 ± 9,820 EU/ml, p < 1 × 10-6). Treatment of mice with hICOS-Fc
during the OVA aerosol challenge period had no effect on this up-regulation induced
by OVA challenge (59,141 ± 11,594 EU/ml).
Cellular and cytokine composition of the BALF
The number of various leukocytes in the BALF was used as a measure for the
infiltration of these cells in the airways and was determined at 24 h after the last
OVA aerosol challenge. In naïve or OVA-sensitized, saline-challenged mice only
some mononuclear cells (monocytes, macrophages and lymphocytes) could be
observed in the BALF (chapters 2, 3 and 5) (Figure 4C). In OVA-sensitized, control-
treated mice, OVA aerosol challenge resulted in an influx of inflammatory cells in
the BALF, consisting predominantly of eosinophils besides an increase in
mononuclear cells and the appearance of a few neutrophils (Figure 3C). In the group
of mice treated with hICOS-Fc during the OVA aerosol challenge period, very similar
percentages of each cell type were observed compared with control-treated mice.
However, the total number of cells in the BALF induced by OVA challenge was
significantly inhibited in hICOS-Fc-treated mice compared with control-treated
animals (p < 0.01) and consequently the absolute numbers of eosinophils and
mononuclear cells (p = 0.06 and p < 0.05, respectively).
The influx of inflammatory cells in the BALF upon OVA aerosol challenge of
OVA-sensitized, control-treated mice was accompanied by the presence of IL-5 and
IL-10 (1.68 ± 0.33 ng/ml and 0.91 ± 0.20 ng/ml, respectively), but no detectable
levels of IFN-γ, pointing to a Th2-dominated allergic inflammatory response (Figure
3D). Treatment of mice with hICOS-Fc during the OVA aerosol challenge period
had no effect on the level of IL-5 in the BALF (1.92 ± 0.65 ng/ml) induced by OVA
challenge, but resulted in a significantly reduced level of IL-10 (0.29 ± 0.13 ng/ml,
p < 0.05) compared with control-treated animals.
So, blockade of ICOS during the allergen challenge period of OVA-sensitized
mice had no effect on the development of airway hyperresponsiveness in vivo and
the up-regulation of OVA-specific IgE levels in serum. However, the total number
of cells and the level of IL-10 but not IL-5 in the BALF were significantly reduced.
Effects of ICOS blockade in an ongoing murine model of allergic asthma
Subsequently, we sought to determine the effects of ICOS blockade in an ongoing
murine model of allergic asthma (see Table 1). Group 4 was included in the experiment
to compare the effects of hICOS-Fc on established asthma manifestations with
ongoing OVA exposures (Group 3) to stopping with OVA aerosols and continuing
with saline aerosols (hereafter referred to as the “spontaneous resolution group”).
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Table 1: Experimental design to determine the effects of ICOS blockade in an ongoing murine model
of allergic asthma.
Mice were sensitized, challenged, and treated as described in MATERIALS AND METHODS. Each
experimental group consisted of eight animals.
Airway hyperresponsiveness in vivo
Airway responsiveness to methacholine in vivo was determined at 24 h after the last
(sixth) aerosol challenge. In control-treated mice, OVA aerosol challenge of OVA-
sensitized mice resulted in non-specific airway hyperresponsiveness because the
complete methacholine DRC of this group of mice was significantly different (p <
0.00005) from that of saline-challenged mice (Figure 4A). Treatment of mice with
hICOS-Fc after the development of asthma manifestations during ongoing OVA
aerosols had no effect on the final airway hyperresponsiveness. The spontaneous
resolution group showed a reduced final non-specific hyperresponsiveness in vivo
compared with control-treated, OVA-challenged mice (Group 2), but the difference
between the methacholine DRCs of these two groups of animals did not reach
statistical significance (p = 0.12).
OVA-specific IgE levels in serum
After measurement of airway responsiveness in vivo, mice were sacrificed and bled
by cardiac puncture to determine allergen-specific IgE levels in serum. In control-
treated mice, OVA aerosol challenge of OVA-sensitized mice resulted in an up-
regulation of serum OVA-specific IgE compared with saline-challenged animals
(49,991 ± 6,094 EU/ml versus 28,982 ± 11,911 EU/ml, p = 0.14) (Figure 4B).
Treatment of mice with hICOS-Fc after the development of asthma manifestations
during ongoing OVA aerosols had no effect on the final levels of antigen-specific
IgE in serum induced by OVA aerosol challenge (52,767 ± 9,625 EU/ml). Also the
serum OVA-specific IgE levels from the spontaneous resolution group were similar
to those of control-treated, OVA-challenged mice (44,435 ± 8,051 EU/ml).
Cellular composition of the BALF
After cardiac puncture, the lungs were lavaged to determine the numbers of various
inflammatory cell types that had infiltrated the airway lumen. In control-treated mice,
OVA aerosol challenge of OVA-sensitized mice resulted in a significant (p < 0.0001)
increase in the number of eosinophils, mononuclear cells and hence the total number
Group Sensitization Challenge
Aerosol 1-3 Aerosol 4-6
Treatment
(throughout aerosol 4-6)
1 OVA/alum Saline Saline Human total IgG
2 OVA/alum OVA OVA Human total IgG
3 OVA/alum OVA OVA Human ICOS-human Fc
4 OVA/alum OVA Saline (spontaneous
resolution group)
Human total IgG
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of cells, compared with saline-challenged animals (Figure 4C). The appearance of a
few neutrophils in the BALF of some animals upon OVA-challenge is too small to
be seen in Figure 4C (9,842 ± 5,386). Treatment of mice with hICOS-Fc after the
development of asthma manifestations during ongoing OVA aerosols slightly reduced
the total number of inflammatory cells and therefore the numbers of eosinophils and
mononuclear cells compared with control-treated mice, but none of these reductions
did reach statistical significance (p = 0.14, p = 0.28 and p = 0.08, for the total number
of cells, the number of eosinophils and mononuclear cells, respectively). In the
spontaneous resolution group, the final number of eosinophils and consequently the
total number of cells were significantly reduced compared with control-treated, OVA-
challenged animals (p < 0.0005 for the number of eosinophils and total number of
cells).
Figure 4: Effects of ICOS blockade in an ongoing murine model of allergic asthma. BALB/c mice
were sensitized to OVA adsorbed to alum and challenged with six saline aerosols (shaded bars; n =
8), six OVA aerosols (open bars and closed bars; n = 8 per group) or three OVA aerosols followed by
three saline aerosols (lightly shaded bars; spontaneous resolution group; n = 8). Throughout the period
of the fourth to sixth aerosol challenge, mice received control treatment (human total IgG, (lightly)
shaded bars and open bars) or hICOS-Fc (closed bars). Airway responsiveness in vivo to aerosolized
methacholine (A), OVA-specific IgE levels in serum (B) and the cellular compostion of the BALF (C)
were determined at 24 h after the last aerosol. Values are expressed as mean ± SEM. *** p < 0.001, as
compared with control-treated, saline-challenged animals. ### p < 0.001, as compared with control-
treated, OVA-challenged animals.
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So, blockade of ICOS after the development of asthma-like symptoms in mice
that were subjected to ongoing OVA aerosols had no effect on the final airway
hyperresponsiveness in vivo, OVA-specific IgE levels in serum and inflammatory
cell numbers.
DISCUSSION
Asthma patients usually start therapy after the development of airway symptoms,
while exposure to environmental allergen mostly continues. Studies on the role of
ICOS in murine models of allergic asthma suggest that ICOS-mediated co-stimulation
might play a more prominent role in the effector phase than in the initiation phase of
Th2-dominated allergic inflammatory responses (26-29). In the present study, we
compared the effects of ICOS blockade by hICOS-Fc during the development of
asthma-like symptoms by aerosol challenge of OVA-sensitized mice (induction
model) or after the development when antigen exposures were continued (ongoing
model). In the induction model, treatment of mice with hICOS-Fc resulted in
significantly decreased numbers of inflammatory cells in the BALF, but had no
effect on non-specific airway hyperresponsiveness and serum OVA-specific IgE
levels. In the ongoing model, administration of hICOS-Fc did not alter any of the
final asthma-like symptoms. Similarly, IL-5 production by primed lung cells was
unaffected upon re-stimulation with OVA in the presence hICOS-Fc ex vivo.
With regard to the role of ICOS in the development of asthma-like symptoms,
it has been shown that sensitization and aerosol challenge of ICOS−/− mice with
OVA resulted in strongly inhibited serum OVA-specific IgE levels compared with
wild-type mice (26). However, ICOS−/− mice exhibited similar numbers of eosinophils,
lymphocytes and monocytes/macrophages as wild-type mice. In contrast, in a study
using a murine model of allergic asthma induced by the Schistosoma mansoni parasite,
it was demonstrated that administration of ICOS-Ig during sensitization and challenge
of C57BL/6 mice, resulted in a reduced number of inflammatory cells in the BALF
accompanied by a decrease in the level of IL-5 (27), but no effect on the serum total
IgE level was observed. Whereas we used OVA as antigen and BALB/c mice, our
results are very much in agreement with this latter study. Tesciuba et al. showed that
the reduced number of inflammatory cells in the airways was not due to a lack of T-
cell priming nor to a defect in Th2 differentiation as determined by unaltered
proliferation and Th2 cytokine production of both splenocytes and lung lymphocytes
upon antigenic re-stimulation ex vivo. Likewise, we observed no difference in IL-5
and IL-10 production between lung cell cultures derived from control- and hICOS-
Fc-treated mice re-stimulated with OVA in vitro (data not shown). The reduced
amount of IL-10 in the BALF of hICOS-Fc-treated mice compared with control-
treated mice observed in the present study may be in agreement with the generally
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agreed role for ICOS in T-cell IL-10 production (24). However, because IL-10 is a
potent anti-inflammatory mediator (32), this is unlikely to explain the reduced amount
of BALF inflammatory cells seen in both studies. A unique finding of the present
study is that the development of airway hyperresponsiveness, that is dependent on
CD4+ T-cells (33, 34), was not affected by the interruption of the ICOS:B7RP-1
pathway. So, T-cell co-stimulation via ICOS appears not to be essential for the
development of Th2-dominated allergic inflammatory responses in mice.
Interestingly, hICOS-Fc dose-dependently inhibited the production of the
prototypical Th2 cytokine IL-5 by TLN cell cultures derived from OVA-sensitized
and challenged mice, but lung IL-5 production was unaffected (Figure 2). In a previous
study by our laboratory, differences in antigen-induced proliferation and cytokine
production between these TLN and lung cell cultures were demonstrated (35). In the
supernatant of TLN cell cultures also IL-4 was found upon OVA re-stimulation,
whereas lung cells produced only IL-5. Moreover, TLN cells proliferated upon
polyclonal stimulation and antigenic re-stimulation, but lung cells failed to do so.
Collectively, these data suggest that different populations of antigen-specific T-cells
are present in the TLNs and lung tissue in this model that are differentially dependent
on ICOS signaling for cytokine production. In agreement herewith is the observation
by Garlisi et al. that IL-5 mRNA, but not IL-4 mRNA, was detected in BALF T-cells
after sensitization and challenge of mice with OVA (36). Likewise, bronchial explant
cultures from moderately severe asthma patients produced only IL-5 upon allergen
stimulation, whereas peripheral blood mononuclear cells cultures from the same
subjects produced also IL-13 and granulocyte-macrophage-colony stimulating factor
(37). Moreover, Campbell et al. identified specialized “B helper” and “tissue
inflammatory” CD4+ T effector subsets that developed concurrently from common
naïve precursors during the primary immune response in BALB/c mice (38). These
separable populations were distinguishable by their expression of chemoattractant
receptors for chemokines expressed in peripheral lymphoid organs and inflamed
tissue, respectively. Similarly, two distinct types of human CD4+ and CD8+ memory
cells have been identified on the basis of chemokine receptor expression: “central
memory” cells present in secondary lymphoid tissues and “effector memory” cells
residing in peripheral tissues (see 39). In the ongoing murine model, we observed no
effects by hICOS-Fc administration on the final asthma-like symptoms. This might
indicate that the population of OVA-specific T-cells in the lung that are insensitive
to blockade of ICOS in vitro, is mainly involved in the maintenance of the ongoing
allergic inflammatory Th2 response.
The lack of effect by hICOS-Fc in the ongoing murine model of allergic asthma
appears to be in contrast with studies of Coyle and colleagues in murine models of
allergic asthma in which effector Th2 cells dominate at the time of ICOS blockade
(28, 29). In their first study, CD4+ T-cells of BALB/c mice with a transgenic TCR
ICOS and the Th2-dominated effector phase of allergic asthma
87
that recognizes residues 323-339 of OVA were differentiated in vitro towards the
Th2 phenotype before adoptive transfer to wild-type BALB/c mice. Administration
of ICOS-Ig inhibited the ability of these cells to mediate eosinophilic lung
inflammation and airway hyperresponsiveness following airway challenge (28). The
generation of Th2 cells in vitro may result in effector T-cells with migratory and
functional properties that are uncommon in vivo. However, in the second study of
this group, mice were actively sensitized and aerosol challenged with OVA (29).
The authors observed that administration of mAb 12A8 against ICOS solely during
the last (seventh) aerosol challenge of OVA-sensitized mice significantly reduced
the amount of BALF inflammatory cells and airway hyperresponsiveness, whereas
ICOS blockade only at the time of sensitization had little effect upon subsequent
airway challenge. The various parameters in this study were measured at 3 h after
the last OVA aerosol challenge. When we administered the same dose of the 12A8
mAb in the murine model of ongoing disease, we observed, at 24 h after the last
OVA aerosol challenge, no alteration in the final manifestations of allergic asthma,
similar to administration of hICOS-Fc (D.T. Deurloo, unpublished observations).
Perhaps, ICOS exerts its inhibitory effect in a narrow time window of the T-cell
effector phase.
In contrast with this study of Gonzalo et al. (29), we sensitized mice to OVA in
the presence of alum adjuvant that induces a Th2-dominant response in vivo resulting
in relatively stronger inflammatory responses compared with immunization without
adjuvant (chapters 3 and 5). It is generally acknowledged that not only the mode of
sensitization but also the challenge protocol might influence the outcome of an
experimental study (23, 40, 41). However, in ICOS−/− mice, it has been shown that
immunization with antigen in the presence of alum did not bypass the requirement
for ICOS (26, 42, 43). Moreover, the challenge protocols were fairly similar in both
studies. Lastly, the genetic background may have had a role in the different results
because Gonzalo et al. used C57BL/6 mice for their experiments, whereas we made
use of BALB/c mice. Future experiments might explain the discrepancies between
this study and those of Coyle and colleagues.
Apart from its role in co-stimulation of Th2 responses, a new role for ICOS co-
stimulation was recently shown in T-cell tolerance to respiratory allergens (44).
Pulmonary dendritic cells (DCs) have been shown to induce the development of
allergy-mediating Th2 cells (45) and CD4+ regulatory T-cells -producing primarily
IL-10 and low levels of IL-4 (46)- that inhibit Th2 cells, thus protecting against
asthma development (44, 47). The specific signals that preferentially induce
development of CD4+ regulatory T-cells rather than Th2 cells are not entirely clear,
but may involve IL-10 production by DCs (44, 47). However, both the development
and inhibitory function of CD4+ regulatory T-cells were shown to be dependent on
the ICOS:B7RP-1 signaling pathway (44). In these studies, CD4+ regulatory T-cells
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were induced by intranasal exposure to OVA that inhibited the development of asthma
manifestations upon subsequent re-challenge with OVA. Adoptive transfer of these
CD4+ regulatory T-cells into OVA-sensitized mice potently inhibited asthma-like
symptoms following aerosol challenge (44). Although it is unclear if regulatory T-
cells play a role in our models in which mice are not previously exposed to intranasal
OVA, blockade of ICOS may on the one hand alleviate airway symptoms by the
inhibition of Th2 cells and on the other hand aggravate symptoms by the inhibition
of regulatory T-cells.
The experimental murine model of ongoing disease has been designed in an
attempt to more closely resemble the clinical situation in which patients start treatment
after the onset of airway symptoms and demonstrates the difficulty of reversing
established symptoms with ongoing antigen exposures in mice. Whereas CTLA4-
IgG and the “gold-standard” dexamethasone were partially effective in this model in
that serum antigen-specific IgE levels and BALF eosinophilia could be reduced (23),
hICOS-Fc had no effect. In addition, the combined administration of CTLA4-IgG
and mAb 12A8 against ICOS did not have a synergistic effect (data not shown).
Future studies using the ongoing model may elucidate which (combination of) other
signals are required for allergic inflammatory responses dominated by antigen-
experienced CD4+ T-cells.
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ABSTRACT
In the present study, we investigated if blockade of T-cell co-stimulation during the
aerosol challenge period of antigen-sensitized mice results in long-term amelioration
of asthma-like symptoms that is, not only immediately after challenge but also upon
antigen re-challenge after serum clearance of experimental treatment. BALB/c mice
were sensitized to alum-adsorbed ovalbumin (OVA) and challenged with saline or
OVA aerosols. Before the first aerosol challenge, mice received control treatment,
anti-CD40 ligand (CD40L) mAb (MR1), murine CTLA4-IgG or the combination of
anti-CD40L mAb and CTLA4-IgG. In control-treated animals, OVA-challenge
induced airway hyperresponsiveness (AHR) in vivo and up-regulated levels of serum
OVA-specific IgE compared with saline-challenged mice. CTLA4-IgG prevented
both parameters, whereas anti-CD40L mAb solely prevented the up-regulation of
serum OVA-IgE levels. Eleven weeks later, after serum clearance of treatments,
OVA re-challenge induced AHR, up-regulated levels of serum OVA-IgE and the
influx of eosinophils in the broncho-alveolar lavage fluid (BALF) in control-treated
animals compared with saline-challenged mice. Only CTLA4-IgG-treated mice
demonstrated tolerance with respect to the number of eosinophils in the BALF induced
by OVA re-challenge (46% inhibition). Interestingly, in a “mild” model of allergic
asthma, in which mice are sensitized without adjuvant and challenged with lower
doses of OVA, CTLA4-IgG had a long-term effect on both OVA-specific IgE levels
and BALF esoinophilia (69% and 80% inhibition, respectively). So, CTLA4-IgG
can induce partial tolerance in OVA-induced murine models of allergic asthma, its
effectiveness being dependent on the “severity” of the model used.
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INTRODUCTION
Allergic asthma is a complex inflammatory disease of the lung characterized by
reversible airflow obstruction, persistent airway hyperresponsiveness and chronic
airway inflammation. As a result of the chronic inflammation, airway tissue is
continuously being injured and healed resulting in structural changes (called
remodeling) of airway tissue that further aggravates the disease (1).
Allergen-specific T helper (Th) type 2 cells play a pivotal role in the pathogenesis
and progression of allergic asthma by orchestrating the inflammatory response (2).
Th2 cells are characterized by the array of cytokines they secrete, such as IL-4, IL-
5, IL-9, IL-10 and IL-13, which are optimized to combat parasite infections (3).
However, Th2 cells are developed undesirably in allergic disorders such as asthma,
their cytokines causing airway symptoms either directly or mediated by other immune
cells and their mediators (4). Therefore, silencing the allergen-specific T-cells,
preferably not temporarily, but long lasting, is an interesting therapeutic approach.
One therapeutic strategy to silence allergen-specific CD4+ T-cells is the
prevention of optimal activation by blocking their co-stimulatory requirements. For
optimal activation, naïve CD4+ T-cells require nonspecific co-stimulatory signals
in addition to the antigen-specific signal conferred by the T-cell receptor (5). CD28
is the primary co-stimulatory molecule, present on the surface of naïve T-cells. Upon
interaction with its ligands B7-1 (CD80) or B7-2 (CD86) on antigen-presenting cells
(APCs) CD28 tranduces a potent signal that enhances T-cell proliferation and cytokine
secretion and sustains the T-cell response. The second receptor for the B7-1 and B7-
2 ligands, CTLA4 (CD152), is expressed on activated T-cells and delivers an
inhibitory signal to terminate the T-cell response (6). Another well-known pathway
of T-cell co-stimulation is CD40 ligand (CD40L; CD154) expressed on activated T-
cells that interacts with CD40 found on many cell types, including APCs. In addition
to evidence for direct T-cell co-stimulation via CD40L, triggering of CD40 contributes
indirectly to T-cell co-stimulation by the upregulation of the B7-1 and B7-2 expression
on APCs, thus enhancing T-cell activation through CD28-mediated signaling (7).
In experimental murine models of allergic asthma, blocking the CD28/
CTLA4:B7-1/B7-2 pathway of T-cell co-stimulation –not only during antigen
sensitization (8), but also solely during the challenge period (8-12) and even in an
ongoing response (13)- inhibits asthma-like symptoms such as airway
hyperresponsiveness in vivo, the levels of antigen-specific IgE in serum and the
influx of eosinophils in the broncho-alveolar lavage fluid (BALF). The importance
of the CD40L:CD40 pathway in the induction of asthma-like symptoms has only
been investigated in mice deficient in either CD40L or CD40 (14-16). Because ligation
of CD40 on B-cells, together with IL-4 (17), is critical for their activation and the
induction of IgE isotype switching (18), the absence of (allergen-specific) IgE in
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serum was anticipated in all of these studies. However, conflicting results were
obtained regarding the involvement of the CD40L:CD40 pathway in the development
of airway hyperresponsiveness and BALF eosinophilia (14-16).
In the above-mentioned studies, the immediate effects of the lack of a T-cell
co-stimulatory pathway -either by blockade or gene deficiency- on the induction of
manifestations of allergic asthma in mice were investigated. Studies in vitro, however,
have demonstrated that in the absence of co-stimulation, antigen-stimulated T-cells
besides being not optimally activated are also rendered anergic that is, unresponsive
to antigenic re-stimulation in the presence of co-stimulation (19). In vivo, blockade
of T-cell co-stimulation around the time of engraftment was shown to allow for
long-term allograft survival in several transplantation models (see 20). So, blockade
of T-cell co-stimulation not only results in the immediate suppression of the immune
response but in some cases induces long-term antigen-specific tolerance. Short-lived
treatment of asthma patients that results in tolerance to the inhalant allergen and
hence long-lasting improved clinical status would be a very attractive therapeutic
approach. However, the long-term effects of T-cell co-stimulation blockade during
the development of antigen-induced asthma-like symptoms in mice have not been
studied so far.
Therefore, in the present study, we investigated if blockade of T-cell co-
stimulation during the aerosol challenge period of antigen-sensitized mice results in
long-term amelioration of asthma-like symptoms that is, not only immediately after
the aerosol challenge period but also upon antigen re-challenge after serum clearance
of experimental treatment. A number of studies in vitro and in vivo on the induction
of antigen-specific tolerance have demonstrated that blockade of both the CD28/
CTLA4:B7-1/B7-2 and the CD40L:CD40 pathway is more effective than blockade
of either pathway alone (21-25). Therefore, we compared the immediate and long-
term effects of a monoclonal antibody (mAb) against CD40L (MR1), murine CTLA4-
IgG or the combination of these treatments in an ovalbumin (OVA)-induced murine
model of allergic asthma.
After the first series of OVA aerosol challenges, CTLA4-IgG -in the absence or
presence of anti-CD40L mAb- prevented both airway hyperresponsiveness in vivo
and the up-regulation of OVA-specific IgE levels in serum, whereas anti-CD40L
mAb alone solely prevented the up-regulation of serum OVA-specific IgE levels.
We are the first to demonstrate that, 11 wk later, after serum clearance of treatments,
only CTLA4-IgG-treated mice demonstrated tolerance with respect to the number
of eosinophils in the BALF induced by OVA re-challenge. Interestingly, in a “mild”
model of allergic asthma, in which mice are sensitized without adjuvant and
challenged with low doses of OVA, the long-term effect of CTLA4-IgG was not
limited to the inhibition of BALF eosinophilia but extended to reduced levels of
OVA-specific IgE in serum. So, CTLA4-IgG can induce tolerance to some of the
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OVA-induced asthma-like symptoms in mice, its effectiveness being dependent on
the “severity” of murine model used.
MATERIALS AND METHODS
Animals
Specific pathogen-free male BALB/c mice were obtained from the Central Laboratory
Animal Institute (Utrecht, The Netherlands). The animals were used at 6-9 wk of
age and housed in macrolon cages in a laminar flow cabinet and provided with food
and water ad libitum. Animal care and use were performed in accordance with the
guidelines of the Dutch Committee of Animal Experiments as described in DEC-fsb
protocol 98.23.
Antigen sensitization and challenge
For the experiment in the more “severe” model of allergic asthma, all mice were
sensitized to OVA (chicken egg albumin, crude grade V, Sigma, St. Louis, MO,
USA). Systemic sensitization was performed by two intraperitoneal (i.p.) injections
of 10 µg OVA adsorbed onto 2.25 mg aluminum hydroxide (alum; ImjectAlum,
Pierce, Rockford, IL, USA) in 0.1 ml pyrogen-free saline on day 0 and 7. On day 28,
31 and 34 mice were exposed to a saline aerosol or an OVA aerosol (10 mg/ml in
pyrogen-free saline) challenge in a plexiglass exposure chamber (5 liter) for 20 min.
On day 112, 115 and 118 (11 wk later), saline-exposed mice received either three
saline aerosols or three OVA aerosol challenges (“secondary responses group”) and
OVA-challenged mice were re-challenged with three OVA aerosols (see Table 1).
For the experiment in the “mild” model of allergic asthma, all mice were
systemically sensitized to OVA without adjuvant by seven i.p. injections of 10 µg
OVA in 0.5 ml pyrogen-free saline on day 0, 2, 4, 7, 9, 11 and 14 (one injection per
day). On day 42-49, mice were exposed to a saline aerosol or an OVA aerosol (2 mg/
ml in pyrogen-free saline) challenge in a plexiglass exposure chamber (5 liter) for 5
min on consecutive days (one aerosol per day). On day 127-134 (11 wk later), saline-
exposed mice received eight saline aerosols and OVA-challenged mice were re-
challenged with eight OVA aerosols (see Table 2).
The aerosols were generated by nebulizing an OVA solution or saline only
using a Pari LC Star nebulizer (PARI Respiratory Equipment, Richmond, VA, USA;
particle size 2.5–3.1 µm) driven by compressed air at a flow rate of 6 liters/min.
Experimental treatment protocols
In each experiment, mice received a single intravenous administration of experimental
treatment shortly before the first aerosol. As indicated in Tables I and II, one of the
four following treatments, dissolved in 0.2 ml pyrogen-free saline, was administered:
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a) control treatment (350 µg Armenian hamster IgG control antibody [Ha4/8] and
280 µg human total IgG), b) 350 µg hamster anti-mouse CD40L mAb (MR1) and
280 µg total human IgG, c) 280 µg murine CTLA4-IgG1 and 350 µg Ha4/8 or d) 350
µg MR1 and 280 µg murine CTLA4-IgG1. The half-life of the MR1 mAb in BALB/
c mice is about 8.4 d (26). Sera of mice that received either murine CTLA4-IgG or
human total IgG, contained less than 0.3 µg/ml of the respective treatment at the
time of sacrifice as determined by ELISA. All animals were sacrificed at 24 h after
the last aerosol re-challenge (on day 119 [more “severe” model], day 135 [“mild”
model]).
The MR1 and Ha4/8 hamster antibodies were kindly provided by Biogen
(Cambridge, MA, USA). Murine CTLA4-IgG fusion protein composed of murine
CTLA4 fused via an ECD-immunoglobulin junction to the hinge and Fc regions of
human IgG1 as described in detail previously (11) was kindly provided by Genentech
(South San Francisco, CA, USA). Human total IgG was purchased from ICN
Pharmaceuticals (Costa Mesa, CA, USA) and dissolved in pyrogen-free saline. This
solution was treated with 10% (v/v) polymyxin B-agarose (Sigma; washed twice
with saline) for 1 h at 4°C to remove lipopolysaccharide. After incubation, agarose
beads were removed by centrifugation, and the supernatant was sterilized. The
endotoxin level in all treatment preparations was less than 1 endotoxin U/mg.
Measurement of airway responsiveness in vivo
Airway responsiveness was measured in conscious, unrestrained mice at 24 h after
the last aerosol challenge (on day 35 [more “severe” model] or day 50 [“mild” model])
and at 24 h after the last re-challenge (on day 119 [more “severe” model], day 135
[“mild” model]) by recording respiratory pressure curves in response to inhaled
nebulized methacholine (acetyl-β-methylcholine chloride; Sigma) using barometric
whole-body plethysmography (Buxco; EMKA Technologies, Paris, France). Airway
responses were expressed in enhanced pause (Penh), an index of airway obstruction
as described in detail previously (27). Briefly, mice were placed in a whole-body
chamber and pressure differences between this chamber and a reference chamber
were recorded. After baseline Penh values were obtained for 3 min and averaged,
animals were exposed to a saline aerosol and a series of methacholine aerosols
(solutions doubling in concentration, ranging from 1.56–50 mg/ml in saline). Aerosols
were generated by a Pari LC Star nebulizer for 3 min and after each nebulization
readings were taken for 3 min and averaged.
Determination of OVA-specific IgE levels in serum
In the experiment using the more “severe” model of allergic asthma, approximately
0.25 ml blood was recovered from mice by an incision the tail vein at day 39 (4 d
after the last aerosol challenge). In both experiments, after measurement of airway
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responsiveness in vivo at 24 h after the last aerosol re-challenge, mice were sacrificed
by i.p. injection of 1 ml 10% urethane (Sigma) in sterile saline and bled by cardiac
puncture. Serum was prepared from blood samples and stored at -20°C until
determination of OVA-specific IgE levels by ELISA. Briefly, 96-wells maxisorp
microtiter plates (Nunc A/S, Roskilde, Denmark) were coated overnight at 4°C with
1 µg/ml rat anti-mouse IgE mAb (clone R35-72, PharMingen, San Diego, CA, USA)
diluted in phosphate-buffered saline (PBS). The next day, the ELISA was performed
at room temperature using ELISA buffer (PBS containing 0.5% bovine serum albumin
[Sigma], 2 mM EDTA, 136.9 mM NaCl, 50 mM Tris, 0.05% Tween-20 [Merck,
Whitehouse Station, NJ, USA], pH 7.2) for blocking and dilution of samples, standard
and reagents and PBS containing 0.05% Tween-20 for washing between incubations.
After blocking of wells for 1 h, serum samples and a duplicate dilution series of an
OVA-specific reference serum (starting 1:40) were added to the wells and incubated
for 2 h. An OVA-specific IgE reference serum was obtained by sensitization and
challenge of mice with OVA as above-described for the more “severe” model of
allergic asthma and arbitrarily assigned a value of 1,000 experimental units/ml (EU/
ml). Hereafter, 1 µg/ml of OVA labeled to digoxigenin (DIG) by a DIG protein
labeling kit (Roche Diagnostics, Basel, Switzerland) was added for 1.5 h, followed
by incubation with 1:500 diluted anti-DIG-Fab fragments coupled to horseradish
peroxidase (Roche Diagnostics) for 1 h. Color development was performed with o-
phenylenediamine-dichloride substrate (0.4 mg/ml, Sigma) and 4 mM H2O2 in PBS
and the reaction was stopped by adding 4 M H2SO4. The optical density was read at
490 nm, using a Benchmark microplate reader (Bio-Rad Laboratories, Hercules,
CA). Results were analyzed with Microplate Manager PC software (Bio-Rad
Laboratories). The lower detection limit of the ELISA was 4 EU/ml IgE.
Analysis of the BALF
BAL was performed immediately after bleeding of the mice as described in detail
previously (28). Briefly, the airways were lavaged five times through a tracheal
cannula with 1 ml saline at 37°C. The recovered fluid of the five lavages was pooled
and cells were pelleted (387 × g, 4°C, 10 min), and resuspended in 0.15 ml cold
PBS. The total number of cells in the BALF was counted using a Bürker-Türk
counting-chamber (Karl Hecht Assistent KG, Sondheim/Röhm, Germany). For
differential BALF cell counts, cytospin preparations were made (15 × g, 4°C, 5 min)
using a cell container (Kendro Heraues Instruments, Asheville, NC, USA), and cells
were fixed and stained with Diff-Quick (Dade AG, Düdingen, Switzerland). Per
cytospin, at least 400 cells were counted and differentiated into mononuclear cells
(monocytes, macrophages and lymphocytes), eosinophils and neutrophils by standard
morphology and staining characteristics. The investigator counting the cells was
blinded to the treatment groups.
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Statistical analysis
All data are expressed as mean ± standard error of mean (SEM). The airway dose-
response curves to methacholine were statistically analyzed by a general linear model
of repeated measurements followed by post-hoc comparison between groups. Data
were log10 transformed before analysis to equalize variances in all groups. Statistical
analysis on BALF cell counts was performed using the non-parametric Mann Whitney
U test. For all other parameters, results were statistically analyzed using a Student’s
t test (two-tailed, homosedastic). Differences between groups were considered
statistically significant at the p < 0.05 level. Statistical analyses were performed
using SPSS for Windows version 10.0.5 (SPSS, Chicago, IL, USA).
RESULTS
Table 1 shows the design of the experiment to determine the long-term effects of
blocking T-cell co-stimulation during the development of antigen-induced asthma-
like symptoms in mice. Upon sensitization to the experimental allergen OVA, OVA-
specific memory T-cells developed (primary response). Subsequently, mice received
experimental treatment and were challenged with an OVA aerosol to develop asthma-
like symptoms (secondary responses). Finally, after serum clearance of the treatments,
mice were re-challenged with OVA to re-induce airway symptoms (tertiary
responses). One might speculate that in OVA-sensitized, control-treated mice, tertiary
responses after OVA re-challenge are higher compared with the secondary responses
induced by the first series of OVA aerosol challenges (Group 2, see Table 1).
Therefore, to be able to compare the magnitude of the tertiary responses with time-
matched secondary allergic responses, Group 6 was included in the experiment
consisting of mice that received saline aerosols directly after administration of control
treatment and OVA aerosols during the re-challenge period (hereafter referred to as
the “secondary responses group”).
Table 1: Experimental design to determine the long-term effects of blocking T-cell co-stimulation
during the development of antigen-induced asthma-like symptoms in mice.
Definition of abbreviations: h, human; ham, hamster. Mice were sensitized, challenged and treated
as described in MATERIALS AND METHODS. Each experimental group consisted of eight animals.
Group Sensitization
(Prim response)
Treatment
before aerosol 1
Challenge
aerosol 1-3
(Sec responses)
Re-challenge, 11 wk later
aerosol 4-6
(Tertiary responses)
1 OVA/alum Ham IgG and h total IgG Saline Saline
2 OVA/alum Ham IgG and h total IgG OVA OVA
3 OVA/alum Anti-CD40L and h total IgG OVA OVA
4 OVA/alum CTLA4-IgG and hamIgG OVA OVA
5 OVA/alum CTLA4-IgG and anti-CD40L OVA OVA
6 OVA/alum Ham IgG and h total IgG Saline OVA
(Sec responses group)
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Immediate and long-term effects of T-cell co-stimulatory blockade on airway
hyperresponsiveness in vivo
First, the immediate effects of T-cell co-stimulatory blockade on OVA-induced airway
hyperresponsiveness in vivo were determined at 24 h after the last aerosol challenge.
The airway responses to doubling concentrations of aerosolized methacholine were
measured in conscious, unrestrained mice by whole-body plethysmography. In
control-treated mice, OVA aerosol challenge of OVA-sensitized mice resulted in
hyperresponsiveness to methacholine because the complete dose-response curve
(DRC) to methacholine of this group of mice was significantly different (p < 0.01)
from that of saline-challenged mice. For brevity, only the maximal responses are
shown in Figure 1A. Administration of the anti-CD40L mAb MR1 before the first
OVA aerosol challenge had no effect on the development of airway
hyperresponsiveness. In contrast, murine CTLA4-IgG, in the absence or presence of
anti-CD40L mAb, prevented the development of OVA-induced airway
hyperresponsiveness (p < 0.05 and p < 0.05, respectively). At this time point of the
experiment, the secondary responses group (Group 6, see Table 1) was a duplicate
of Group 1. Therefore, the airway responses of mice from these two groups are
averaged and depicted together as one bar in Figure 1A.
Figure 1: Immediate and long-term effects of T-cell co-stimulatory blockade on airway
hyperresponsiveness in vivo. Airway responsiveness in vivo to aerosolized methacholine was measured
in conscious, unrestrained mice by whole-body plethysmography at 24 h after the last aerosol challenge
(A) and at 24 h after the last re-challenge (B). For brevity, only the maximal responses (to the highest
concentration of the methacholine DRC (50 mg/ml)) are shown. (A) BALB/c mice were sensitized to
OVA adsorbed to alum and challenged with three saline aerosols (open bar; n = 16) or three OVA
aerosols (closed bars; n = 8-9 per group). Shortly before the first aerosol challenge, mice received
control treatment, anti-CD40L mAb, mCTLA4-IgG or the combination of anti-CD40L mAb and
CTLA4-IgG. (B) Eleven weeks later, after serum clearance of treatments, saline-challenged mice
were re-challenged with three saline aerosols (open bar; n = 7) or three OVA aerosols (shaded bar; n
= 8) and OVA-challenged mice were re-challenged with three OVA aerosols (closed bars; n = 7-9 per
group). Values are expressed as mean ± SEM. * p < 0.01 and ** p < 0.005, as compared with saline-
challenged animals of the same treatment group. # p < 0.05, as compared with control-treated, OVA-
challenged animals.
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Eleven weeks after the last aerosol challenge, when the treatments had been
cleared from the sera of mice, animals were re-challenged with either three saline or
three OVA aerosols (see Table 1) to determine the long-term effects of blockade of
T-cell co-stimulation on asthma-like symptoms re-induced by OVA re-challenge.
Airway hyperresponsiveness to methacholine in vivo was measured again at 24 h
after the last aerosol re-challenge. In control-treated mice, OVA aerosol re-challenge
of OVA-sensitized and challenged mice resulted in a significantly different maximal
airway response compared with saline re-challenged mice (p < 0.01) (Figure 1B).
The secondary responses group showed a similar increase in the maximal airway
response compared with saline re-challenged animals (p < 0.05). Earlier
administration of anti-CD40L mAb, CTLA4-IgG or the combination of these
treatments before the development of asthma manifestations by the first series of
OVA aerosols had no long-term effect on airway hyperresponsiveness induced by
OVA re-challenge.
So, administration of anti-CD40L mAb had no immediate effect on OVA-
induced airway hyperresponsiveness in vivo to methacholine in mice. In contrast,
CTLA4-IgG - in the absence or presence of anti-CD40L mAb - prevented the
development of airway hyperresponsiveness, but had no long-term effect on this
parameter. The magnitude of airway hyperresponsiveness of mice from the secondary
responses group was very similar to the level of tertiary response hyperresponsiveness.
Immediate and long-term effects of T-cell co-stimulatory blockade on the up-
regulation of OVA-specific IgE levels in serum
Four days after the last aerosol challenge, blood was withdrawn from mice to
determine the immediate effects of T-cell co-stimulatory blockade on the OVA-
induced up-regulation of antigen-specific IgE in serum. In control-treated mice, OVA
aerosol challenge of OVA-sensitized mice resulted in a significant up-regulation of
OVA-specific IgE compared with saline-challenged animals (168% increase, p <
0.0005) (Figure 2A). Administration of anti-CD40L mAb, CTLA4-IgG or the
combination of these treatments before the first OVA aerosol challenge inhibited
the up-regulation of serum OVA-specific IgE significantly (70% inhibition, p < 0.005,
55% inhibition, p < 0.05 and 88% inhibition, p < 0.0005, respectively). Because at
this time point of the experiment the secondary responses group was a duplicate of
Group 1, the levels of OVA-specific IgE in the sera of mice from these two groups
are averaged and depicted as one bar in Figure 2A.
After measurement of airway responsiveness in vivo at 24 h after the last aerosol
re-challenge, mice were killed and bled by cardiac puncture to determine the long-
term effects of T-cell co-stimulatory blockade on OVA-specific IgE levels in serum
induced by OVA re-challenge. In control-treated mice, OVA re-challenge of OVA-
sensitized and challenged mice resulted in a significant up-regulation of OVA-specific
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IgE levels compared with saline re-challenged animals (334% increase, p < 0.05)
(Figure 2B). The secondary responses group showed a similar up-regulation of serum
OVA-specific IgE levels compared with saline re-challenged animals (415% increase,
p < 0.01). Earlier administration of anti-CD40L mAb, CTLA4-IgG or the combination
of these treatments before the development of asthma manifestations by the first
series of OVA aerosols had no significant long-term effect on the levels of OVA-
specific IgE in serum induced by OVA re-challenge.
Figure 2: Immediate and long-term effects of T-cell co-stimulatory blockade on the up-regulation of
OVA-specific IgE levels in serum. OVA-specific IgE was determined in the sera of mice at 24 h after
the last aerosol challenge (A) and at 24 h after the last re-challenge (B). (A) BALB/c mice were
sensitized to OVA adsorbed to alum and challenged with three saline aerosols (open bar; n = 12) or
three OVA aerosols (closed bars; n = 5-6 per group). Shortly before the first aerosol challenge, mice
received control treatment, anti-CD40L mAb, mCTLA4-IgG or the combination of anti-CD40L mAb
and CTLA4-IgG. (B) Eleven weeks later, after serum clearance of treatments, saline-challenged mice
were re-challenged with three saline aerosols (open bar; n = 8) or three OVA aerosols (shaded bar; n
= 8) and OVA-challenged mice were re-challenged with three OVA aerosols (closed bars; n = 7-9 per
group). Values are expressed as mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.0005, as compared
with saline-challenged animals of the same treatment group. # p < 0.05, ## p < 0.005 and ### p <
0.0005, as compared with control-treated, OVA-challenged animals.
So, administration of anti-CD40L mAb, CTLA4-IgG or the combination of
these treatments inhibited the OVA-induced up-regulation of serum antigen-specific
IgE levels in mice. However, none of these treatments had a long-term effect on this
parameter. The secondary responses group showed a similar up-regulation of serum
OVA-specific IgE levels as the animals with tertiary responses.
Long-term effects of T-cell co-stimulatory blockade on the number of eosinophils in
the BALF
Lavage of the lungs, to determine the number of various cell types that infiltrated the
airway lumen, can only be performed in euthanasized mice. Therefore, only the
long-term effects of T-cell co-stimulatory blockade on the cellular composition of
the BALF could be determined in this experiment. Because there are no or sometimes
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only a few eosinophils in OVA-sensitized, saline-challenged mice, the open bar
representing the group of control-treated, saline re-challenged animals cannot be
seen in Figure 3. However, OVA re-challenge of OVA-sensitized and challenged
mice resulted in a significant increase in the number of eosinophils in the BALF
compared with saline re-challenged animals (p < 0.0001). The secondary responses
group showed a similar increase in the number of BALF eosinophils compared with
saline re-challenged animals (p < 0.0005). Earlier administration of anti-CD40L
mAb before the development of asthma manifestations by the first series of OVA
aerosols had no long-term effect on the number of eosinophils in the BALF induced
by OVA re-challenge. In contrast, CTLA4-IgG-treated mice showed significantly
reduced numbers of BALF eosinophils upon OVA re-challenge compared with
control-treated mice (46% inhibition, p < 0.01). In the presence of anti-CD40L mAb,
CTLA4-IgG attenuated the number of eosinophils induced by OVA re-challenge
compared with control-treated mice, but this reduction did not reach statistical
significance (35% inhibition, p = 0.14).
Figure 3: Long-term effects of T-cell co-stimulatory blockade on the number of eosinophils in the
BALF. The number of eosinophils in the BALF was determined at 24 h after the last aerosol re-
challenge. BALB/c mice were sensitized to OVA adsorbed to alum and challenged with three saline
aerosols or three OVA aerosols. Shortly before the first aerosol challenge, mice received control
treatment, anti-CD40L mAb, mCTLA4-IgG or the combination of anti-CD40L mAb and CTLA4-
IgG. Eleven weeks later, after serum clearance of treatments, saline-challenged mice were re-challenged
with three saline aerosols (open bar; n = 8) or three OVA aerosols (shaded bar; n = 8) and OVA-
challenged mice were re-challenged with three OVA aerosols (closed bars; n = 7-9 per group). Values
are expressed as mean ± SEM. * p < 0.0005 and ** p < 0.0001, as compared with saline-challenged
animals of the same treatment group. # p < 0.01, as compared with control-treated, OVA-challenged
animals.
So, earlier administration of anti-CD40L mAb before the development of asthma-
like symptoms in mice had no long-term effect on airway eosinophilia. In contrast,
earlier administration of CTLA4-IgG inhibited the number of BALF eosinophils
induced by OVA re-challenge. The number of eosinophils in the BALF of mice
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from the secondary responses group was very similar to the number observed in
animals with tertiary response airway eosinophilia.
Long-term effects of T-cell co-stimulatory blockade in a “mild” model of allergic
asthma
For the above-described experiment, animals were sensitized to OVA in the presence
of alum adjuvant that induces a Th2-dominant response in vivo and challenged with
high doses of OVA. This protocol results in relatively strong inflammatory responses
that appear to represent a more “severe” type of allergic asthma. In our laboratory,
we also use a “mild” model of allergic asthma in which mice are sensitized to OVA
without adjuvant and challenged with lower doses of antigen. After the last OVA
aerosol challenge, mice subjected to this protocol, show a similar extent of airway
hyperresponsiveness in vivo, but animals display only ~ one tenth of serum OVA-
specific IgE levels and less than half of the number of BALF eosinophils observed
in the more “severe” murine model of allergic asthma. Interestingly, previous studies
by others and us have demonstrated that the various models respond differently to
modulation in both a quantitative and qualitative way (13, 29, 30). Therefore, we
determined the long-term effects of T-cell co-stimulatory blockade in a “mild” murine
model of allergic asthma as well. Table 2 shows the design of this experiment.
Table 2: Experimental design to determine the long-term effects of blocking T-cell co-stimulation
during the development of antigen-induced asthma-like symptoms in mice in a “mild” model of
allergic asthma.
Definition of abbreviations: adj, adjuvant; h, human; ham, hamster. Mice were sensitized, challenged
and treated as described in MATERIALS AND METHODS. Each experimental group consisted of
eight animals.
Airway hyperresponsiveness in vivo
In accordance with the more “severe” model of allergic asthma, earlier administration
of anti-CD40L mAb, CTLA4-IgG or the combination of these treatments before the
development of asthma manifestations by the first series of OVA aerosols had also
in this “mild” model of allergic asthma no long-term effect on airway
hyperresponsiveness induced by OVA re-challenge (data not shown).
Group Sensitization
(Prim response)
Treatment
before aerosol 1
Challenge
aerosol 1-8
(Sec responses)
Re-challenge, 11 wk later
aerosol 9-16
(Tertiary responses)
1 OVA w/o adj Ham IgG and h total IgG Saline Saline
2 OVA w/o adj Ham IgG and h total IgG OVA OVA
3 OVA w/o adj Anti-CD40L and h total IgG OVA OVA
4 OVA w/o adj CTLA4-IgG and ham IgG OVA OVA
5 OVA w/o adj CTLA4-IgG and anti-CD40L Saline Saline
6 OVA w/o adj CTLA4-IgG and anti-CD40L OVA OVA
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OVA-specific IgE levels in serum
After measurement of airway responsiveness in vivo at 24 h after the last aerosol re-
challenge, mice were killed and bled by cardiac puncture to determine the long-term
effects of T-cell co-stimulatory blockade on OVA-specific IgE levels in serum. In
control-treated mice, OVA re-challenge of OVA-sensitized and challenged mice
resulted in a significant up-regulation of OVA-specific IgE levels compared with
saline re-challenged animals (513% increase, p < 0.01) (Figure 4A). Earlier
administration of anti-CD40L mAb before the development of asthma manifestations
by the first series of OVA aerosols had no long-term effect on the levels of OVA-
specific IgE in serum induced by OVA re-challenge. In contrast, CTLA4-IgG, in the
absence or presence of anti-CD40L mAb, significantly reduced the up-regulation of
OVA-specific IgE upon OVA re-challenge compared with control-treated mice (69%
inhibition, p < 0.05 and 61% inhibition, p < 0.05, respectively). Treatment of mice
with the combination of anti-CD40L mAb and CTLA4-IgG had no long-term effect
by itself (Group 5, see Table 2) on the levels of OVA-specific IgE as similar levels
were found in the sera of control-treated, saline re-challenged mice.
Figure 4: Long-term effects of T-cell co-stimulatory blockade in a “mild” murine model of allergic
asthma. OVA-specific IgE in the sera of mice (A) and the number of eosinophils in the BALF (B)
were determined at 24 h after the last aerosol re-challenge. BALB/c mice were sensitized to OVA
without adjuvant and challenged with eight saline aerosols or eight OVA aerosols. Shortly before the
first aerosol challenge, mice received control treatment, anti-CD40L mAb, mCTLA4-IgG or the
combination of anti-CD40L mAb and CTLA4-IgG. Eleven weeks later, after serum clearance of
treatments, saline-challenged mice were re-challenged with eight saline aerosols (open bars; n = 6 per
group) and OVA-challenged mice were re-challenged with eight OVA aerosols (closed bars; n = 5-6
per group). Values are expressed as mean ± SEM. * p < 0.01 and ** p < 0.005, as compared with
saline-challenged animals of the same treatment group. # p < 0.05 and ## p < 0.01, as compared with
control-treated, OVA-challenged animals.
BALF eosinophilia
Again, no eosinophils were observed in OVA-sensitized, saline re-challenged mice
(Figure 4B). However, OVA re-challenge of OVA-sensitized and challenged mice
resulted in a significant increase in the number of eosinophils in the BALF compared
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with saline re-challenged animals (p < 0.005). Earlier administration of anti-CD40L
mAb before the development of asthma manifestations by the first series of OVA
aerosols attenuated the number of eosinophils in the BALF induced by OVA re-
challenge, but this reduction did not reach statistical significance (46% inhibition, p
= 0.065). In contrast, mice treated with CTLA4-IgG, in the absence or presence of
anti-CD40L mAb showed significantly reduced numbers of BALF eosinophils upon
OVA re-challenge compared with control-treated mice (80% inhibition, p < 0.01
and 73% inhibition, p < 0.05, respectively). Treatment of mice with the combination
of anti-CD40L mAb and CTLA4-IgG had no long-term effect by itself on the number
of eosinophils in the BALF as similar numbers were found in the sera of control-
treated, saline re-challenged mice.
So, in a “mild” murine model of allergic asthma, earlier administration of anti-
CD40L mAb before the development of asthma-like symptoms had no significant
long-term effect on any of the asthma-like symptoms. In contrast, treatment of mice
with CTLA4-IgG – in the absence or presence of anti-CD40L mAb- inhibited both
the up-regulation of antigen-specific IgE in serum and the number of BALF
eosinophils induced by OVA aerosol re-challenge, but had no long-term effect on
airway hyperresponsiveness.
DISCUSSION
Blockade of T-cell co-stimulation has been shown not only to result in the immediate
suppression of the immune response but to induce in some disease models long-term
antigen-specific tolerance as well. Short-lived treatment of asthma patients that results
in long-term tolerance to the inhalant allergen and hence long-lasting improved
clinical status would be a very attractive therapeutic approach. Therefore, in the
present study, we investigated if blockade of T-cell co-stimulation the during the
aerosol challenge period of OVA-sensitized mice results in long-term amelioration
of asthma-like symptoms that is, not only immediately after the aerosol challenge
period but also upon antigen re-challenge after serum clearance of experimental
treatment. After the first series of OVA aerosol challenges, CTLA4-IgG prevented
both the development of non-specific airway hyperresponsiveness in vivo and the
up-regulation of OVA-specific IgE levels in serum, whereas anti-CD40L mAb (MR1)
solely prevented the up-regulation of serum OVA-specific IgE levels. After serum
clearance of treatments, only CTLA4-IgG-treated mice demonstrated tolerance with
respect to the number of eosinophils in the BALF induced by OVA re-challenge.
Interestingly, in a “mild” model of allergic asthma, in which mice are sensitized
without adjuvant and challenged with lower doses of OVA, the long-term effect of
CTLA4-IgG was not limited to the inhibition of BALF eosinophilia but extended to
reduced levels of OVA-specific IgE in serum.
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Previous studies have already shown that blocking the CD28/CTLA4:B7-1/
B7-2 pathway in mice - during antigen sensitization (8), solely during the challenge
period (8-12) and even in an ongoing response (13)- inhibited the development of
airway hyperresponsiveness in vivo and the up-regulation of serum IgE levels. In
addition, a reduction in airway eosinophilia was observed in all of these studies.
Here, we present the first demonstration that in OVA-induced murine models of
allergic asthma, CTLA4-IgG induced tolerance to this experimental allergen.
Interestingly, tolerance could be induced for airway eosinophilia and OVA-specific
IgE but not for non-specific airway hyperresponsiveness. So, whereas CTLA4-IgG
inhibits the development of the three afore-mentioned manifestations of allergic
asthma, the tolerization of these parameters was dissociated in this study. Therefore,
our results suggest that the various CD4+ T-cell-dependent asthma-like symptoms
in mice are differentially modulated by CTLA4-IgG administration.
How can the selective tolerization of CD4+ T-cell effector functions by CTLA4-
IgG be explained? One possibility is that CTLA4-IgG selectively tolerizes B7-1/B7-
2-dependent T-cell signal transduction pathways. For example, in mice deficient for
signal transducer and activator of transcription (STAT)-6 (STAT-6−/−), airway
eosinophilia was found to be partially inhibited in contrast to the complete absence
of airway hyperresponsiveness and antigen-specific IgE in these mice (31, 32). These
studies suggest that the various T-cell effector functions observed in mice are
differentially dependent on STAT-6. Because CD28 has been shown to activate
STAT-6 (33), a differential sensitivity to tolerance induction by blockade of the
CD28/CTLA4:B7-1/B7-2 pathway of the asthma-like symptoms in mice is possible.
Interestingly, CTLA4-Ig induced long-term engraftment of cardiac allografts and
donor-specific tolerance in both BALB/c wild-type and STAT-6−/− recipients (34).
However, in another study, STAT-6 signaling was shown to be involved, at least in
part, in CTLA4-Ig-mediated long-term maintenance of tolerance (35). Moreover,
other research groups found that airway hyperresponsiveness and eosinophilia are
equally dependent on STAT-6 (36, 37).
Another possibility is that the various manifestations of allergic asthma are
controlled by different subsets of (allergen-specific) CD4+ T-cells that might differ
in their sensitivity to tolerance induction by CTLA4-IgG. Notably, Campbell et al.
identified specialized “B helper” and “tissue inflammatory” CD4+ T-cell subsets
that developed concurrently from common naive precursors during the primary
immune response in BALB/c mice (38). This observation seems to contrast with
studies demonstrating that Th1 and Th2 cells polarized in vitro can mediate immune
responses in peripheral tissues as well as provide B cell help in lymphoid follicles
upon adoptive transfer (39, 40). However, analysis of Th1 and Th2 populations at
the single cell or clone level has demonstrated remarkable diversity in their cytokine
profiles (41). In addition, individual Th1 and Th2 clones have been shown to be
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functionally heterogeneous (42). Future studies may clarify whether specialized T-
cell subsets are contained within polarized populations of Th1 and Th2 cells.
Moreover, the generation of Th2 cells in vitro may result in effector T-cells with
migratory and functional properties that are uncommon in vivo.
In vitro, it was found that the successful induction of unresponsiveness toward
soluble antigens with CTLA4-Ig required complete blockade of antigen-induced
proliferation during the induction culture (43). Along this line, although CTLA4-
IgG greatly reduced the asthma-like symptoms in both the more “severe” and “mild”
model of allergic asthma (this study and Ref 11), the symptoms were not fully blocked
suggesting that not all OVA-specific CD4+ T-cells were inhibited and hence
(selectively) tolerized. These non-tolerized antigen-specific T-cells are likely to be
responsible for the residual airway eosinophilia (and OVA-IgE levels) observed upon
OVA re-challenge. In addition, the more pronounced long-term effect of CTLA4-
IgG on airway eosinophilia in the “mild” model of allergic asthma might be explained
by our observation that the development of this parameter is more readily inhibited
by CTLA4-IgG in this model compared with the more “severe” model of allergic
asthma. This in turn might be clarified by a study demonstrating that the stringent
requirement for CD28 in CD4+ T-cell activation can be overcome by higher
concentrations of antigen or longer durations of exposure to antigen (44). Interestingly,
human CTLA4-Ig inhibited IL-5 and IL-13 production by allergen-exposed bronchial
explant cultures derived from mild asthmatics (45), but not from moderately severe
asthmatics (46).
However, in both the “mild” and more “severe” murine model of allergic asthma,
administration of CTLA4-IgG failed to fully block the development of asthma-like
symptoms induced by OVA challenge (this study and Ref 11). Possibly, CTLA4-Ig
leaves in vivo some B7-1 and B7-2 molecules uncovered (47) that may bind CD28
(and CTLA4). In addition, other molecules than CD28, may provide important co-
stimulatory signals to the T-cells in our models. With regard to the CD40L:CD40
pathway of T-cell co-stimulation, studies in vitro and in vivo have demonstrated that
disruption of this pathway inhibits the T-cell response (21-25). Interestingly, an
additional or synergistic effect on the induction of antigen-specific tolerance was
observed when both the CD28/CTLA4:B7-1/B7-2 pathway and the CD40L:CD40
pathway were blocked in comparison with blockade of either pathway alone in these
studies. Therefore, we compared the immediate and long-term effects of blockade
of T-cell co-stimulation by anti-CD40L mAb, CTLA4-IgG or the combination of
these treatments during the aerosol challenge period of antigen-sensitized mice. The
anti-CD40L mAb MR1 inhibited the up-regulation of serum OVA-IgE but had no
effect on the development of OVA-induced airway hyperresponsiveness in vivo.
Because ligation of CD40 on B-cells, together with IL-4 (17), is critical for their
activation and the induction of isotype switching to IgE (18), the inhibition of allergen-
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specific IgE in serum observed in mice treated with anti-CD40L mAb clearly
demonstrates the success of this treatment. The experimental set-ups used in this
study did not allow the determination of the immediate effect of this antibody on the
development of BALF eosinophilia. However, in separate experiments –using either
the “mild” or the more “severe” murine model of allergic asthma-, we observed no
effect on BALF eosinophilia induced by OVA-challenge by the same anti-CD40L
mAb (D.T. Deurloo and H. Scheerens et al., unpublished observations). Moreover,
after serum clearance of treatments, anti-CD40L mAb did not add to the tolerance
induced by CTLA4-IgG nor had a significant long-term effect by itself. Perhaps the
blockade of yet other T-cell co-stimulatory molecule(s) -e.g. inducible T-cell co-
stimulator (ICOS)- in combination with CTLA4-Ig is required to completely block
T-cell activation in mice during the aerosol challenge period and to induce antigen-
specific tolerance to all manifestations of allergic asthma.
The importance of the CD40L:CD40 pathway in the induction of asthma-like
symptoms has only been investigated in mice deficient in either CD40L or CD40
(14-16). Comparing CD40-/- mice with wild-type mice, two groups found that lack
of CD40 has no effect on antigen-induced BALF eosinophilia and airway
hyperresponsiveness in vivo (14, 16). CD40L−/− mice, on the other hand, show a
reduction in BALF eosinophilia compared with wild-type mice in one study (15) but
not in another study (16). The latter group also investigated the effect of CD40L
deficiency on the development of non-specific hyperresponsiveness in vivo and
observed that hyperresponsiveness was prevented by the lack of CD40L, in contrast
with CD40−/− mice (16). Notwithstanding these conflicting data, however, we conclude
that, in the murine models we used, blockade of the CD28/CTLA4:B7-1/B7-2 pathway
is much more effective in comparison with the interruption of the CD40L:CD40
pathway.
The extra long-term effect of CTLA4-IgG on the serum levels of OVA-specific
IgE in the “mild” model of allergic asthma compared with the more “severe” model
exemplifies the qualitative differences besides the quantitative differences between
these two murine models. It appears that tolerance induction of the CD4+ T-cell
signal transduction pathway or subset involved in B-cell IgE production is
differentially regulated under the various conditions of allergen exposure. We believe
that the use of diverse sensitization and challenge protocols combined with various
mouse strains is valuable because the group of asthma patients is very heterogeneous,
both genetically and in the severity of the disease.
The secondary responses group provided some interesting information about
the dynamics of the allergic immune response. First, in control-treated mice the
magnitude of secondary responses upon OVA aerosol challenge is very similar at
three and 14 wk after sensitization, revealing that antigen-specific memory persists
for up to 14 wk. Second, re-challenge of control-treated mice does not increase the
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magnitude of the tertiary responses compared with those from the secondary response
group. This might indicate that the OVA-specific memory T-cell numbers are very
similar before aerosol challenge and re-challenge. Alternatively, an increase in
memory T-cells upon challenge does not contribute to enhancement of airway
manifestations upon re-challenge because the number of OVA-specific memory T-
cells induced by systemic sensitization is already sufficient to induce maximal
pathological responses. Importantly, the number of eosinophils (and OVA-specific
IgE levels) of the secondary responses group is higher compared with those from
CTLA4-IgG-treated, OVA-challenged and re-challenged mice. Therefore, this
reduction by CTLA4-IgG cannot be ascribed to inhibition of secondary responses
resulting in lower tertiary responses.
In summary, this is the first demonstration that in OVA-induced murine models
of allergic asthma, CTLA4-IgG induced tolerance to this experimental allergen.
Interestingly, tolerance could be induced for airway eosinophilia and OVA-specific
IgE but not for non-specific airway hyperresponsiveness, whereas CTLA4-IgG
inhibits the development of all of these parameters. This selective tolerization of
CD4+ T-cell-dependent effector functions suggests that these effector functions are
regulated by different T-cell signal transduction pathways or different CD4+ T-cell
subsets in mice (and man) that might differ in their sensitivity to tolerance induction
by CTLA4-IgG. Elucidation of the regulation of the various manifestations of allergic
asthma will be very helpful in optimizing therapies directed at the allergen-specific
T-cell including blockade of co-stimulation. Perhaps the blockade of other T-cell
co-stimulatory molecule(s) -e.g. ICOS- in combination with CTLA4-Ig is required
to completely block T-cell activation in mice during the aerosol challenge period
and to induce antigen-specific tolerance to all asthma-like symptoms.
ACKNOWLEDGEMENTS
D.T.D. and E.C.A.M.v.E. are supported by Research Grant 3.2.97.09 from The
Netherlands Asthma Foundation. We thank Biogen (Inc., Cambridge, MA, USA)
and Genentech (South San Francisco, CA, USA) for kindly providing the hamster
antibodies (MR1 and Ha4/8) and murine CTLA4-IgG, respectively. We are grateful
to Mirjam Kool and Ilse Bruijstens for expert technical assistance.
REFERENCES
1.  Maddox L, Schwartz DA: The pathophysiology of asthma. Annu Rev Med 2002;53:477-98
2.  Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR,
Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N
Engl J Med 1992;326(5):298-304
Chapter 5
112
3.  Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper
T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J
Immunol 1986;136(7):2348-57
4.  Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma. From bronchoconstriction
to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161(5):1720-45
5.  Baxter AG, Hodgkin PD: Activation rules: the two-signal theories of immune activation. Nat Rev
Immunol 2002;2(6):439-46
6.  Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev
Immunol 1996;14:233-58
7.  Van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000;67(1):2-17
8.  Keane-Myers A, Gause WC, Linsley PS, Chen SJ, Wills-Karp M: B7-CD28/CTLA-4 costimulatory
pathways are required for the development of T helper cell 2-mediated allergic airway responses
to inhaled antigens. J Immunol 1997;158(5):2042-9
9.  Krinzman SJ, De Sanctis GT, Cernadas M, Mark D, Wang Y, Listman J, Kobzik L, Donovan C,
Nassr K, Katona I, Christiani DC, Perkins DL, Finn PW: Inhibition of T cell costimulation
abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996;98(12):2693-9
10. Tsuyuki S, Tsuyuki J, Einsle K, Kopf M, Coyle AJ: Costimulation through B7-2 (CD86) is required
for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway
responsiveness. J Exp Med 1997;185(9):1671-9
11. Van Oosterhout AJ, Hofstra CL, Shields R, Chan B, van Ark I, Jardieu PM, Nijkamp FP: Murine
CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE
upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997;17(3):386-92
12. Padrid PA, Mathur M, Li X, Herrmann K, Qin Y, Cattamanchi A, Weinstock J, Elliott D, Sperling
AI, Bluestone JA: CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating
the development of Th1/Th2 subsets in a murine model of asthma. Am J Respir Cell Mol Biol
1998;18(4):453-62
13. Deurloo DT, van Esch BC, Hofstra CL, Nijkamp FP, van Oosterhout AJ: CTLA4-IgG reverses
asthma manifestations in a mild but not in a more “severe” ongoing murine model. Am J Respir
Cell Mol Biol 2001;25(6):751-60
14. Hogan SP, Mould A, Kikutani H, Ramsay AJ, Foster PS: Aeroallergen-induced eosinophilic
inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-
4 and allergen-specific immunoglobulins. J Clin Invest 1997;99(6):1329-39
15. Lei XF, Ohkawara Y, Stampfli MR, Mastruzzo C, Marr RA, Snider D, Xing Z, Jordana M:
Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J Clin
Invest 1998;101(6):1342-53
16. Mehlhop PD, van de Rijn M, Brewer JP, Kisselgof AB, Geha RS, Oettgen HC, Martin TR: CD40L,
but not CD40, is required for allergen-induced bronchial hyperresponsiveness in mice. Am J
Respir Cell Mol Biol 2000;23(5):646-51
17. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE: B cell stimulatory factor-1 enhances
the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986;136(12):4538-41
18. Jabara HH, Fu SM, Geha RS, Vercelli D: CD40 and IgE: synergism between anti-CD40 monoclonal
antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J
Exp Med 1990;172(6):1861-4
19. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: a
costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.
Annu Rev Immunol 1989;7:445-80
20. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in
autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52
21. Tang A, Judge TA, Nickoloff BJ, Turka LA: Suppression of murine allergic contact dermatitis by
CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J
Immunol 1996;157(1):117-25
CTLA4-IgG-mediated partial tolerance in murine models of allergic asthma
113
22. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo
A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC: Long-term acceptance of skin and cardiac
allografts after blocking CD40 and CD28 pathways. Nature 1996;381(6581):434-8
23. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner
JH, Jr., Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
Proc Natl Acad Sci U S A 1997;94(16):8789-94
24. Howland KC, Ausubel LJ, London CA, Abbas AK: The roles of CD28 and CD40 ligand in T cell
activation and tolerance. J Immunol 2000;164(9):4465-70
25. Koenen HJ, Joosten I: Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory
T cells that remain anergic even after reversal of hyporesponsiveness. Blood 2000;95(10):3153-
61
26. Kalled SL, Cutler AH, Ferrant JL: Long-term anti-CD154 dosing in nephritic mice is required to
maintain survival and inhibit mediators of renal fibrosis. Lupus 2001;10(1):9-22
27. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive
measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J
Respir Crit Care Med 1997;156(3 Pt 1):766-75
28. Hessel EM, van Oosterhout AJ, van Ark I, van Esch B, Hofman G, van Loveren H, Savelkoul HF,
Nijkamp FP: Development of airway hyperresponsiveness is dependent on interferon-gamma
and independent of eosinophil infiltration. Am J Respir Cell Mol Biol 1997;16(3):325-34
29. Kobayashi T, Miura T, Haba T, Sato M, Serizawa I, Nagai H, Ishizaka K: An essential role of mast
cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol
2000;164(7):3855-61
30. Williams CM, Galli SJ: Mast cells can amplify airway reactivity and features of chronic inflammation
in an asthma model in mice. J Exp Med 2000;192(3):455-62
31. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ: Signal transducer and activator of
transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway
hyperresponsiveness and mucus production. J Exp Med 1998;187(6):939-48
32. Trifilieff A, El-Hasim A, Corteling R, Owen CE: Abrogation of lung inflammation in sensitized
Stat6-deficient mice is dependent on the allergen inhalation procedure. Br J Pharmacol
2000;130(7):1581-8
33. Oki S, Otsuki N, Kohsaka T, Azuma M: Stat6 activation and Th2 cell differentiation driven by
CD28. Eur J Immunol 2000;30(5):1416-24
34. Kishimoto K, Dong VM, Issazadeh S, Fedoseyeva EV, Waaga AM, Yamada A, Sho M, Benichou
G, Auchincloss H, Jr., Grusby MJ, Khoury SJ, Sayegh MH: The role of CD154-CD40 versus
CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin
Invest 2000;106(1):63-72
35. Zhou P, Szot GL, Guo Z, Kim O, He G, Wang J, Grusby MJ, Newell KA, Thistlethwaite JR,
Bluestone JA, Alegre ML: Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-
Ig-mediated tolerance. J Immunol 2000;165(10):5580-7
36. Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, Takashi T, Takeda K, Akira S:
Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers
and activators of transcription (STAT)6-deficient mice. J Exp Med 1998;187(9):1537-42
37. Mathew A, MacLean JA, DeHaan E, Tager AM, Green FH, Luster AD: Signal transducer and
activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking
in allergic pulmonary inflammation. J Exp Med 2001;193(9):1087-96
38. Campbell DJ, Kim CH, Butcher EC: Separable effector T cell populations specialized for B cell
help or tissue inflammation. Nat Immunol 2001;2(9):876-81
39. Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K: Induction of airway mucus production by
T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production.
J Exp Med 1997;186(10):1737-47
Chapter 5
114
40. Hansen G, Berry G, DeKruyff RH, Umetsu DT: Allergen-specific Th1 cells fail to counterbalance
Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest
1999;103(2):175-83
41. Kelso A: Th1 and Th2 subsets: paradigms lost? Immunol Today 1995;16(8):374-9
42. DeKruyff RH, Ju ST, Hunt AJ, Mosmann TR, Umetsu DT: Induction of antigen-specific antibody
responses in primed and unprimed B cells. Functional heterogeneity among Th1 and Th2 T cell
clones. J Immunol 1989;142(8):2575-82
43. Yi-qun Z, Lorre K, de Boer M, Ceuppens JL: B7-blocking agents, alone or in combination with
cyclosporin A, induce antigen-specific anergy of human memory T cells. J Immunol
1997;158(10):4734-40
44. Viola A, Lanzavecchia A: T cell activation determined by T cell receptor number and tunable
thresholds. Science 1996;273(5271):104-6
45. Jaffar Z, Roberts K, Pandit A, Linsley P, Djukanovic R, Holgate S: B7 costimulation is required
for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response
to allergen stimulation. Am J Respir Cell Mol Biol 1999;20(1):153-62
46. Lordan JL, Davies DE, Wilson SJ, Dent G, Corkhill A, Jaffar Z, Roberts K, Djukanovic R, Holgate
ST: The role of CD28-B7 costimulation in allergen-induced cytokine release by bronchial mucosa
from patients with moderately severe asthma. J Allergy Clin Immunol 2001;108(6):976-81
47. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA: The role of CD80, CD86, and
CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol
1999;162(4):1947-51
Chapter 6
General summary and discussion
Chapter 6
116
1 Short introduction
Allergic asthma is a chronic inflammatory disorder of the airways characterized by
reversible airflow obstruction, persistent airway hyperresponsiveness, chronic airway
inflammation and airway remodeling (1). Allergen-specific type 2 T-helper (Th2)
cells play a pivotal role in both the initiation and progression of allergic asthma by
orchestrating the inflammatory response (2, 3). In animal models of allergic asthma,
various experimental treatments have therefore been explored that target the allergen-
specific T-cell, including blockade of their co-stimulatory requirements (4, 5).
For optimal activation, CD4+ T-cells require specific antigen recognition by
the T-cell receptor (TCR) (signal 1) and additional signals (collectively called signal
2 or co-stimulatory signals), delivered by the same antigen-presenting cell (APC)
(6-8). Indeed, antigen binding to the TCR in the absence of co-stimulation not only
fails to activate the cell; it also leads to a state of antigen-specific unresponsiveness,
called anergy. Such anergic T-cells are refractory to antigen-specific re-stimulation
even when the antigen is presented by a professional APC (9-13). In this thesis, the
role and therapeutic potential of three main T-cell co-stimulatory pathways in
ovalbumin (OVA)-induced murine models of allergic asthma was further investigated
(see Table 1).
Table1: Overview of T-cell co-stimulatory pathways studied in this thesis
With our studies, we aimed to answer the following questions:
1) What is the role of these T-cell co-stimulatory pathways in the development
of Th2-dominated allergic inflammatory responses in mice (paragraph 2)?
2) Asthma patients usually start therapy after the development of airway
symptoms while exposure to environmental allergen mostly continues.
Therefore, a new murine model of ongoing disease was designed in which
treatment starts after development of asthma-like symptoms in mice and
antigen exposures are continued (ongoing model). This model was used to
investigate the role of two T-cell co-stimulatory pathways in an ongoing
response after the development of asthma-like symptoms (paragraph 3).
3) Short-lived treatment that induces selective tolerance to the inhalant allergen
would greatly improve the prospects for asthma patients. Not only would
they be released from regular intake of medicine but also, more importantly,
Receptor on T-cell Ligand(s) Reviewed in
CD28/CTLA4 (CD152) B7-1 (CD80)/B7-2 (CD86) (14-17)
ICOS B7RP-1 (B7h, GL50, LICOS, B7-H2, ICOSL) (17-19)
CD40L (CD154) CD40 (20, 21)
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the increased risk for infections and cancer due to continuous antigen-specific
T-cell suppression would be avoided. Therefore, the long-term effects of
blockade of T-cell co-stimulatory pathways during the development of
asthma-like symptoms in mice were examined, that is after serum clearance
of the blocking agents when mice are re-exposed to the antigen (paragraph
4).
2 Role of T-cell co-stimulatory molecules in the development of Th2-dominated
allergic inflammatory responses
2.1.1 The CD28/CTLA4:B7-1/B7-2 pathway
CD28 is the primary co-stimulatory molecule, present on the surface of naïve T-
cells. Upon interaction with its ligands B7-1 (CD80) or B7-2 (CD86) on APCs,
CD28 tranduces a potent signal that enhances T-cell proliferation and cytokine
secretion and sustains the T-cell response.
This research project was based on studies by others and us demonstrating that
blockade of the primary T-cell co-stimulatory molecule, CD28, by CTLA4-Ig during
antigen sensitization and/or challenge of mice strongly inhibited the development of
asthma-like symptoms (22-25). In addition to these blocking studies, the critical
role of CD28 signaling in the development of Th2-dominated allergic inflammatory
responses in mice has been demonstrated since by gene targeting studies. No asthma-
like symptoms could be induced in CD28-deficient (CD28−/−) mice (26-28) or B7-1/
B7-2−/− mice (29). In all of these studies a decrease in Th2 cytokines in either broncho-
alveolar lavage fluid (BALF) or supernatants of antigen re-stimulated lung T-cells
in vitro was observed. This is in agreement with reports demonstrating the contribution
of CD28 signaling to T-cell activation (reviewed in 14-17) and differentiation towards
the Th2 phenotype (30-33) and provides a likely explanation for the reduced Th2-
dependent asthma-like symptoms in mice by CD28 blockade.
B7-1 and B7-2 appear to support T-cell activation equivalently (34). On most
APC populations, B7-2 is expressed constitutively at low levels and is rapidly up-
regulated, whereas B7-1 is inducibly expressed later after activation. The earlier
expression pattern of B7-2 suggests that B7-2 is the more important co-stimulator
for initiating T-cell responses. Blockade of B7-2 by monoclonal antibody (mAb)
administration has consistently been shown to inhibit allergic airway manifestations
in mice although to a variable degree (24, 35-37). In contrast, the contribution of
B7-1 to the development of these manifestations is more controversial. In some
studies it was demonstrated that treatment of mice with anti-B7-1 mAbs (24, 35) or
a mutated form of CTLA4-Ig that selectively binds to B7-1 (38) had no effect (37) or
only (partially) diminished airway eosinophilia (24, 35). Other studies supported a
partial but similar role for B7-1 and B7-2 in the development of airway hyper-
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responsiveness and serum IgE as well (26, 36). Moreover, comparison of mice
deficient in B7-1 or B7-2 demonstrated that these molecules have complementary
roles in the development of Th2-dominated allergic inflammatory responses (29).
Some factors that may account for the diverse results include different protocols,
mouse strains, doses and kinetics of inhibitors and receptor blockade versus active
signaling.
With regard to peripheral blood T-cells derived from atopic asthmatics, B7-2
appears to be the principal co-stimulatory ligand for allergen-induced proliferation
and cytokine production (39, 40). However, resident allergen-specific T-cells in
asthmatic bronchial tissue were shown to require both B7-1 and B7-2 ligation for
allergen-induced cytokine production (40). These differential requirements for B7-1
and B7-2 engagement observed in bronchial tissue and blood may reflect differences
between the two sites in the availability of B7-1.
The second receptor for the B7-1 and B7-2 ligands, CTLA4 (CD152), is
expressed on activated T-cells and delivers an inhibitory signal to terminate the T-
cell response. CTLA4 not only inhibits T-cell proliferation (41-43), but also has
been implicated in Th2 differentiation. CTLA4−/− CD4+ T-cells demonstrate a Th2
cytokine profile (44, 45) and naïve CD4+ T-cells show a Th1 cytokine profile after
CTLA4 ligation in vitro (46) and in vivo (47). Together, this would mean that blockade
of CTLA4 aggravates Th2-dominated asthma manifestations in mice. Indeed,
administration of an anti-CTLA4 mAb during OVA sensitization of BALB/c mice
resulted in an enhanced Th2 priming in vivo and an elevation of asthma-like symptoms
following aerosol challenge compared with control-treated mice (48). In addition, a
marked reduction in transforming growth factor (TGF)-β was observed both in vitro
and in vivo. Because CTLA4 has been described to induce TGF-β production by
murine CD4+ cells (49) and TGF-β in turn has been demonstrated to inhibit airway
eosinophilia (50, 51) and airway hyperresponsiveness (51, 52), this might offer an
explanation for the increased Th2-dominated allergic inflammatory responses in mice
treated with anti-CTLA4 mAb. In contrast with BALB/c mice, Th2 priming, asthma
manifestations and TGF-β production were not affected in C57BL/6 mice (48) that
are genetically less prone to Th2 responses. In accordance herewith, it has been
reported that CTLA4 engagement does not to regulate TGF-β production in T-cells
of C57BL/6 mice (53). Lastly, when anti-CTLA4 mAb was administered solely during
challenge of OVA-sensitized BALB/c mice the asthma phenotype was unaltered
(48). This latter finding was corroborated in a similar study using the same mAb
performed in our laboratory (D.T. Deurloo and E.C.A.M. van Esch, unpublished
observations) and suggests that memory T-cells are refractory to CTLA4-mediated
inhibition of allergic responses.
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2.1.2 A putative additional B7-1/B7-2 receptor
Since the unraveling of the human genome, the CD28 and B7 families are rapidly
growing (reviewed in 17, 18, 54, 55). Moreover, generation of mice lacking both
CD28 and CTLA-4 has produced evidence for a third B7-1/B7-2 receptor (56). In
this study, CD28/CTLA4−/− CD4+ T-cells demonstrated considerable residual B7-1/
B7-2-dependent proliferation upon polyclonal stimulation in vitro. In addition, T-
cell co-stimulation via this putative B7-1/B7-2 receptor was shown to contribute
substantially to Th1-mediated cardiac allograft rejection in vivo, in contrast with
long-term allograft survival in B7-1/B7-2−/− mice (57, 58).
Although no manifestations of allergic asthma can be induced in CD28−/− mice
(26-28), the presence of lymphocytes and interferon-γ in the BALF (26, 27) and the
priming of lymphocytes in the lungs, spleen and lymph nodes (26-28) is observed in
these mice. These data on residual T-cell activation in CD28−/− mice but not in B7-1/
B7-2−/− mice (29) suggested a potential role for the putative B7-1/B7-2 receptor. Co-
stimulation by the supposed B7-1/B7-2 receptor would then result in allergen-specific
T-cell activation that is not strong enough to induce the asthma-like symptoms.
However, the failure to induce these symptoms in CD28−/− mice might also be due to
the presence of CTLA4 that can signal negatively on its own (59-61), thus opposing
potential T-cell co-stimulation via the putative B7-1/B7-2 receptor. So, unmasking
the possible role of co-stimulation by the supposed B7-1/B7-2 receptor in T-cell
activation required the absence of both CD28 and CTLA4.
Therefore, we investigated if T-cell co-stimulation via the putative B7-1/B7-2
receptor contributes to the induction of Th2-dominated model of allergic asthma
using the novel CD28/CTLA4−/− mouse strain (chapter 2). In agreement with an
earlier study by Mark et al. (29), we failed to induce any of these asthma-like
symptoms in the B7-1/B7-2−/− mice. Interestingly, also CD28/CTLA4−/− mice showed
no manifestations of allergic asthma upon sensitization and challenge with OVA.
Moreover, we were unable to demonstrate any sign of residual T-cell activation in
both the thoracic lymph nodes and lungs from CD28/CTLA4−/− mice upon OVA-
sensitization and challenge in vivo.
So, T-cell co-stimulation via the putative B7-1/B7-2 receptor appears to have
no role in the induction of Th2-mediated asthma-like symptoms in the murine model
that we used. Conversely, further evidence is provided for the critical role of CD28
signaling in the development of Th2 responses (26-28, 32).
However, the prerequisite of CD28-mediated T-cell co-stimulation for the
induction of asthma-like symptoms in mice does not exclude important contributions
by other co-stimulatory molecules at various stages in the (re-)activation of T-cells.
Therefore, the effects of blockade of two other well-known receptor-ligand pairs of
T-cell co-stimulation, the ICOS:B7RP-1 and CD40L:CD40 pathways in the
development of Th2-dominated allergic inflammatory responses were studied in this
thesis.
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2.2 The ICOS:B7RP-1 pathway
Inducible co-stimulator (ICOS) is a recently discovered CD28 family member that
binds its own B7 family member, B7 related protein 1 (B7RP-1) (also known as
B7h, B7-H2, GL50 or ICOSL or LICOS) (reviewed in 17-19). ICOS is induced
rapidly on T-cells after TCR engagement and is retained on many memory T-cells,
suggesting that ICOS provides co-stimulatory signals to activated T-cells. Indeed,
during the initial activation of naïve T-cells, the effects of ICOS on T-cell proliferation
and interleukin (IL)-2 production are modest in comparison to those of CD28. Signals
through ICOS seem to be more important for the regulation of cytokine production
by effector T-cells.
With regard to the role of ICOS in the development of asthma-like symptoms,
it has been shown that sensitization and aerosol challenge of ICOS−/− mice with
OVA resulted in strongly inhibited serum OVA-specific IgE levels compared with
wild-type mice (62). However, ICOS−/− mice exhibited similar numbers of eosinophils,
lymphocytes and monocytes/macrophages as wild-type mice. In contrast, in a study
using a murine model of allergic asthma induced by the Schistosoma mansoni parasite,
it was demonstrated that administration of ICOS-Ig during sensitization and challenge
of C57BL/6 mice resulted in a reduced number of inflammatory cells in the BALF
accompanied by a decrease in the level of IL-5 (63), but no effect on the serum total
IgE level was observed.
In chapter 4, it is reported that treatment of mice with hICOS-Fc throughout the
aerosol challenge period significantly reduced the number of inflammatory cells in
the BALF compared with control-treated animals, but no changes in airway
hyperresponsiveness in vivo and serum OVA-specific IgE levels were observed.
Whereas we used OVA as antigen and BALB/c mice, our results are thus very much
in agreement with those of Tesciuba et al. (63). The mechanism responsible for the
reduced amount of BALF inflammatory cells by ICOS blockade observed in both
studies is unknown at present but is not due to a lack of T-cell priming nor to a defect
in Th2 differentiation as determined by unaltered proliferation and Th2 cytokine
production.
To date, no studies on the role of ICOS in human asthma have been reported.
2.3 The CD40L:CD40 pathway
The CD40 ligand (CD40L; CD154):CD40 pair of counter-receptors (reviewed in 20,
21) is the best-characterized pathway of T-cell co-stimulation from the tumor necrosis
factor (TNF) receptor-ligand families (reviewed in 64-66).
CD40L is transiently expressed on activated CD4+ T-cells that interacts with
CD40 found on many cell types, including endothelial cells, fibroblasts, epithelial
cells, mast cells and professional APCs. In addition to evidence for direct T-cell co-
stimulation via CD40L (67-72), triggering of CD40 contributes indirectly to T-cell
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co-stimulation by the up-regulation of B7-1 and B7-2 expression on APCs, thus
enhancing T-cell activation through CD28-mediated signaling (73, 74).
The importance of the CD40L:CD40 pathway in the induction of asthma-like
symptoms has previously only been investigated in mice deficient in either CD40L
or CD40 (75-77). Because ligation of CD40 on B cells, together with IL-4 (78), is
critical for their activation and the induction of IgE isotype switching (79), the absence
of (allergen-specific) IgE in serum was anticipated and demonstrated in all of these
studies. Comparing CD40−/− mice with wild-type mice, two groups found that lack
of CD40 has no effect on antigen-induced BALF eosinophilia and airway
hyperresponsiveness in vivo (75, 77). CD40L−/− mice, on the other hand, show a
reduction in BALF eosinophilia compared with wild-type mice in one study (76) but
not in another study (77). The latter group also investigated the effect of CD40L
deficiency on the development of non-specific hyperresponsiveness in vivo and
observed that hyperresponsiveness was prevented by the lack of CD40L, in contrast
with CD40−/− mice (77).
In the study described in chapter 5, we described the effects of administration
of the anti-CD40L mAb MR1 during OVA-challenge of sensitized mice on the
development of asthma-like symptoms. Anti-CD40L mAb prevented the up-
regulation of serum OVA-specific IgE levels, thus clearly demonstrating the success
of this treatment, but did not alter the degree of OVA-induced airway
hyperresponsiveness in vivo and BALF eosinophilia. Moreover, when administered
in the presence of CTLA4-IgG, anti-CD40L mAb did not add to the inhibitory effects
of CTLA4-IgG in the model. Recently, very similar results were obtained with the
same anti-CD40L mAb in a murine model of allergic asthma when administered
during OVA-sensitization or challenge (80).
The levels of Th2 cytokines produced by bronchial tissue or peripheral blood
T-cells from asthmatics in response to allergen were not affected by the interruption
of the CD40L:CD40 pathway (40). In fact, it has been shown that CD40 signals
delivered by alveolar macrophages can suppress IL-5 production by peripheral blood
CD4+ cells in an allergen-stimulated co-culture system. Alveolar macrophages
derived from patients with atopic asthma were shown to express lower levels of
CD40 that was related to lower IL-12 production by alveolar macrophages and higher
IL-5 production by CD4+ T-cells (81).
So, all of the three pathways of T-cell co-stimulation studied contribute to the
development of Th2-dominated allergic inflammatory responses in mice. Blockade
of the CD40L:CD40 interaction prevented the up-regulation of antigen-specific IgE,
whereas hICOS-Fc administration reduced the total number of inflammatory cells
in the BALF. However, blocking- and gene targeting studies demonstrated that only
the CD28/CTLA4:B7-1/B7-2 pathway is essential for the development of all asthma-
like symptoms in mice.
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3 Role of T-cell co-stimulatory molecules in ongoing Th2-dominated allergic
inflammatory responses
In contrast to the experimental studies that investigated the role of T-cell co-
stimulatory molecules in the development of Th2-mediated asthma-like symptoms
in mice, asthmatic patients start therapy after the development of airway symptoms,
while exposure to environmental allergen mostly continues.
3.1 The CD28/CTLA4:B7-1/B7-2 pathway
Notably, studies in vitro have demonstrated that effector and memory T-cells are
less dependent on CD28-mediated co-stimulation in comparison with naïve T-cells
(31, 82, 83), whereas studies in vivo on the effectiveness of giving CTLA4-Ig after
priming of immune responses have yielded conflicting results (84).
In the study described in chapter 3, it was investigated whether CTLA4-IgG
can reverse established asthma manifestations in a novel murine model of ongoing
disease, in which therapy starts after the development of asthma-like symptoms while
OVA exposures are continued. In OVA-sensitized mice, airway manifestations were
induced by a first series of aerosol challenges. CTLA4-IgG was then administered
followed directly by a second series of aerosols. Thus, at the time of CTLA4-IgG
administration, not only naïve but also antigen-experienced (memory and effectors)
OVA-specific T-cells are present that may be regulated by other co-stimulatory
molecules. In this ongoing murine model of allergic asthma -that was validated by
the “gold-standard” corticosteroid dexamethasone- CTLA4-IgG was still effective
(85). However, airway eosinophilia and OVA-specific IgE levels could only be
partially inhibited and airway hyperresponsiveness was unaffected. CTLA4-IgG may
have inhibited antigen-experienced OVA-specific T-cells in this model. In agreement
herewith, CTLA4-Ig was shown to inhibit allergen-induced cytokine production by
resident T-cells in asthmatic bronchial tissue derived from mild atopic asthmatics
(86). In addition, allergen-induced proliferation of BALF T-cells from atopic subjects
was inhibited by anti-B7-2 mAb (39).
In addition, when newly recruited- or resident naïve CD4+ T-cells that were
not previously activated, contribute to disease, the effectiveness of CTLA4-IgG may
be due to its inhibition of the activation of these cells. T-cells develop from a common
lymphoid progenitor in the bone marrow that also gives rise to B-cells, but those
progeny destined to give rise to T-cells leave the bone marrow and migrate to the
thymus. This is the reason they are called thymus-dependent (T) lymphocytes or T-
cells. With increasing age, the lymphatic thymic mass decreases and thymocyte
production correspondingly declines (thymic involution) (87). Interestingly, recent
data suggest, however, that the adult thymus can remain active even late in life
supplying functional T-cells to the periphery (called recent thymic emigrants) in
humans (88, 89), sheep (90) and mice (91, 92). On the one hand, it will be of interest
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to determine the contribution of these recent thymic emigrants to T-cell-mediated
diseases, including allergic asthma, in people already suffering from full-blown
disease. On the other hand, it will be important to resolve the life span of effector
and memory antigen-specific T-cells. From animal studies, it is concluded that the
average life span of a memory T-cell is determined by how frequently the antigen is
encountered, as well as by how much space is available in the T-cell compartment
(93). Several recent reports have confirmed the presence of antigen-specific memory
T-cells in non-lymphoid compartments long after priming in mice (94, 95). Future
studies are needed to clarify whether CTLA4-IgG mediated its inhibitory effect on
recent thymic emigrants and/or is able to inhibit antigen-experienced T-cells.
3.2 The ICOS:B7RP-1 pathway
In the ongoing murine model of allergic asthma, the partial inhibition by CTLA4-
IgG may be due to the predominance of antigen-experienced- over newly recruited-
or resident naïve OVA-specific T-cells at the time of treatment. Other co-stimulatory
molecules may regulate these antigen-experienced T-cells.
Interestingly, two studies of Coyle and colleagues provided evidence that ICOS
co-stimulation might contribute more to the effector phase than to the initiation of
Th2-dominated allergic inflammatory responses (96, 97). In the first study, ICOS
blockade during antigen challenge reduced lung inflammation and non-specific airway
hyperresponsiveness following adoptive transfer of highly polarized Th2 effector
populations to naïve mice (96). In the second study, administration of mAb 12A8
against ICOS solely during the last (seventh) aerosol challenge of OVA-sensitized
mice significantly reduced the amount of BALF inflammatory cells and airway
hyperresponsiveness, whereas ICOS blockade only at the time of sensitization had
little effect upon subsequent airway challenge (97). Therefore, in the study described
in chapter 4, we investigated the effects of ICOS blockade by ICOS-Fc in the ongoing
murine model of allergic asthma. Surprisingly, in the ongoing model, administration
of ICOS-Fc had no effect on any of the final asthma-like symptoms. Likewise, ICOS-
Fc did not inhibit IL-5 production by primed lung T-cells upon OVA re-stimulation
ex vivo. When we administered the same dose of the 12A8 mAb in the murine model
of ongoing disease, also no alteration of the final manifestations of allergic asthma
was observed. In addition, the combined administration of CTLA4-IgG and mAb
12A8 against ICOS did not have a synergistic effect in the ongoing murine model of
allergic asthma. The discrepancies between the results of Coyle and colleagues and
our results might be explained by the use of Th2 cells that were generated in vitro
and may result in effector T-cells with migratory and functional properties that are
uncommon in vivo (96) or differences in the time point of measurement of the various
parameters after the last aerosol challenge, the sensitization and challenge protocol
and the strain of mouse used (Ref 97 versus chapter 4).
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So, in an ongoing murine model of allergic asthma, only CTLA4-IgG was
effective in that it could partially inhibit airway eosinophilia and the OVA-specific
IgE levels (85), whereas ICOS-Fc had no effect on any of the final asthma-like
symptoms. Future studies using the ongoing model may elucidate which (combination
of) other signals are required for allergic inflammatory responses dominated by
antigen-experienced CD4+ T-cells.
4 Long-term effects of blockade of T-cell co-stimulatory molecules
Studies in vitro have demonstrated that in the absence of co-stimulation, antigen-
stimulated T-cells besides being not optimally activated are also rendered anergic
that is, unresponsive to antigenic re-stimulation in the presence of co-stimulation (9-
13). In vivo, blockade of T-cell co-stimulation around the time of engraftment was
shown to allow for long-term allograft survival in several transplantation models
(see 98). Short-lived treatment that induces selective tolerance to the inhalant allergen
would greatly improve the prospects for asthma patients. Not only would they be
released from regular intake of medicine but also more importantly, the increased
risk for infections and cancer due to continuous antigen-specific T-cell suppression
would be avoided. However, the long-term effects of T-cell co-stimulation blockade
during the development of antigen-induced asthma-like symptoms in mice had not
been studied so far.
4.1 The CD28/CTLA4:B7-1/B7-2 pathway
In the study described in chapter 5, it was investigated if blockade of the CD28/
CTLA4:B7-1/B7-2 pathway during the aerosol challenge period of antigen-sensitized
mice results in long-term amelioration of asthma-like symptoms that is, not only
immediately after challenge but also upon antigen re-challenge after serum clearance
of experimental treatment, eleven weeks later. Interestingly, CTLA4-IgG could induce
tolerance for airway eosinophilia and OVA-specific IgE but not for non-specific
airway hyperresponsiveness. So, whereas CTLA4-Ig inhibits the development of all
of these manifestations of allergic asthma (22-25, 99) as described above in paragraph
2.1, the tolerization of these parameters was dissociated in this study. Perhaps,
CTLA4-IgG had selectively tolerized B7-1/B7-2-dependent T-cell signal transduction
pathways. Alternatively, the various manifestations of allergic asthma are controlled
by different subsets of (allergen-specific) CD4+ T-cells that might differ in their
sensitivity to tolerance induction by CTLA4-IgG. Notably, Campbell et al. identified
specialized “B helper” and “tissue inflammatory” CD4+ T-cell effector subsets that
developed concurrently from common naïve precursors during the primary immune
response in BALB/c mice (100). Similarly, two distinct types of human CD4+ and
CD8+ memory cells have been identified: “central memory” cells present in secondary
lymphoid tissues and “effector memory” cells residing in peripheral tissues that have
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been suggested to perform different functions upon antigenic re-encounter (see 101).
Elucidation of the regulation of the various manifestations of allergic asthma will be
very helpful in optimizing therapies directed at the allergen-specific T-cell including
blockade of co-stimulation.
4.2 The CD40L:CD40 pathway
In vitro, it was found that the successful induction of unresponsiveness toward soluble
antigens with CTLA4-Ig needed complete blockade of antigen-induced proliferation
during the induction culture (102). Along this line, although CTLA4-IgG greatly
reduced the asthma-like symptoms in mice, the symptoms were not fully blocked
suggesting that not all OVA-specific CD4+ T-cells were inhibited and hence
(selectively) tolerized. These non-tolerized antigen-specific T-cells are likely to be
responsible for the residual airway eosinophilia and OVA-IgE levels observed upon
OVA re-challenge. Interestingly, a number of studies in vitro and in vivo on the
induction of antigen-specific tolerance have demonstrated that blockade of both the
CD28/CTLA4:B7-1/B7-2 and the CD40L:CD40 pathway is more effective than
blockade of either pathway alone (103-108). Therefore, the immediate and long-
term effects of blockade of T-cell co-stimulation by the anti-CD40L mAb MR1,
CTLA4-IgG or the combination of these treatments during the aerosol challenge
period of antigen-sensitized mice were compared. However, anti-CD40L mAb had
not a long-term effect by itself. Moreover, in combination with CTLA4-IgG, anti-
CD40L mAb did not augment the CTLA4-IgG-mediated inhibition of asthma-like
symptoms (as discussed above in paragraph 2.3) or the tolerance induced by CTLA4-
IgG. Perhaps the blockade of yet other T-cell co-stimulatory molecule(s) in
combination with CTLA4-Ig is required to completely block T-cell activation in
mice during the aerosol challenge period and to induce antigen-specific tolerance to
all manifestations of allergic asthma. Administration of anti-ICOS mAb 12A8 alone
or in combination with CTLA4-Ig during the challenge period of OVA-sensitized
mice demonstrated that this mAb had no long-term effect by itself or adds to the
tolerance induced by CTLA4-IgG (D.T. Deurloo, unpublished observations).
So, CTLA4-IgG could induce partial tolerance in an OVA-induced murine model
of allergic asthma for BALF eosinophilia and serum OVA-specific IgE levels. In
contrast, mAbs against CD40L or ICOS appeared to have no long-term effect upon
OVA re-challenge of mice after serum clearance in our models.
5 T-cell co-stimulatory molecules and regulatory T-cells
In our studies, T-cell co-stimulation was blocked with the purpose of inhibiting
allergen-specific Th2 cells. Interestingly, in recent years T-cell co-stimulatory
receptors have also been found on the surface of so-called regulatory T-cells, a subset
of lymphocytes that specifically suppresses immune responses (see 109, 110). Some
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T-cells that have suppressor activity are part of a unique lineage of CD4+ T-cells
that are “naturally occurring” and are present in the thymus and peripheral lymphoid
tissues of mice and humans (reviewed in 110-112). The “naturally occurring”
suppressor T-cell population can be identified in naïve animals by expression of the
CD25 antigen. CD4+CD25+ T-cells are potent suppressors of the activation of both
CD4+ and CD8+ T-cells in vitro. Transfer of BALB/c splenic cell suspensions
eliminated of CD4+CD25+ cells to syngeneic T-cell deficient mice has been shown
to induce various auto-immune diseases (113), demonstrating that these cells provide
an additional mechanism for peripheral tolerance besides anergy. The suppression
of these CD4+CD25+ cells might be mediated by both suppressor cytokines - such
as IL-4, IL-10 and TGF-β - and cell-contact-dependent mechanisms (110-112).
CD28 has been shown to control the development and homeostasis of
CD4+CD25+ T-cells (114), but is dispensable for their suppressive function in vitro
(115) and in vivo (116). In fact, CD4+CD25+ regulatory T-cells were shown to
display an anergic phenotype in vitro, and CD28 co-stimulation of regulatory T-
cells reverses their anergic phenotype and abolishes their suppressive capabilities
(15, 117). Another feature of CD4+ CD25+ regulatory T-cells is their constitutive
expression of CTLA4 (115). However, the potential functional role of CTLA4 in
CD4+CD25+ T-cell function remains controversial (110-112).
In one study, it was determined whether CD4+CD25+ T-cells down-regulate
Th2 cell-mediated OVA-induced eosinophil recruitment in the airways (118). BALB/
c Rag-2-/- mice -which lack mature T- and B-cells- received CD4+CD25+ T-cell-
depleted splenocytes or unfractioned splenocytes from non-immunized OVA-specific
TCR transgenic mice. However, the depletion of CD4+CD25+ T-cells reduced the
number of eosinophils and levels of IL-4 and IL-5 in the BALF upon sensitization
and challenge with OVA, whereas an increase in neutrophils, characteristic for Th1-
mediated inflammation (119), was observed. In agreement herewith, the depletion
of CD4+CD25+ T-cells prevented antigen-induced Th2 cell differentiation in vitro
but increased the differentiation of Th1 cells. So, this study suggests that CD4+CD25+
T-cells modulate T helper differentiation towards the Th2 phenotype and thus up-
regulate Th2 cell-mediated allergic inflammation in the airways.
Other types of suppressor T-cells can be induced from conventional CD4+ T-
cells by specific experimental manipulations in vitro that produce predominantly
TGF-β or IL-10 (designated T helper 3 (120) or T regulatory 1 (121), respectively).
In vivo, intranasal exposure to OVA has been shown to result in the induction of
CD4+ regulatory T-cells -producing primarily IL-10 and low levels of IL-4 (121) -
that inhibited the development of asthma manifestations upon subsequent re-challenge
of mice with OVA (122, 123). Interestingly, both the development and inhibitory
function of CD4+ regulatory T-cells were shown to be dependent on the ICOS:B7RP-
1 signaling pathway (123).
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Although it is unclear if the various regulatory T-cells play a role in the murine
models of allergic asthma that we used, the functional consequences of CTLA4-IgG
or ICOS-Fc administration in our studies may have been influenced by their effects
not only on Th2 cells but also on regulatory T-cells. Possibly, the specific targeting
of regulatory T-cell function is an interesting strategy in the treatment of allergic
diseases.
6 Clinical implications from our studies
Murine models of allergic asthma have been very valuable in unraveling the
underlying cellular and molecular mechanisms. The concept of the role of T-cells,
their heterogeneity, and specialized functions all first emerged in the mouse and
subsequently these findings were confirmed in humans (124, 125).
However, some of the experimental therapies that were very effective in mice
had limited benefit in humans (126, 127). Nevertheless, at this place, we would like
to extrapolate the results from our studies with great care to the human situation.
Notably, some experiments were performed in both a “mild” and a more “severe”
murine model of allergic asthma as a representation of the varied disease severity
that is observed among asthma patients as well. In addition, in some of our studies
we also made use of an ongoing murine model of allergic asthma in an attempt to
more closely resemble the clinical situation.
Based on the essential role of the CD28/CTLA4:B7-1/B7-2 pathway in the
development of Th2-dominated allergic inflammatory responses (chapter 2), blockade
of this pathway may be an effective alternative therapy for asthma patients that are
in clinical remission. For example, people suffering from seasonal allergies or patients
that avoided the allergen for a long period of time. This prediction is done with the
assumption that the number of antigen-experienced cells has severely declined in
these cases. Because CTLA4-IgG could induce partial tolerance (chapter 5), these
patients might then even develop tolerance to the inhalant allergen, thus experiencing
long-lasting improvement of their clinical situation.
For asthma patients with ongoing disease (e.g. people allergic to common
allergens such as the excrements of house dust mite), blockade of T-cell co-stimulation
by CTLA4-Ig may not be sufficient. The level of serum OVA-specific IgE and BALF
eosinophilia were only partially reduced by CTLA4-IgG administration in the ongoing
murine model of allergic asthma (chapter 3). Especially patients with more severe
ongoing disease may require additional anti-inflammatory drugs as a clear difference
in the effectiveness of CTLA4-Ig between the “mild” and more “severe” model was
observed. For asthma patients with ongoing disease, CTLA4-Ig might serve as an
“add-on” therapy to reduce the potential side effects by inhaled corticosteroids when
used in escalating doses. Moreover, up to 25% of patients with severe asthma show
poor clinical responses to high doses of glucocorticosteroids (128).
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Blockade of the other pathways of T-cell co-stimulation studied in this thesis,
the ICOS:B7RP-1 and CD40L:CD40 pathways, was in all studies less effective
compared with CTLA4-IgG. So, CTLA4-Ig appears to have the greatest therapeutic
potential.
7 Possible future directions for research
Concerning the regulation of asthma-like symptoms in mice, it will be of interest to
determine:
• the contribution of recent thymic emigrants to T-cell mediated diseases, including
allergic asthma, in mice already suffering from full-blown disease,
• the life-span of antigen-specific effector and memory T-cells,
• the specific functions of T-cell subsets present in lymphoid and peripheral tissues,
• the activation requirements of T-cell signaling pathways or T-cell subsets involved
in the various manifestations of allergic asthma in mice,
• the role and regulation of the various regulatory T-cells.
Concerning T-cell co-stimulation, it will be of interest to determine:
• the expression and function of the last to be discovered members of the expanding
families of T-cell co-stimulatory receptors and their ligands,
• the unique and overlapping biochemical signals and functional responses of the
individual members of the T-cell co-stimulatory receptor families,
• how the signals from the various T-cell co-stimulatory and inhibitory receptors
are integrated,
• which interactions are critical at the various stages of the immune responses,
• the role of localized T-cell co-stimulation in peripheral tissues,
• which immuno(patho)logical responses are influenced by which T-cell co-
stimulatory pathways.
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LIST OF ABBREVIATIONS
−/− homozygous deficiency
AHR airway hyper-
responsiveness
Alum aluminiumhydroxide
APC antigen presenting cell
BAL(F) bronchoalveolar lavage
(fluid)
BSA bovine serum albumin
CD cluster of differentiation
CD80 B7-1
CD86 B7-2
CD152 CTLA4
CD154 CD40 ligand
CD40L CD40 ligand
cDNA complementary
Deoxyribo Nucleic Acid
CHO cells Chinese Hamster Ovary
cells
CTLA4 Cytotoxic T Lymphocyte-
associated Antigen 4
d days
DC dendritic cell
DIG digoxigenin
DRC dose-response curve
EDTA ethylene diamine-tetra-
acetic acid
ELISA enzyme-linked
immunosorbent assay
eo eosinophils
EU experimental units
Fab antigen-binding fragment
FACS fluorescence-activated
cell sorter
Fc constant region
FcR Fc receptors (e.g., FcγRI)
FCS fetal calf serum
FITC fluorescin isothiocyanate
h hours/human
ham hamster
IFN-γ interferon-γ
Ig immunoglobulin
IL interleukin
i.p. intraperitoneal
i.v. intravenous
L ligand
LN lymph node
m murine
mAb monoclonal antibody
MHC-II major histocompatibility
complex class II
MNC mononuclear cells
mo months
mRNA messenger ribonucleic acid
n number of subjects
neutro neutrophils
OVA ovalbumin
p probability value
PBS phosphate-buffered saline
PD programmed death
Penh enhanced pause
R receptor
SEM standard error of the mean
STAT signal transducer and
activator of transcription
TCR T-cell receptor
Th cell T helper cell
TLN thoracic lymph nodes
wk weeks
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SAMENVATTING IN HET NEDERLANDS
Allergisch astma
Allergisch astma is een veel voorkomende ziekte waarbij mensen benauwd worden
wanneer ze de stof inademen waar ze allergisch voor zijn geworden. Daarnaast trekken
de spieren in de luchtwegen van astmapatiënten zich sterker samen bij koude lucht,
sigarettenrook en luchtwegvernauwende stoffen zoals histamine en methacholine.
Dit wordt aspecifieke luchtweghyperreactiviteit genoemd.
Het immuunsysteem (de afweer) dat het lichaam beschermt tegen schadelijke
indringers zoals virussen en bacteriën, speelt ook een cruciale rol bij allergisch astma.
Bij mensen die allergisch zijn, treedt er namelijk een overgevoeligheidsreactie op
van het immuunsysteem voor bepaalde stoffen, de zogenaamde allergenen. De
allergische reactie kan plaatsvinden in de neus (rhinitis), in de longen (astma), in de
darmen (voedselallergie) of in de huid (eczeem).
Het immuunsysteem bestaat uit vele soorten cellen met elk een specifieke taak.
Als het allergeen in de slijmvliezen van de longen komt, wordt het opgenomen door
antigeen-presenterende cellen. Deze cellen “knippen” het allergeen in stukjes en
brengen deze deeltjes in de lymfknopen in contact met zogenaamde T-cellen. De
miljoenen T-cellen die in het lichaam aanwezig zijn verschillen van elkaar omdat ze
allemaal een andere T-cel receptor hebben die elk een specifiek stukje eiwit kan
herkennen. Er zijn ook enkele allergeen-specifieke T-cellen die elk een ander stukje
van het allergeen kunnen herkennen. Na herkenning van het stukje allergeen,
vermenigvuldigen deze T-cellen zich door deling en scheiden ze zogenaamde
cytokinen uit (zie figuur 1 op pagina 9). Deze cytokinen kunnen andere typen
immuuncellen bij de allergische reactie betrekken. Het cytokine interleukine-4 dat
door de allergeen-specifieke T-cel geproduceerd wordt, zorgt er voor dat B-cellen
immunoglobuline E (IgE) tegen het allergeen gaan maken. Het allergeen-specieke
IgE bindt aan receptoren op het oppervlak van mestcellen. Dit wordt sensibilisatie
genoemd. Wanneer het allergeen opnieuw in de luchtwegen komt (provocatie) en
aan het allergeen-specieke IgE op de mestcel bindt, worden de mestcellen
gestimuleerd en geven hun luchtwegvernauwende stoffen en ontstekingsmediatoren
vrij. Een ander cytokine, interleukine-5, betrekt eosinofiele granulocyten
(eosinofielen) bij de allergische reactie. Eosinofielen kunnen ook
ontstekingsmediatoren uitscheiden. Het cytokine interleukine-13 speelt een
belangrijke rol bij het ontstaan van luchtweghyperreactiviteit en bij de overmatige
slijmproductie.
Naast de aanvallen van benauwdheid is de voortdurende aanwezigheid van
verhoogde aantallen T-cellen, eosinofielen en diverse andere immuuncellen
(chronische ontsteking) in de longen een belangrijk kenmerk van allergisch astma.
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Tengevolge van deze chronische ontsteking verandert de structuur van het
longweefsel. Hierdoor vermindert de longfunctie van astmapatiënten in de loop der
jaren.
T-cel co-stimulatie
Voor activatie van de T-cel is niet alleen herkenning van een stukje eiwit door de T-
cel receptor nodig, maar ook aspecifieke, zogenaamde co-stimulatie signalen.
Antigeen-presenterende cellen die een virus, bacterie of allergeen hebben opgenomen,
brengen op hun oppervlak moleculen (liganden) tot expressie die aan co-stimulatie
receptoren op de T-cel kunnen binden. Omdat voor volledige activatie van de T-cel
beide signalen nodig zijn, kan een stukje eiwit van het lichaam zelf een T-cel niet
activeren aangezien de co-stimulatie signalen ontbreken. Zonder co-stimulatie zal
een T-cel zich niet delen en geen cytokinen produceren.
Muizenmodellen voor allergisch astma
Om mechanismen die leiden tot allergisch astma te onderzoeken en om nieuwe
medicijnen te ontwikkelen, kunnen symptomen van astma in de muis geïnduceerd
worden. Voor de experimenten beschreven in dit proefschrift werd het eiwit
ovalbumine als modelallergeen gebruikt. De dieren krijgen eerst een injectie met
ovalbumine in de buikholte om ze te sensibiliseren. Als de muizen vervolgens na
enige tijd een vernevelde oplossing van ovalbumine inademen (provocatie) ontstaat
er een ontstekingsreactie in de longen met symptomen die ook bij astmapatiënten
aangetroffen worden. Hiertoe behoren luchtweghyperreactiviteit voor methacholine
en de infiltratie van ontstekingscellen, met name eosinofielen, in de longen. Daarnaast
wordt een grote hoeveelheid ovalbumine-specifiek IgE in het bloed gevonden.
Doel van dit proefschrift
De huidige therapie voor astmapatiënten bestaat uit medicijnen die de luchtwegen
verwijden bij een astma-aanval en uit ontstekingsremmers, voornamelijk
glucocorticosteroïden. Deze corticosteroïden geven bij  hoge dosis echter veel
bijwerkingen. Omdat allergeen-specifieke T-cellen een centrale rol spelen bij het
ontstaan en de voortgang van allergisch astma, zou het remmen van alleen deze T-
cellen een goede therapie kunnen zijn.
In dit proefschrift is de rol van verschillende T-cel co-stimulatie moleculen in
diverse muizenmodellen voor allergisch astma onderzocht. Dit om te onderzoeken
of blokkade van deze moleculen een nieuwe behandeling voor allergisch astma zou
kunnen zijn. Bovendien is onderzocht of de T-cellen ook enkele weken na blokkade
nog inactief zijn en als gevolg daarvan geen kenmerken van astma meer kunnen
veroorzaken.
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Hoofdstuk 2
Het belangrijkste co-stimulatie molecuul op de T-cel is CD28. Er zijn twee liganden
voor deze receptor op antigeen-presenterende cellen, B7-1 en B7-2. Deze liganden
binden niet alleen aan CD28 maar ook aan een tweede receptor op de T-cel, CTLA4
(zie figuur 2 op pagina 13). CTLA4 komt alleen op het oppervlak van geactiveerde
T-cellen voor en geeft in tegenstelling tot CD28 een remmend signaal aan de T-cel.
Naast de CD28 en CTLA4 receptoren is er mogelijk nog een derde receptor
voor de B7 liganden. Dit bleek uit experimenten waarin muizen die door een
verandering in hun genen geen CD28 en CTLA4 moleculen hebben (CD28/CTLA4−
/−
 muizen) werden vergeleken met muizen die de B7 liganden missen (B7-1/B7-2−/−
muizen). In CD28/CTLA4−/− muizen vond een T-cel-afhankelijke afstoting van een
transplantaat plaats, terwijl B7-1/B7-2−/− muizen het transplantaat accepteerden. In
andere ziekten die door T-cellen worden veroorzaakt zoals allergisch astma was de
rol van deze veronderstelde B7 receptor nog onbekend.
In de studie die wordt beschreven in hoofdstuk 2 van dit proefschrift is daarom
onderzocht of T-cel co-stimulatie via deze veronderstelde receptor bijdraagt aan het
ontstaan van astma symptomen in de muis. Het bleek echter dat zowel in CD28/
CTLA4−/− muizen als in B7-1/B7-2−/− muizen geen enkel astmasymptoom met
ovalbumine geïnduceerd kon worden. De veronderstelde receptor speelt dus geen
rol bij het ontstaan van astma symptomen in ons diermodel. Gebleken is echter dat
CD28 hiervoor cruciaal is.
Hoofdstuk 3
Om de interactie tussen de B7 liganden en CD28 in muizen te verhinderen wordt
door veel onderzoekers CTLA4-Ig gebruikt. Wanneer muizen CTLA4-Ig (vrij
CTLA4) toegediend krijgen, zal dit molecuul aan de B7-1 en B7-2 moleculen binden
waardoor deze liganden niet meer aan CD28 kunnen binden. In studies van diverse
onderzoekers is aangetoond dat behandeling van muizen met CTLA4-Ig ten tijde
van de sensibilisatie en/of provocatie (= toediening tijdens de inductie van astma
symptomen), het ontstaan van deze symptomen voorkomt. Bij astmapatiënten is het
echter gebruikelijk dat ze pas nà het ontstaan van hun luchtwegklachten met een
behandeling beginnen. Daarnaast staan veel patiënten onafgebroken bloot aan de
stof waar ze allergisch voor zijn. De resultaten van studies waarbij CTLA4-Ig werd
toegediend tijdens de inductie van astma symptomen hoeven dus niet representatief
te zijn voor de klinische situatie.
In de studie beschreven in hoofdstuk 3 is onderzocht of behandeling met CTLA4-
Ig bestaande astma symptomen kan verminderen. Hiervoor werd CTLA4-Ig pas nà
inductie van de astma symptomen aan de muizen toegediend terwijl de blootstelling
aan ovalbumine provocaties werd voortgezet (het zogenaamde “chronische” model).
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In muizen behandeld met CTLA4-Ig was het aantal eosinofielen in de longen en de
hoeveelheid ovalbumine-specifiek IgE in het bloed met respectievelijk 83% en 43%
geremd. Toediening van CTLA4-Ig was effectiever dan de “gouden standaard”
corticosteroïde dexamethasone omdat toediening hiervan alleen het aantal
eosinofielen in de longen met 97% verminderde en geen effect had op de hoeveelheid
ovalbumine-specifiek IgE.
Behandeling met CTLA4-Ig in het “chronische” model was echter minder
effectief vergeleken met toediening tijdens de inductie van de astma symptomen.
Het is in vitro (in de reageerbuis) aangetoond dat T-cellen bij een tweede stimulatie
minder co-stimulatie via CD28 nodig hebben dan naïeve T-cellen. De verminderde
effectiviteit van CTLA4-Ig in het “chronische” model kan wellicht verklaard worden
doordat niet alleen naïeve-, maar ook veel reeds geactiveerde ovalbumine-specifieke
T-cellen aanwezig zijn op het moment van CTLA4-Ig toediening. Deze reeds
geactiveerde T-cellen kunnen waarschijnlijk ook via een van de vele andere co-
stimulatie moleculen geactiveerd worden (zie ook hoofdstuk 4).
Astmapatiënten verschillen onderling veel van elkaar, zowel genetisch als in
de ernst van hun ziekte. Daarom is het gebruik van diverse muizenstammen en
protocollen voor inductie van de astma symptomen erg zinvol. In bovengenoemde
studie is CTLA4-Ig ook toegediend in een “chronisch” model met “ernstiger”
kenmerken van allergisch astma. Voor dit model werd een ander protocol gebruikt
waardoor er twee keer zoveel eosinofielen in de longen en ongeveer tien keer zoveel
ovalbumine-specifiek IgE in het bloed terechtkomen vergeleken met het tot nu toe
beschreven “milde” model. In dit “chronische” model voor allergisch astma bleek
behandeling met CTLA4-Ig minder effectief te zijn; alleen het aantal eosinofielen in
de longen was verminderd met 40%, terwijl de hoeveelheid ovalbumine-specifiek
IgE onveranderd bleef. Dexamethasone behandeling van de muizen remde het aantal
eosinofielen in de longen met 73%.
Hoofdstuk 4
Korte tijd nadat wij onze experimenten met CTLA4-Ig in de “chronische” modellen
voor allergisch astma hadden uitgevoerd, werd het aan CD28 verwante T-cel co-
stimulatie molecuul ICOS ontdekt. Op basis van de talrijke eerste studies naar de rol
van ICOS bij de T-cel activatie, werd al snel duidelijk dat dit molecuul een mogelijke
co-stimulator van reeds geactiveerde T-cellen zou kunnen zijn. In tegenstelling tot
CD28, komt ICOS namelijk alleen voor op het oppervlak van geactiveerde T-cellen.
Uit studies naar de rol van ICOS in muizenmodellen voor allergisch astma, bleek dat
ICOS een grotere rol speelt aan het einde van de provocatie periode (wanneer veel
allergeen-specifieke T-cellen geactiveerd zijn) dan tijdens de sensibilisatie (wanneer
de T-cellen nog naief zijn).
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In de studie beschreven in hoofdstuk 4 zijn de effecten van ICOS blokkade
tijdens de inductie van astma symptomen vergeleken met de effecten van ICOS
blokkade nà de inductie periode. Blokkade van ICOS tijdens de inductie leidde tot
een vermindering in het aantal ontstekingscellen in de longen, maar niet tot een
verandering in de hoeveelheid ovalbumine-specifiek IgE in het bloed en de
luchtweghyperreactiviteit voor methacholine. In het “chronische” model had blokkade
van ICOS echter geen enkel effect op de astma symptomen. In onze modellen voor
allergisch astma lijkt ICOS dus geen rol te spelen bij de activatie van reeds
geactiveerde ovalbumine-specifieke T-cellen. Deze resultaten lijken in tegenspraak
te zijn met eerdere studies naar de rol van ICOS in muizenmodellen voor allergisch
astma. Mogelijk liggen verschillen in de uitvoering van de experimenten (gebruikte
muizenstam, protocol voor inductie van de astma symptomen) ten grondslag aan de
tegengestelde uitkomsten. Aanvullende experimenten zijn noodzakelijk om de rol
van ICOS in allergisch astma verder op te helderen.
Hoofdstuk 5
In vitro is aangetoond dat een naïve T-cel die alleen een signaal via de T-cel receptor
ontvangt zonder co-stimulatie, de eerst volgende keer wanneer hij wel beide signalen
krijgt, niet kan reageren. Het blokkeren van co-stimulatie moleculen bij orgaan
transplantatie in proefdieren heeft in sommige studies geleid tot langdurige acceptatie
van het transplantaat (tolerantie). Dit houdt in dat de T-cellen ook geremd waren
nadat de stoffen die de co-stimulatie moleculen blokkeerden uit het lichaam
verdwenen waren. Deze resultaten zouden kunnen betekenen dat ook bij astma een
kortdurende behandeling met co-stimulatie blokkade leidt tot tolerantie voor het
allergeen en dus langdurige verbetering van de symptomen.
In de studie beschreven in hoofdstuk 5, is onderzocht of blokkade van T-cel co-
stimulatie moleculen tijdens de inductie van de astma symptomen tot langdurige
verbetering van deze symptomen leidt. Dat wil zeggen, niet alleen een verbetering
van de astma symptomen direct na de inductie maar ook elf weken later nadat de
muizen opnieuw aan ovalbumine provocaties worden blootgesteld (de tweede
provocatie periode) als de blokkerende stoffen uit het bloed van de muizen verdwenen
zijn. In sommige andere studies werd aangetoond dat voor het ontstaan van tolerantie
het blokkeren van CD28 in combinatie met blokkade van CD40 Ligand (een ander
bekend T-cel co-stimulatie molecuul) effectiever is dan het blokkeren van één van
beide moleculen afzonderlijk. Daarom zijn in de studie beschreven in hoofdstuk 5,
CTLA4-Ig en een antistof tegen CD40 Ligand zowel afzonderlijk als in combinatie
toegediend.
In overeenstemming met eerdere studies, voorkomt behandeling van muizen
met CTLA4-Ig tijdens de inductie van astma symptomen het ontstaan hiervan. Na
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de tweede provocatie periode, elf weken later, was het aantal eosinofielen in de
longen nog steeds verminderd. In het “milde” muizenmodel voor allergisch astma
was na elf weken niet alleen het aantal eosinofielen in de longen maar ook de
hoeveelheid ovalbumine-specifiek IgE in het bloed afgenomen. In beide modellen
was er geen lange-termijn effect op de luchtweghyperreactiviteit voor methacholine.
Kennelijk zijn niet alle astma symptomen even gevoelig voor het ontstaan van
tolerantie.
Toediening van de antistof tegen CD40 Ligand bleek na de inductie periode
alleen de toename van ovalbumine-specifiek IgE in het bloed te voorkomen en had
geen enkel lange-termijn effect. Behandeling met de combinatie was net zo effectief
als behandeling met alleen CTLA4-Ig.
Conclusies
Muizenmodellen voor allergisch astma hebben al veel bijgedragen aan de huidige
kennis van de onderliggende mechanismen die aan het ontstaan van deze ziekte
bijdragen. Experimentele therapieën die in de muis zeer succesvol waren, bleken bij
astmapatiënten helaas soms minder succesvol te zijn. Dit kan veroorzaakt zijn doordat
het gebruikte muizenmodel te weinig overeenkwam met de klinische situatie. Om
de voorspelbaarheid van onze studies te vergroten is daarom het “chronische” model
ontworpen en zijn sommige experimenten zowel in een “mild”- als in een “ernstiger”
model voor allergisch astma uitgevoerd.
In alle studies was blokkade van CD28 door CTLA4-Ig in muizenmodellen
voor allergisch astma het meest effectief vergeleken met blokkade van ICOS en
CD40 Ligand. CTLA4-Ig lijkt dus de beste therapeutische mogelijkheden te hebben.
Vanwege de belangrijke rol van CD28 bij het ontstaan van astma symptomen in de
muis (hoofdstuk 2) zou CTLA4-Ig een alternatieve therapie kunnen zijn voor
astmapatiënten die enige tijd niet aan het allergeen hebben blootgestaan zoals bij
seizoensgebonden allergieën. Het aantal T-cellen die geactiveerd zijn geweest moet
dan wel behoorlijk zijn afgenomen in die periode zodat het aantal (nieuwe) naïeve
cellen die voor hun stimulatie sterk afhankelijk zijn van co-stimulatie groter is.
Tijdelijke blokkade van CD28 zou bij deze patiënten zelfs tot langdurige verbetering
van sommige astma symptomen kunnen leiden (hoofdstuk 5). In de mens is echter
nog weinig bekend over de levensduur van geactiveerde T-cellen en de bijdrage van
nieuwe naïeve allergeen-specifieke T-cellen aan de ziekte.
Voor astmapatiënten met symptomen, zal behandeling met alleen CTLA4-Ig
waarschijnlijk onvoldoende zijn. Het aantal eosinofielen in de longen en de
hoeveelheid ovalbumine-specifiek IgE in het bloed was slechts gedeeltelijk geremd
door behandeling met CTLA4-Ig in het “chronische” muizenmodel voor allergisch
astma (hoofdstuk 3). Vooral mensen met ernstiger vormen van astma zullen extra
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medicatie nodig hebben naast CTLA4-Ig omdat een duidelijk verschil in effectiviteit
van CTLA4-Ig tussen het “milde” en “ernstiger” muizenmodel voor allergisch astma
werd gevonden. Omdat de resultaten van CTLA4-Ig toediening in het “chronische”
model even goed of zelfs beter waren dan dexamethasone toediening, zou CTLA4-
Ig echter een alternatief kunnen zijn voor corticosteroïden die bij een hoge dosis
veel bijwerkingen geven. Dit geldt ook voor astmapatiënten die ongevoelig zijn voor
corticosteroïden.
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